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Pyrophosphate (PPi) has been known since the 1960s as an inhibitor of calcium renal stone 
formation. Naturally occurring mutations in a putative PPi transporter, ANK, causes renal 
calcification in mice. We hypothesised that the human homologue, ANKH, plays a role in 
PPi transport in the human kidney. 
Immunocytochemical localisation of ANKH in human kidney showed greater abundance in 
the cortical collecting duct than elsewhere in the nephron.  
The transport function of ANKH was investigated by heterologous expression of ANKH in 
Xenopus oocytes. Despite confirmation of ANKH expression at the oocyte plasma 
membrane, neither ANKH-mediated PPi efflux (the physiological mode of operation) nor 
influx was detectable compared to water-injected oocytes. Pyrophosphatase activity was 
detected at the surface of oocytes, suggesting hydrolysis of PPi to inorganic phosphate.  
Screening using a yeast two-hybrid method of the N-terminal of ANKH against a mouse 
renal library identified a possible protein-protein interaction with the fatty acid transporter 
SLC27A2, whose acyl-CoA synthetase activity yields PPi as an end product. This suggests 
that ANKH and protein partners such as SLC27A2 may form a biochemical couple whereby 
PPi is sequestered by transmembrane transport rather than by hydrolysis. Since there is no 
pyrophosphatase activity in peroxisomes, we suggest that the ANKH/SLC27A2 complex is 
a candidate protein for the peroxisomal membrane PPi transporter. 
AVP mediates increased expression and localisation of ANK to the apical membrane of a 
collecting duct model (mpkCCDcl4) in vitro, suggesting physiologically appropriate 
regulation, analogous to that of aquaporin-2. 
These findings offer insights into the cellular homeostasis of PPi. Instead of cytosolic 
hydrolysis, coupling of PPi generation and ANKH-mediated transport as part of a protein 
complex may allow PPi to be compartmentalised, preserving it for use within vesicular 
structures elsewhere in the cell or allowing export to the extracellular medium to assist in 
the regulation of apatite deposition. 
iii 
To my beautiful daughter 
Zahabia 
who gave me immense joy, love and inspiration 
during her wonderful life 
iv 
ACKNOWLEDGEMENTS 
Firstly, I would like to thank my supervisors, Professor Nicholas Simmons and Dr John 
Sayer - a “dream team” who combine vast experience, enthusiasm, wisdom and 
encouragement. It has been a true pleasure to work closely with them.  
Many thanks are due to Dr Georgina Carr, ‘Queen of the Confocal’, whose scientific 
expertise, good humour and resilience kept me going during the long, late hours in the lab. 
I am very grateful to the following:  
• Alison Howard for molecular biology and qPCR advice, Andi Werner for oocyte 
advice, Dan Swan for help with microarray analysis, Max, Cat, Amy, Emily and all 
the members of the friendly Epithelial lab at Newcastle University 
• Wendy Robson, the patients and urological surgeons at the Freeman Hospital, 
Newcastle upon Tyne 
• Noel, Mark and BBC Radio 2 - for good chat and company in the oocyte room 
• and especially to the Northern Counties Kidney Research Fund and the Wellcome 
Trust for generously funding me. 
Special thanks go to Rani, my beautiful wife whom I met and married during my PhD 
studies, and who never once complained during the long hours spent in the lab and writing 
this thesis.  
And final thanks go to my parents, who have always supported and encouraged me and 




Moochhala SH, Carr G, Sayer JA, Simmons NL (2007). The pyrophosphate transporter, 
ANK, is expressed in mouse and human kidney and co-localises with aquaporin-2 in renal 
collecting ducts (poster). J Am Soc Nephrol 18, 595A.  
Sayer JA, Korkmaz C, Moochhala SH, Carr G (2008). ANKH polymorphisms, ankylosing 
spondylitis and renal stone disease J Am Soc Nephrol Abstracts Issue 19, 935A. 
Moochhala SH, Carr G, Sayer JA, Simmons NL (2009). The Pyrophosphate Transporter, 
ANK, Traffics with Aquaporin-2 to the Apical Membrane after Arginine Vasopressin 
Stimulation in the Mouse Renal Collecting Duct Cell Line, mpkCCDCl4. J Am Soc Nephrol 
Abstracts Issue 20, 761A. 
Papers 
Moochhala SH, Sayer JA, Carr G, Simmons NL (2008). Renal calcium stones: insights from 
the control of bone mineralization. Exp Physiol 93,  43-49.  
Carr G, Moochhala SH, Eley L, Vandewalle A, Simmons NL, Sayer JA (2009). The 
pyrophosphate transporter ANKH is expressed in kidney and bone cells and colocalises to 
the primary cilium / basal body complex. Cell Physiol Biochem 24, 595-604. 
Sayer JA, Moochhala SH, Thomas DJ (2010). The medical management of urolithiasis. Br J 
Med Surg Urol 3, 87-95. 
Book chapter 
Sayer JA, Carr G, Moochhala SH, Simmons NL (2008). Pyrophosphate Transport and 
Stones. In: Proc 2nd Intl Urolithiasis Res Symp, Eds. Evan AP, Lingeman JE, McAteer JA, 
Williams JC. Pub. by Amer. Institute of Physics, Melville, NY, pp. 71-80. 
vi 
TABLE OF CONTENTS 
LIST OF FIGURES .................................................................................................. X
LIST OF TABLES .................................................................................................. XII
ABBREVIATIONS ................................................................................................ XIII
1 INTRODUCTION ............................................................................................ 15
1.1 Kidneys and pyrophosphate .................................................................................................................. 15
1.1.1 Requirement for inhibitors of calcification in the kidney ............................................................... 15
1.2 Chemistry of PPi..................................................................................................................................... 15
1.2.1 Role as crystallisation inhibitor ...................................................................................................... 15
1.2.2 Reactions which generate PPi ......................................................................................................... 16
1.2.3 Measurement of PPi in biological systems ..................................................................................... 16
1.3 Molecular biology of ANKH .................................................................................................................. 17
1.3.1 ANKH is evolutionarily highly conserved...................................................................................... 17
1.3.2 ANKH is implicated in altering PPi levels locally.......................................................................... 17
1.3.3 ANKH single gene disorders in humans cause clinical effects via altered PPi levels ..................... 18
1.4 PPi, ANKH and inhibition of renal calcification ................................................................................. 20
1.4.1 Mechanisms of nephrocalcinosis/nephrolithiasis ............................................................................ 20
1.4.2 PPi and other calcification inhibitors in the kidney ........................................................................ 20
1.4.3 Clinical effects of abnormal ANKH function in human kidney ..................................................... 21
1.4.4 Origin of PPi in urine ...................................................................................................................... 21
1.4.5 Localisation of ANK in the kidney ................................................................................................. 23
1.5 Aims of this study ................................................................................................................................... 24
1.5.1 Benefits of understanding ANKH function in the kidney ............................................................... 24
1.5.2 Experimental strategy ..................................................................................................................... 24
2 MATERIALS AND METHODS ....................................................................... 25
2.1 Human renal tissue................................................................................................................................. 25
2.1.1 Collection of tissue ......................................................................................................................... 25
2.1.2 Preparation of tissue ....................................................................................................................... 25
2.2 RT-PCR of ANKH from whole tissue and cell culture lines ............................................................... 25
2.2.1 Overview ........................................................................................................................................ 25
2.2.2 RNA extraction from tissue and cell lines ...................................................................................... 26
2.2.3 Reverse transcription ...................................................................................................................... 27
2.2.4 Polymerase chain reaction .............................................................................................................. 27
2.2.5 Primers ............................................................................................................................................ 28
2.2.6 Agarose gel electrophoresis ............................................................................................................ 31
2.3 Molecular constructs and cloning of PCR products ............................................................................ 31
2.3.1 Overview of cloning procedure ...................................................................................................... 31
2.3.2 Cloning and transformation reactions ............................................................................................. 32
2.3.3 Creation of constructs ..................................................................................................................... 33
2.4 Preparation of capped RNA for oocyte micro-injection ..................................................................... 40
2.4.1 Overview ........................................................................................................................................ 40
2.4.2 Method ............................................................................................................................................ 40
vii 
2.4.3 cRNA types made ........................................................................................................................... 41
2.5 Immunofluorescence .............................................................................................................................. 43
2.5.1 Overview ........................................................................................................................................ 43
2.5.2 Fixation ........................................................................................................................................... 43
2.5.3 Primary antibodies .......................................................................................................................... 43
2.5.4 Secondary antibodies ...................................................................................................................... 45
2.5.5 General method ............................................................................................................................... 45
2.5.6 Specific methods ............................................................................................................................. 45
2.5.7 Confocal microscopy ...................................................................................................................... 46
2.6 Western blotting ..................................................................................................................................... 47
2.6.1 General outline................................................................................................................................ 47
2.6.2 Preparation of protein lysate ........................................................................................................... 47
2.6.3 Protein electrophoresis .................................................................................................................... 48
2.6.4 Protein transfer................................................................................................................................ 48
2.6.5 Immunodetection of protein ............................................................................................................ 49
2.7 Tissue culture procedures ...................................................................................................................... 50
2.7.1 Cell lines ......................................................................................................................................... 50
2.7.2 Cell culture ..................................................................................................................................... 51
2.7.3 Serial passages ................................................................................................................................ 51
2.8 Flux experiments using the Xenopus oocyte expression system ......................................................... 52
2.8.1 Preparation of oocytes .................................................................................................................... 52
2.8.2 Microinjection of oocytes ............................................................................................................... 52
2.8.3 Radiolabelled substrates ................................................................................................................. 52
2.8.4 Influx of radiolabelled substrate ..................................................................................................... 54
2.8.5 Efflux of radiolabelled substrate ..................................................................................................... 54
2.8.6 Variables affecting transporter kinetics .......................................................................................... 56
2.8.7 Control experiments for efflux protocol ......................................................................................... 60
2.8.8 Data quality and statistics ............................................................................................................... 65
2.9 Pyrophosphate assay .............................................................................................................................. 66
2.9.1 Background ..................................................................................................................................... 66
2.9.2 Validation of PPi assay ................................................................................................................... 67
2.9.3 Estimation of oocyte surface PPase activity ................................................................................... 67
2.10 Identification of proteins interacting with ANK by yeast two-hybrid screening ......................... 68
2.10.1 Choice and overview of yeast two-hybrid screening ...................................................................... 68
2.10.2 Choosing the bait ............................................................................................................................ 68
2.10.3 Experimental protocol..................................................................................................................... 69
2.10.4 Weaknesses of the yeast two-hybrid technique .............................................................................. 73
2.11 Expression profiling .......................................................................................................................... 74
2.11.1 Aims and benefits of expression profiling ...................................................................................... 74
2.11.2 Validation of total RNA quality ...................................................................................................... 75
2.11.3 Overview of experiment ................................................................................................................. 75
2.11.4 Data analysis ................................................................................................................................... 77
2.12 Quantitative RT-PCR ....................................................................................................................... 83
2.12.1 Outline ............................................................................................................................................ 83
2.12.2 Method ............................................................................................................................................ 83
2.12.3 Data analysis ................................................................................................................................... 85
3 RESULTS (I): EXPRESSION AND LOCALISATION OF ANKH IN HUMAN 
KIDNEY ................................................................................................................. 87
3.1 Introduction ............................................................................................................................................ 87
3.1.1 Anti-ANK antibodies ...................................................................................................................... 87
3.1.2 Aims of this section ........................................................................................................................ 87
viii 
3.2 Results ..................................................................................................................................................... 90
3.2.1 Comparison of human ANKH sequence with other species ........................................................... 90
3.2.2 ANK mRNA is expressed in human kidney, and in human and mouse cell lines .......................... 90
3.2.3 ANKH full-length coding sequence is confirmed in 6 human subjects ........................................... 93
3.2.4 Western analysis of ANKH protein expression in human kidney .................................................. 99
3.2.5 Specificity of Ab3 staining in human renal cortex........................................................................ 104
3.2.6 ANKH localises to the collecting duct in human kidney .............................................................. 104
3.2.7 ANKH expression elsewhere in the human nephron .................................................................... 104
3.2.8 Localisation of NPP enzymes in human kidney ........................................................................... 105
3.3 Discussion .............................................................................................................................................. 116
3.3.1 Expression of ANKH mRNA in human subjects .......................................................................... 116
3.3.2 Detection of ANKH in human kidney tissue using Western blotting ........................................... 117
3.3.3 Detection of ANKH in human kidney tissue using immunofluorescence with Ab3 .................... 118
3.3.4 Implications .................................................................................................................................. 119
4 RESULTS (II): INTRACELLULAR AND PLASMA MEMBRANE 
EXPRESSION OF ANKH OVEREXPRESSED IN XENOPUS OOCYTES .......... 120
4.1 Introduction .......................................................................................................................................... 120
4.1.1 Confirmation of heterologous overexpression in oocytes ............................................................. 120
4.1.2 Aim of this section ........................................................................................................................ 120
4.2 Expression of ANKH protein in Xenopus oocytes ............................................................................. 121
4.2.1 Confirmation of purity of oocyte membrane fraction preparation ................................................ 121
4.2.2 Expression of the ANKH-FLAG construct in oocytes ................................................................. 121
4.2.3 Results with Ab3 agree with results of anti-FLAG in detection of ANKH-FLAG in oocyte 
membrane ..................................................................................................................................... 121
4.2.4 Attempts to localise ANKH to the plasma membrane on immunofluorescence ........................... 122
4.2.5 Ab3, but not anti-N-terminal ANK antibody, colocalises with FLAG ......................................... 122
4.2.6 ANKH-FLAG expression in oocytes occurs at the plasma membrane ......................................... 123
4.3 Discussion .............................................................................................................................................. 141
4.3.1 Purity of oocyte membrane fractions and definition of the plasma membrane outline ................. 141
4.3.2 Confirmation of ANKH expression in oocytes ............................................................................. 141
4.3.3 ANKH-FLAG localises to the plasma membrane when overexpressed in oocytes ...................... 142
4.3.4 The pattern of oocyte immunofluorescence is consistent with previously published studies ....... 142
4.4 Conclusions ........................................................................................................................................... 143
5 RESULTS (III): FUNCTIONAL STUDIES OF ANKH IN XENOPUS OOCYTES
 145
5.1 Introduction .......................................................................................................................................... 145
5.1.1 Rationale for transport measurements in Xenopus oocytes ........................................................... 145
5.1.2 Aims of this section ...................................................................................................................... 146
5.2 Results ................................................................................................................................................... 146
5.2.1 Demonstration of an endogenous sodium-dependent phosphate influx in oocytes, and confirmation 
of phosphate influx into NaPi-injected oocytes ........................................................................... 146
5.2.2 Investigation of the substrate specificity of NaPi-IIb for Pi and PPi ............................................ 149
5.2.3 ANKH-mediated influx of 32PPi into oocytes ............................................................................... 150
5.2.4 Hydrolysis of PPi .......................................................................................................................... 156
5.2.5 ANKH-mediated efflux of 32PPi from oocytes ............................................................................. 159
5.2.6 Yeast two-hybrid screen ............................................................................................................... 172
5.3 Discussion .............................................................................................................................................. 177
5.3.1 Meaningful PPi influx across membranes is not proven ............................................................... 177
5.3.2 Endogenous phosphate transporters in oocytes ............................................................................ 177
5.3.3 Is the recorded influx due to PPi or Pi? ........................................................................................ 178
ix 
5.3.4 PPi in buffer is ionised and available for measurement using a sensitive bioassay ...................... 178
5.3.5 PPase activity is present on the surface of oocytes ....................................................................... 179
5.3.6 Significant efflux from ANKH-injected oocytes was not detected under a wide variety of 
experimental conditions ............................................................................................................... 180
5.3.7 Yeast two-hybrid screen ............................................................................................................... 181
5.4 Conclusions ........................................................................................................................................... 183
5.4.1 Possible reasons for apparent lack of transmembrane PPi flux mediated by ANK ...................... 183
5.4.2 An alternative strategy for investigating ANK function ............................................................... 184
6 RESULTS (IV): REGULATION OF ANK USING A MOUSE COLLECTING 
DUCT CELL LINE, MPKCCDCL4 ......................................................................... 186
6.1 Introduction .......................................................................................................................................... 186
6.1.1 Introduction and hypothesis .......................................................................................................... 186
6.1.2 Justification for using mpkCCDcl4 cells to investigate regulation................................................. 186
6.1.3 Likelihood of ANK being regulated ............................................................................................. 187
6.1.4 Aim of this section ........................................................................................................................ 187
6.2 Effect of AVP stimulation on expression of ANK protein ................................................................ 187
6.2.1 Results .......................................................................................................................................... 187
6.2.2 Discussion ..................................................................................................................................... 194
6.3 Effect of AVP on the expression profile of mpkCCDcl4 cells ............................................................ 196
6.3.1 Aims of expression profile analysis .............................................................................................. 196
6.3.2 Results .......................................................................................................................................... 196
6.3.3 Discussion ..................................................................................................................................... 197
6.4 Confirmation of upregulated genes by quantitative RT-PCR .......................................................... 210
6.4.1 Aim ............................................................................................................................................... 210
6.4.2 Results .......................................................................................................................................... 210
6.4.3 Discussion ..................................................................................................................................... 221
6.5 Conclusion ............................................................................................................................................. 224
7 CONCLUDING DISCUSSION ...................................................................... 225
7.1 Existing knowledge and unanswered questions ................................................................................. 225
7.1.1 The role of ANKH in the renal collecting duct ............................................................................. 225
7.1.2 Drawbacks of using the oocyte expression system for PPi flux experiments ............................... 225
7.1.3 Production of PPi and the importance of membrane transport ..................................................... 226
7.2 Function of ANKH in the distal nephron ........................................................................................... 227
7.2.1 Role of ANK at the plasma membrane of collecting ducts ........................................................... 227
7.2.2 Evidence for an interacting partner protein ................................................................................... 227
7.2.3 Regulatory mechanisms and possible linkage of PPi and calcium membrane transport............... 228
7.2.4 Source of PPi in the collecting duct .............................................................................................. 229
7.3 Summary of ANKH function in the collecting duct .......................................................................... 230
7.3.1 Summary of main findings of this thesis ...................................................................................... 230
7.3.2 A model of ANKH function ......................................................................................................... 232
7.3.3 Final conclusions .......................................................................................................................... 233




LIST OF FIGURES 
Figure 2.1 Map of primer combinations designed to amplify contiguous sequences from ANKH coding 
sequence ................................................................................................................................................... 30 
Figure 2.2 Sequencing of ANKH-NT-GFP construct ........................................................................................ 34 
Figure 2.3 Sequencing of ANKH-pcDNA3.1 construct .................................................................................... 35 
Figure 2.4 Sequencing of ANKH-pTNT construct ............................................................................................ 38 
Figure 2.5 Sequencing of ANKH-NT-3XFLAG construct subcloned into a T7-containing mammalian 
expression vector ...................................................................................................................................... 39 
Figure 2.6 Diagram illustrating effect on flux (rate of radiolabel transport) of increasing substrate 
concentration. ........................................................................................................................................... 58 
Figure 2.7 Effect of prior water-injection on subsequent detection of 32P activity in oocytes. .......................... 62 
Figure 2.8 Contamination of non-injected oocytes with activity acquired from surrounding buffer. ................ 63 
Figure 2.9 Location of the ANK N-terminal fragment (residues 24-85) used for the bait fusion construct. ..... 70 
Figure 2.10 Classical yeast two-hybrid system with ANK as the protein of interest. ........................................ 71 
Figure 2.11 Validation of total RNA quality ..................................................................................................... 76 
Figure 2.12 Normalisation of raw data .............................................................................................................. 79 
Figure 2.13 Hierarchical clustering of normalised microarray data ................................................................... 80 
Figure 2.14 Hybridisation controls forming a ‘spike’ plot................................................................................. 81 
Figure 3.1 Evolutionary conservation of ANK (amino acid sequences) ............................................................ 88 
Figure 3.2 Evolutionary conservation of ANK (nucleotide sequences) ............................................................. 89 
Figure 3.3 Putative domains of the ANKH protein ............................................................................................ 91 
Figure 3.4 Expression of an ANK amplification product in human kidney cell line and tissue ........................ 92 
Figure 3.5 RT-PCR of ANKH products from human renal cortex. ................................................................... 94 
Figure 3.6 Example of full length ANKH sequence from a human subject. ...................................................... 96 
Figure 3.7 Detection of a single nucleotide polymorphism in ANKH coding sequence in six human subjects 98 
Figure 3.8 Western blot analysis of human renal cortex, probed with ANK N- and C-terminal antibodies. ... 100 
Figure 3.9 Western blot controls for ANK detection in human renal tissue. ................................................... 102 
Figure 3.10 ANK immunofluorescence using the Ab3 antibody in human kidney ......................................... 106 
Figure 3.11 Preadsorption of Ab3 antibody by its immunising peptide........................................................... 107 
Figure 3.12 Colocalisation of ANK with AQP2 in human kidney. ................................................................. 108 
Figure 3.13 Colocalisation of ANK with AE1 in human kidney. .................................................................... 109 
Figure 3.14 ANK is minimally expressed in human proximal tubule. ............................................................. 110 
Figure 3.15 ANK is expressed to a limited extent in Loop of Henle/distal convoluted tubule. ....................... 112 
Figure 3.16 Expression of NPP1 in the collecting duct of human kidney. ...................................................... 113 
Figure 3.17 Expression of NPP3 in the proximal tubule of human kidney. ..................................................... 115 
Figure 3.18 ANKH transcript and protein summaries from Ensembl. ............................................................. 116 
Figure 4.1 Detection of CD98 expressed in oocyte membrane by probing with anti-CD98 antibody ............. 124 
Figure 4.2 Expression of ANKH-FLAG construct in oocytes, detected by anti-FLAG antibody ................... 126 
Figure 4.3 Confirmation of ANKH-FLAG expression in oocytes by detection with Ab3 antibody ................ 128 
xi 
Figure 4.4 Detection of ANKH-pcDNA3.1 expression in oocytes using Ab3 antibody .................................. 130 
Figure 4.5 ANK constructs localise to the oocyte plasma membrane .............................................................. 131 
Figure 4.6 Identical and enhanced staining in ANKH-FLAG-injected oocytes using both Ab3 and anti-FLAG 
antibodies ............................................................................................................................................... 133 
Figure 4.7 Non-identical staining of ANKH-FLAG-injected oocytes using anti-N-terminal ANK and anti-
FLAG antibodies .................................................................................................................................... 135 
Figure 4.8 CD98 marks the plasma membrane of Xenopus oocytes ................................................................ 137 
Figure 4.9 Confirmation of ANKH-FLAG localisation to the oocyte plasma membrane ............................... 139 
Figure 4.10 Schematic diagram of ultrastructure of the vegetal pole of a Stage VI Xenopus oocyte .............. 144 
Figure 5.1 Mean influx of 32P as 20 M NaH2PO4 into Xenopus oocytes over 40 minutes. ............................ 148 
Figure 5.2 Effect of varying external conditions on the influx of labelled Pi into NaPi-IIb and water-injected 
oocytes.................................................................................................................................................... 152 
Figure 5.3 Influx of labelled PPi into ANKH-pcDNA3.1 injected oocytes. .................................................... 153 
Figure 5.4 Influx of labelled PPi into ANKH-pcDNA3.1-injected oocytes under conditions of excess 
unlabelled substrate. ............................................................................................................................... 155
Figure 5.5 Standard curves for PPi assays using a chemical PPi sensor. ......................................................... 157 
Figure 5.6 Determination of pyrophosphatase activity on the surface of Xenopus oocytes. ............................ 158 
Figure 5.7 Estimation of 14C-mannitol leakage after micro-injection into Xenopus oocytes ........................... 160 
Figure 5.8 Active efflux from Xenopus oocytes re-injected with Lucifer Yellow ........................................... 162 
Figure 5.9 Effect of pH on efflux of 32P as sodium pyrophosphate from Xenopus oocytes. ............................ 169 
Figure 5.10 Effect of acute stimulation of ANKH activity on efflux of 32P as sodium pyrophosphate from 
Xenopus oocytes. .................................................................................................................................... 170 
Table 5.7 and Figure 5.11 Efflux of 32P activity as sodium pyrophosphate from Xenopus oocytes co-injected 
with ANKH-pcDNA3.1 cRNA and human kidney total RNA. .............................................................. 171 
Figure 5.12 Alignment of amino acid sequences for Slc27a2 clone fragments that interacted with N-terminal 
ANK bait in a yeast two-hybrid screen. ................................................................................................. 174 
Figure 5.13 Mapping of consensus sequences of interacting Aldh6a1 clones to the coding sequence. ........... 175 
Figure 5.14 Possible interaction between FATP and ANKH. .......................................................................... 185 
Figure 6.1 CLSM images of methanol-fixed mpkCCDcl4 epithelial layers, under control conditions and after 
incubation for 24 h with either arginine vasopressin (AVP; 10-8M) or forskolin (10-5M).  ................... 189 
Figure 6.2 CLSM images of methanol-fixed mpkCCDcl4 epithelial layers, under control conditions and after 
incubation for 24 h with arginine vasopressin (AVP; 10-8M), using anti-calbindin antibody. ............... 192 
Figure 6.3 Change in expression of each probeset (gene) according to array. ................................................. 199 
Figure 6.4 Change in probeset (gene) expression due to AVP treatment, for normalised and quality-controlled 
microarray data. ...................................................................................................................................... 200 
Figure 6.5 Hierarchical clustering of quality controlled probesets (genes), selected for p<0.05 and fold change 
>1.18. ..................................................................................................................................................... 201 
Figure 6.6 Change in expression of five genes with AVP treatment. .............................................................. 203 
Figure 6.7 Summary of rationalisation of microarray data and overlap with Knepper dataset. ....................... 208 
Figure 6.8 Standard curves showing efficiency of DNA amplification of known dilutions of DNA from six 
genes. ...................................................................................................................................................... 211 
Figure 6.9 Examples of amplification curves. ................................................................................................. 213 
Figure 6.10 Identification of amplification products by determination of melting peaks. ............................... 219 
Figure 7.1 Potential roles of ANK in the principal cell of the renal collecting duct ........................................ 235 
xii 
LIST OF TABLES 
Table 1.1 Summary of human and mouse disorders of calcification linked to ANK polymorphisms. ............... 19 
Table 2.1 Oligonucleotide primers.. .................................................................................................................. 29
Table 2.2 Summary of constructs used for synthesis of cRNA, and their usage in downstream applications.. . 42 
Table 2.3 Total RNA types extracted from cells and tissues for co-injection in flux experiments. ................... 42 
Table 2.4 Primary antibodies used for immunofluorescence studies. ................................................................ 44 
Table 2.5 Antibodies used in Western blotting experiments. ............................................................................ 49 
Table 2.6 Radiolabelled substrates..................................................................................................................... 53 
Table 2.7 Primer sequences used in quantitative RT-PCR experiments. ........................................................... 84 
Table 5.1 Influx of 32P activity as sodium phosphate into Xenopus oocytes. .................................................. 147 
Table 5.2 Direct comparison of influx of 32PPi and 32P into variously cRNA-injected oocytes. ..................... 151 
Table 5.3 Influx of 32P activity as sodium pyrophosphate into Xenopus oocytes ............................................ 154 
Table 5.4 Efflux of 32P activity as sodium pyrophosphate from Xenopus oocytes. ......................................... 164 
Table 5.5 Efflux of 32P activity as sodium pyrophosphate from Xenopus oocytes under trans-stimulation 
conditions. .............................................................................................................................................. 166 
Table 5.6 Efflux of 32P activity as ATP/ from Xenopus oocytes. ................................................................. 167 
Table 5.7 and Figure 5.11 Efflux of 32P activity as sodium pyrophosphate from Xenopus oocytes co-injected 
with ANKH-pcDNA3.1 cRNA and human kidney total RNA. .............................................................. 171 
Table 5.8 Positive interacting clones obtained from a yeast two-hybrid screen of an N-terminal ANK fragment.
 ................................................................................................................................................................ 173 
Table 6.1 Some of the genes differentially expressed on AVP-stimulation of mpkCCDcl4 cells. .................... 202 
Table 6.2 Prediction of functional CREs on promoters of mouse genes. ........................................................ 209 
Table 6.3 Results of real time RT-PCR amplification of mpkCCDcl4 samples with and without AVP treatment.
 ................................................................................................................................................................ 216 
Table 6.4 Melting temperatures (°C) for amplification products of experimental samples using ANK-specific 
optimised primers. .................................................................................................................................. 217
Table 6.5 Cp values and fold change calculations for RT-PCR amplification. ............................................... 218 
xiii 
ABBREVIATIONS 
ADH anti-diuretic hormone (=AVP) 
AMP adenosine monophosphate 
ANK progressive ankylosis protein (italics denotes gene name)* 
AQP2 aquaporin-2 
ARCA anti-reverse cap analogue 
ATP adenosine triphosphate 
AVP arginine vasopressin 
BSA bovine serum albumin 
CaPPi calcium pyrophosphate 
CAPS N-cyclohexyl-3-aminopropanesulfonic acid buffer 
CCAL2 chondrocalcinosis type 2 
CCD cortical collecting duct 
cDNA complementary deoxyribose nucleic acid 
CDS coding sequence 
CMD craniometaphyseal dysplasia 
CPPD calcium pyrophosphate deposition disease 
CRE cAMP response element (DNA sequence) 
CREB cAMP response element-binding protein (transcription factor) 
cRNA capped ribose nucleic acid 
dNTP deoxyribonucleotide triphosphate 
dpm disintegrations per minute 
EGTA ethylene glycol tetraacetic acid (chelating agent) 
ePPi extracellular pyrophosphate 
FITC fluorescein isothiocyanate 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GITC guanidine isothiocyanate 
HEK (HEK 293) Human Embryonic Kidney cells 
HPLC High performance liquid chromatography 
IMAGE Integrated Molecular Analysis of Genomes and their 
Expression  
IMCD inner medullary collecting duct 
mpkCCDcl4 murine cortical collecting duct clone 4 cell line 
mRNA messenger ribose nucleic acid 
NAD nicotinamide adenine dinucleotide (NADH is the reduced 
form) 
NIV normalised intensity value 
NPP nucleotide pyrophosphatase phosphodiesterase 
NTPDase nucleoside triphosphate diphosphohydrolase 





PVDF polyvinylidene fluoride 
qPCR quantitative polymerase chain reaction 
RT reverse transcriptase 
RT-PCR  reverse transcriptase – polymerase chain reaction 
xiv 
SNP  single nucleotide polymorphism 
TBE tris-borate ethylenediaminetetraacetic acid buffer 
TNAP tissue-nonspecific alkaline phosphatase 
TRITC tetramethyl rhodamine isothiocyanate 
UDPG uridine diphosphoglucose 
UTP uridine triphosphate 
UTR untranslated region 
UV ultraviolet
* ANK denotes either mouse ANK or ANK generically; whereas ANKH specifically 
denotes human ANK protein, although both terms are increasingly used interchangeably in 
the literature. 











The kidneys maintain salt and water balance in the body by filtering, secreting and 
reabsorbing solutes, and by reabsorbing water from the resulting urine, such that less than 
1% of the total glomerular filtrate is lost. Net solute loss and water reabsorption causes the 
concentration of calcium and phosphate salts in the filtrate to exceed their normal limit of 
solubility resulting in a state of metastable supersaturation especially in the renal distal 
tubule and collecting ducts. Similarly, solutes may accumulate in the renal medullary 
interstitium due to tubular transport and recycling. Calcium stone formation may be initiated 
in the interstitium from a nidus (initiating crystal deposit) of calcium phosphate 
(hydroxyapatite) (Evan et al., 2003), even in the case of idiopathic calcium oxalate stones. 
As metastable saturation of calcium salts increases, the risk of crystallisation increases 
logarithmically. Yet calcification of the tubule lumen or interstitial matrix ultimately leading 
to formation of urinary stones occurs in only a small percentage of individuals. This 
calcification is prevented by inhibitory substances in urine such as citrate, magnesium, and 
urinary proteins together with cellular processes that limit crystal retention and subsequent 
agglomeration (Sayer et al., 2004; Costa-Bauza et al., 2005; Verkoelen & Verhulst, 2007). 
One of the most potent of these crystal inhibitors is pyrophosphate (PPi) (Fleisch & Bisaz, 
1962; Sidhu et al., 1986). PPi binds to the surface of hydroxyapatite (calcium phosphate) 
crystals, directly inhibiting their growth (Jung et al., 1973). 




It has been known for many years that pyrophosphate (PPi) is a potent inhibitor of 
hydroxyapatite crystallisation in the skeleton (Fleisch & Bisaz, 1962; Russell, 1976). Excess 
extracellular PPi inhibits this mineralisation, whereas a higher inorganic phosphate (Pi) : 
PPi ratio leads to increased mineralisation. Too high an extracellular PPi concentration can 
however lead to deposition of crystals of calcium pyrophosphate (CPPD disease, a form of 
chondrocalcinosis). A balance must therefore exist between these opposing effects of PPi, 
and mechanisms must operate both intracellularly (where most PPi is produced) and 
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extracellularly (where most of its crystal inhibitory effects occur) to prevent aberrant 
crystallisation. Mechanisms may include compartmentalisation in membranes or hydrolysis 
of PPi by PPases. Decreased extracellular PPi is now being suggested as an aetiological 
factor in the pathophysiology of uraemic vascular calcification (Lomashvili et al., 2005; 




PPi is involved in many aspects of eukaryotic cellular physiology. It is generated as part of 
numerous reactions that synthesise and modify nucleotides, coenzymes and non-essential 
amino acids. Many of these reactions have been known about since the 1950s (listed in 
Chapter 1 of (Heinonen, 2001), and the source of PPi is often a nucleotide triphosphate 
(such as ATP) (Rachow & Ryan, 1988). Accordingly, in vivo PPi turnover studies suggest 
that most PPi metabolism is intracellular (Jung et al., 1970), yet its crystal inhibitory effects 
are mainly extracellular (Harmey et al., 2004). For example, the PPi concentration in rat 
liver is relatively high at 130 M, as measured by Davidson & Halestrap (1988; 
concentration calculated in Heinonen, 2001, p. 61), with over 90% of PPi being located in 
mitochondria. This is much higher than in extracellular body fluids such as human urine 
(15-32 M; Baykov & Avaeva, 1982) and human plasma (1.8-3.5 M; (Silcox & McCarty, 
1973; Russell et al., 1971); 1-6 M (Russell, 1976)), and the large difference may account 
for some of the variability in PPi concentrations measured in extracellular fluids. These data 
suggest that PPi is highly segregated into cellular compartments, which necessitates 
movement of the highly charged PPi ion across membranes. Unnecessary hydrolysis of PPi 
would waste energy as heat unless coupled to other processes, suggesting that PPi transport 
must occur either as the free ion, as a complex with another ion (for example calcium), or 
possibly as ATP itself. Although PPi can be generated extracellularly by the action of the 
NPP enzymes, this would not account for PPi movement between compartments. However, 




PPi has until recently always been measured by indirect assays. The first step was typically 
to separate PPi from other phosphate-containing compounds by ion-exchange 
chromatography (Russell et al., 1971), sometimes coupled with boiling to inactivate PPases 
(Russell & Hodgkinson, 1966). The PPi was then either acid hydrolysed and measured as 
phosphate or measured enzymatically by PPi consumption during the formation of UTP 
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from UDPG (Flodgaard & Fleron, 1974). More recently, a zinc-containing organic PPi 
sensor molecule has been developed, which fluoresces in direct proportion to the PPi 
concentration (Dong Hoon et al., 2004). No published reports exist of re-measurement of 
PPi in tissues using such technology, which is a one-step process that is highly selective for 
PPi over other anions also commonly found such as inorganic phosphate and ATP.  




The ANKH gene on chromosome 5p encodes a 492-amino acid 54.3 kDa (Ho et al., 2000) 
multipass transmembrane protein. In mice, a truncating mutation in ANK causes basic 
calcium phosphate deposition, leading to progressive ankylosis (fusion) of joints, giving the 
gene its name.  There is significant conservation of this gene across many vertebrate species 
and the human homologue ANKH is virtually identical to ANK in the mouse (Figure 3.2). 
The protein is called ANKH in humans and ANK in mice, although, perhaps because of 





Mutations affecting the ANK gene in both mouse and humans can cause a range of diseases, 
with most published work in the early 2000s concentrating on bone and joint diseases. The 
phenotypes are either calcium PPi deposition disease (CPPD) or progressive ankylosis 
depending on whether the ANK mutation is activating or inactivating, respectively.  
Ho et al. (2000) were the first to show that ANK has a role in PPi transport. Fibroblasts 
cultured from mutant ANKank/ank mice showed increased intracellular PPi but decreased 
extracellular PPi levels compared to control fibroblasts from wild-type mice. Transfection 
of the mutant fibroblasts to allow expression of normal ANK protein rescued these changes, 
consistent with ANK-mediated PPi transport from cell to medium. This transport could be 
blocked by probenecid at 2.5 mM, a non-specific anion transport inhibitor. More recently, 
expression of ANK in Xenopus oocytes has confirmed 32PPi influx into the oocytes which 
showed saturation by external PPi with an apparent Km of ~2 M (Gurley et al., 2006b). 
ANK is therefore unlikely to be simply an anion channel but little else is known about ANK 
function (whether facilitated transporter, symporter or antiporter) and its specificity with 
respect to anions such as phosphate or even ATP (suggested by (Ryan, 2001).  










Since the role of PPi as a crystal inhibitor had been known for many years, the findings of 
Ho et al. (2000) implicated ANK (ANKH in humans) as a candidate gene in disorders of 
crystallisation. This was enhanced by the observation that the mutations for two disorders of 
calcification, the familial CPPD subtype CCAL2 (OMIM 118600) and craniometaphyseal 
dysplasia (OMIM 123000), were both located on chromosome 5p, the same region as the 
ANKH gene (Nurnberg et al., 1997; Ho et al., 2000). Polymorphisms in the ANKH gene are 
now known that can cause an increase or decrease in gene function, and are found in these 
calcification disorders (Table 1.1). Genetic studies for CCAL2 had identified three 
mutations, M48T, E490del and -11CT, in different families. Pendleton et al. (2002) 
reconstructed these mutations in a full-length ANK expression construct followed by 
transfection into COS-7 cells. This showed a significant increase in measured PPi transport 
extracellularly in vitro when compared to a known inactivating mouse mutant. Although 
this finding suggested increased ANKH gene activity for each mutation, it was found to be 
non-significant with respect to wild type ANKH, and an unchanged subcellular distribution 
of a similar transfected construct for the M48T mutation was recently confirmed by Carr et 
al. (2007). Similarly, three inactivating mutations (two in-frame single amino acid deletions 
and one insertion) were identified by Reichenberger et al. (2001) by direct sequencing in 
families with CMD, although they did not measure PPi levels to confirm the mechanism. 
Interestingly, in all cases these mutations occur in the cytosolic domains of the ANKH 
protein.   
Mutations in the ANKH gene may thus be associated with gain or loss of ANKH function. 
These single gene disorders suggest that ANKH is an important component of PPi 
metabolism in human bone and joints. However, they do not shed light on the mechanism of 
ANKH function. It is unclear whether PPi transport occurs by transport via ANKH itself or 
whether ANKH is associated with a separate PPi transporter. Other transporters of PPi may 
also exist. ANK function in bone is known to be modulated by intracellular and 
extracellular factors (Harmey et al., 2004) but regulation of its function in the kidney is 
unknown. 










1. Chondrocalcinosis type 2 (CCAL2) 
Deposition of calcium pyrophosphate 
dihydrate crystals causing acute attacks of 
pseudogout in large joints. Mild, late onset. 
Autosomal dominant CCAL2: 
M48T (gain), E490del (gain) and -11CT 
(gain) (Pendleton et al., 2002) 
Sporadic CCAL2: 
-4-bp G-to-A SNP (5’UTR) (Zhang & 
Brown, 2005). Demonstrated increased 
ANK expression and extracellular PPi in 
vitro. 
2. Seizures in autosomal dominant CCAL: 
Members of one such family experienced 
early childhood seizures : +4 N-terminal 
amino acids added due to premature 
initiation codon, causing likely gain of 
function (McKee et al., 2004). 




restored joint function over 
ANK
null/null
 but no increased PPi 





1. Craniometaphyseal dysplasia (CMD)
Increased mineralisation causes overgrowth 
and sclerosis of the craniofacial bones and 
abnormal modelling of long bone 
metaphyses, but normal joints. 
Autosomal dominant CMD: 
(Reichenberger et al., 2001): TCT1127–
1129 F376del (loss), CTC1122–1124 
S375del (loss), CAG1139–1141 A380ins 
(loss). 
(Nurnberg et al., 2001): W292R, C331R, 
S375del, F377del, P380insA, G389R. 
Sporadic CMD: 
(Zajac et al., 2010): Complex heterozygous 
mutation in exon 7 
2. Possible link to spondyloarthritides 
Association of non-coding ANKH 
polymorphisms suggested by Canales et al.
(2006) and Korkmaz et al. (2005), but not 
confirmed by Sayer et al. (2008). 
3. Possible cause of nephrocalcinosis in 
humans? 
Circumstantial evidence: Hypopyro-
phosphaturia may be a metabolic risk factor 
in recurrent calcium renal stone formers 
(Laminski et al., 1990).
1. Progressive ankylosis  
Two mouse models featuring 
severe ankylosis, indistinguishable 
from each other: 
ANK
ank/ank
 is a naturally occurring 
nonsense mutation causing a 53 
amino acid C-terminal truncation 
(Ho et al., 2000). ANK
null/null
 had an 
identical phenotype to ANK
ank/ank
(Gurley et al., 2006a). 
But not supported in vitro by Carr et 
al. (2007) and Pendleton et al.
(2002).  
2. Craniometaphyseal dysplasia 
C331R and G389R mutations 
(Nurnberg et al., 2001) abolish PPi 
transport in Xenopus and transgenic 
mice (Gurley et al., 2006b) 
suggesting a dominant negative 
effect on ANK.  
F377del homozygous knock-in is a 
mouse model of CMD (Chen et al.,
2009). 
3. Nephrocalcinosis
Increased calcification in the 
kidneys of adult ANK
ank/ank
 mice was 
reported by Ho et al. (2000). 
Table 1.1 Summary of human and mouse disorders of calcification linked to ANK
polymorphisms. Polymorphisms or mutations in the ANK gene causing either an increase or 
decrease in gene function exist in both human and mouse, and may lead to increased extracellular 
PPi which reduces calcification, or vice versa. 
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Nephrocalcinosis describes the effect of a heterogeneous group of diseases which cause an 
increase in the calcium content of the kidney. Many of these causes have now been defined, 
involving specific mutations in genes encoding tubular transporters (reviewed in Sayer et 
al., 2004). The location of the initial calcium deposits may indicate separate 
pathophysiological entities. Interstitial deposits initially at the renal papilla give rise to 
Randall’s plaques which may eventually rupture through the papillary epithelium to form 
stones within the renal calyces (Evan et al., 2006). Tubular nephrocalcinosis, in contrast, 
results in intratubular deposits that may block urine flow directly (Verkoelen & Verhulst, 







Fleisch & Bisaz (1962) first demonstrated PPi as an inhibitor of calcification routinely 
present in human urine, at concentrations of ~10 M (range 8-32 M; March et al., 2001; 
Baykov & Avaeva, 1982). PPi excreted in urine appears to be relatively stable, with 
complete recovery from an anion exchange resin being possible (March et al., 2001). 
Twenty-four hour urinary outputs of PPi are positively correlated with urine volume 
(Roberts et al., 1992) but PPi is elevated in the most concentrated (low volume) samples 
(Roberts et al., 1992). Calcium stone formers appear, on balance, to show reduced urinary 
PPi excretion (Baumann et al., 1977; Wikström et al., 1983; Roberts et al., 1992), and in a 
group of 107 patients with recurrent calcium stones, 48% had reduced urinary PPi:creatinine 
ratios compared to control subjects (Laminski et al., 1990). 
As already noted, PPi directly inhibits hydroxyapatite crystal growth (Jung et al., 1973). In 
vitro, PPi at concentrations similar to those in normal urine (~30 M) effectively prevents 
crystallisation of hydroxyapatite in artificial urines (Grases et al., 2000; March et al., 2001). 
However PPi is not the only inhibitor of crystallisation. Others include citrate, phytate, 
magnesium, glycosaminoglycans and polyanionic proteins including uromodulin (Tamm-
Horsfall protein) and osteopontin. Osteopontin is synthesised within rat and human kidney 
cells and is excreted in urine. It is normally present at the apical surface of the distal tubule 
in normal cells, but its synthesis is further increased following toxic or ischaemic stress 
(Verstrepen et al., 2001; Verhulst et al., 2002). Some of these crystallisation inhibitors may 
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also act synergistically, for example, PPi and citrate have been shown to have a synergistic 
effect in artificial urine in preventing hydroxyapatite formation (Costa-Bauza et al., 2002), 
and similarly molecular modelling studies suggest that there may be additive effects on 
control of oxalate crystal growth with more than one inhibitor (Qiu et al., 2004). Taken 
together, this evidence strongly suggests that urinary PPi is capable of inhibiting urinary 
calcification at naturally occurring PPi concentrations in the urine, and its effect may be 









Ho et al. (2000) demonstrated in mice that inactivation of ANK not only disrupts skeletal 
mineralisation, but also causes renal calcification. In contrast, the phenotype of disordered 
ANKH gene function in the human kidney is largely unexplored. If ANKH is mutated, might 
we expect a clinical correlation between kidney stones and apatite deposition? In 
spondyloarthritides such as ankylosing spondylitis, large amounts of apatite are deposited 
(Sampson et al., 1991) and the mutant ANKank/ank mouse has been regarded as a valid model 
of this (Mahowald et al., 1988). Polymorphisms in two different regions of the ANKH gene 
were found to be associated with ankylosing spondylitis (Tsui et al., 2005) although this 
linkage remains controversial (Timms et al., 2003). A clinical study (Canales et al., 2006) 
found that there was a higher incidence of kidney stone formation in patients with 
spondyloarthritides compared to rheumatoid arthritis patients (who do not experience apatite 
deposition) as controls, even after correcting for drug use and other stone risk factors. They 







The extracellular PPi concentration is limited by enzymes with inorganic pyrophosphatase 
activity (alkaline and acid phosphatases). Intracellularly, PPi is compartmentalised in 
organelles (e.g. Davidson & Halestrap, 1988) and requires a channel or specific transporter 
to cross cell membranes (Terkeltaub, 2001). As a result, there is little PPi present in the 
cytosol. In bone, chondrocytes are a source of PPi (Ryan et al., 1981), but most PPi present 
in plasma arises from liver metabolism (Rachow & Ryan, 1988). However, 32PPi injected 
intravenously into dogs is rapidly hydrolysed in plasma with PPi also being filtered at the 
glomerulus and subject to further hydrolysis within the kidney, such that less than 5% of 
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intravenous 32PPi appears in urine (Jung et al., 1970). The kidney expresses alkaline 
phosphatases which hydrolyse PPi to inorganic phosphate. Both the intestinal form of 
alkaline phosphatase and the tissue non-specific form of alkaline phosphatase (TNAP) are 
present in kidney (Nouwen & De Broe, 1994). ‘Intestinal’ alkaline phosphatase is restricted 
to the pars recta (S3) of the proximal tubule whilst TNAP is expressed along the proximal 
tubule in the S1, S2 and S3 segments (Nouwen & De Broe, 1994). The proximal location of 
these alkaline phosphatase isozymes ensures that the majority of PPi delivered by 
glomerular filtration will be rapidly hydrolysed. The physiologically important increase in 







Apart from glomerular filtration and intracellular origin routes, PPi in the kidney can also be 
formed entirely extracellularly. ATP has been detected at various locations along the rat 
tubule lumen (Vekaria et al., 2006b) where it may be secreted by proximal tubular cells in 
response to flow stimuli (Jensen et al., 2007). It is then rapidly subjected to enzymatic 
degradation (Vekaria et al., 2006a) by NTPDase and NPP ectoenzymes present in the 
tubule. Hydrolysis of nucleotide triphosphates by NPP enzymes generates PPi. Due to the 
proximal localisation of phosphatases and the relatively small amount of extracellular ATP, 










By far the largest source of PPi generation is as a product of intracellular reactions. Ho et al. 
(2000) showed that ANK functions in the membrane transport of PPi, and demonstrated 
using Northern blotting, that ank mRNA is expressed in many mouse tissues other than 
joints including heart, brain, liver, spleen, lung and muscle, but importantly also kidney. 
The pathological effect of abnormal ANKH function on bones and joints is now accepted 
(section 1.3.3 above), and we hypothesise a similar role for ANKH in suppressing 
inappropriate mineralisation within the urinary system. Indeed, mutant ANKank/ank mice 
exhibit nephrocalcinosis (Ho et al., 2000). Similarities between kidney and joints in this 
regard include the fact that both have cells expressing ANK in areas where extracellular PPi 
is present, and both have an important need to prevent or regulate crystal formation in the 
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ANK expression has been confirmed by RT-PCR in mouse kidney and the model collecting
duct cell-line, mIMCD-3 (Carr et al., 2007). Immunohistochemistry of mouse kidney 
sections showed ANK immunofluorescence in cortical collecting ducts when identified by 
co-staining with aquaporin-2 (Carr et al., 2007). No immunofluorescence was observed in 
the rest of the nephron, including all segments of the proximal tubule, although there was 
weak staining of glomeruli. ANK expression is therefore prominent in those segments of the 
nephron downstream from the alkaline phosphatase-expressing proximal segments. 
In the mIMCD-3 cell-line and in mouse kidney sections, immunofluorescence showed ANK 
to be present at both the apical and basolateral membranes (Carr et al., 2007). 
Overexpression of an ANK-GFP fusion protein in mIMCD-3 cells demonstrated 
colocalisation with both the endoplasmic reticulum and mitochondria (Carr et al., 2007). An 
N-terminal GFP-tagged construct containing the inactivating mutation G440X, of mutant 
ANK
ank/ank mice, resulted in disruption of ANK-GFP trafficking to the cell membrane with 
retention within the endoplasmic reticulum/Golgi apparatus. Mitochondrial localisation was 
unaffected (Carr et al., 2007). ANK-mediated PPi transport across both apical and 
basolateral membranes may therefore occur, allowing locally generated PPi to participate in 








Scanning the ANK protein for potential serine/threonine phosphorylation sites and 
combining this with transmembrane topology (ten or twelve segments, as suggested by Ho
et al. (2000) and Nurnberg et al. (2001) respectively) indicates multiple potential 
cytoplasmic sites for PKA-mediated phosphorylation. The sub-cellular distribution of ANK 
overlaps with that of aquaporin-2 (AQP2) in principal cells (Carr et al., 2007) which 
suggests that the overall activity and perhaps membrane traffic of both proteins is co-
ordinated. In a state of systemic dehydration, arginine vasopressin activates V2 receptors 
causing an increase in adenylate cyclase activity. This will not only increase cAMP but also 
increase intracellular PPi as a substrate for ANK-mediated transport. However evidence for 
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the acute regulation of ANK is still required.  










The notion that extracellular PPi inhibits hydroxyapatite formation within the kidney was 
first proposed in the 1960s. It is clear that the majority of PPi production is intracellular, and 
transport of this highly charged species across membranes is essential but its mechanism has 
still not been elucidated. ANK is now conclusively implicated in the regulation of bone 
mineralisation in both mouse and humans. However little work has been performed in the 
kidney despite there being a physiological need for constitutive inhibition of renal calcium 
crystallisation, the localisation of ANK in the murine nephron segment where this is most 
likely to occur and the demonstration that ANKank/ank mice exhibit renal calcification. 
Clarification of ANK’s physiological role in the kidney may enhance our understanding of a 
key physiological mechanism in the prevention of renal calcium crystallisation. 
, 0*#	

We hypothesise that ANKH has a central role in the transport of PPi across membranes in 
the renal tubule.  
There are no published data on human renal ANKH expression. The first part of this thesis 
will examine the expression and localisation of ANKH in human kidney, demonstrating its 
localisation to the distal nephron and collecting duct segments. Using the method of Gurdon 
et al. (1971), ANKH-containing constructs are heterologously expressed in Xenopus oocytes 
enabling a wide range of flux experiments to be performed. This will allow insights into the 
molecular mechanism of ANK-mediated PPi membrane transport. Finally, given the 
similarity of localisation of ANK and the water channel aquaporin-2, we will explore the 
regulation of ANK and whether there may be a similar regulatory mechanism for both 
proteins which would potentially be of physiological benefit.  
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2 Materials and Methods 
2.1 Human renal tissue 
 &

Tissue was collected from the normal pole of nephrectomised specimens at the Freeman 
Hospital, Newcastle upon Tyne. Ethical approval was obtained from the Sunderland Local 
Research Ethics Committee. Kidney tissue was obtained after informed consent from 
patients undergoing nephrectomy for renal cell carcinoma subject to the following exclusion 
criteria: serum creatinine > 140 mol/l, history of renal stones, nephrocalcinosis or arthritis, 
currently taking bisphosphonate medication, or any evidence of renal scarring. 
Tissue was immediately removed to a renal preservation solution (Ahmad et al., 2006) at 4 
°C and transported to the laboratory on ice. The solution was made up as: sucrose 140 mM, 
Na2HPO4 42.3 mM and NaH2PO4 26.7 mM in distilled water. This was pH corrected to 7.4, 
and followed by autoclaving, aliquoting into sterile containers and storage at 4 °C until 
required for use. This solution has been shown to be superior to other commonly used 
solutions in the preservation of renal tissue after warm ischaemia (Ahmad et al., 2006).  
 #

Tissue was cut on ice in a Class II hood and either stored in RNAlater (Sigma) for future 
RNA extraction or immediately snap frozen in liquid nitrogen-cooled isopentane (2-
methylbutane). This allowed rapid freezing without boiling of liquid nitrogen which could 
damage tissue morphology.  Surplus tissue was disposed of as clinical waste. Cubes of 5 
mm edge length from each of cortex and medulla were mounted using OCT onto a cork 
block and stored at -80 °C until used as described in sections 2.5.6.1.   
2.2 RT-PCR of ANKH from whole tissue and cell culture lines 
 '""
RT-PCR was used for detection and amplification of ANK(H) mRNA from whole human 
kidney and the cell lines HEK and mpkCCDcl4, to allow sequencing of ANK(H). cDNA in 
the form of IMAGE clones could be amplified directly using PCR with gene specific 
primers. 
Total RNA was obtained from human kidney and the cell lines using the RNeasy midi kit 
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(Qiagen). Extracted RNA was reverse transcribed according to the protocol of the 
Omniscript RT kit (Qiagen). Negative controls omitted RNA or reverse transcriptase. 
HotStarTaq DNA polymerase (Qiagen) was used for PCR; negative controls omitted DNA. 
Direct sequencing (Lark Technologies, Essex, UK and MWG, Germany) was used to 





The RNeasy midi kit (Qiagen Ltd, West Sussex, UK) was used to extract total RNA. Spin 
columns contain a silica-gel membrane which adsorbs RNA under high salt conditions, 
allowing elution of bound RNA with water.  
 &
Cell layers could be lysed directly in the culture dish after washing with phosphate buffered 
saline (PBS), by exposure to a highly denaturing guanidine isothiocyanate (GITC) 
containing lysis buffer. This buffer immediately inactivates RNases to ensure isolation of 
intact RNA. Following lysis the sample was homogenised by passing through a 20-gauge 
needle several times. Ethanol was added to provide appropriate binding conditions, and the 
sample was then applied to the RNeasy column containing the silica-gel membrane which 
bound the RNA. Following washing with supplied buffers, the RNA was eluted in 150 l 
RNase-free water, and quality and quantity determined by UV adsorption at 260 nm and 
280 nm with the use of a spectrophotometer (Eppendorf supplied by VWR International 




The Qiagen kit contained a protocol to optimise RNA yield and purity from tissue samples. 
This was important as the total yield of mRNA is only about 2% of total RNA extracted. 
Fresh tissue transported in media (see section 2.1) on ice was stored immediately upon 
receipt in RNAlater RNA stabilisation reagent (Sigma) at 4°C overnight then at -20 °C long 
term. The stabilised tissue was homogenised in the GITC-containing lysis buffer using a 
rotor-stator homogeniser (Qiagen) for 30-60 seconds, and the mixture then centrifuged for 
10 min at 3000x g. The pellet was discarded, ethanol added and the protocol above was then 
followed. 






An RNA-dependent DNA polymerase (reverse transcriptase) was used to obtain cDNA 
from a total RNA template, using the Omniscript RT kit (Qiagen). Each 20 l RT reaction 
contained a final concentration of 1 X RT buffer (Qiagen, proprietary composition), 2 mM 
dNTP mix (dATP, dGTP, dCTP and dTTP at a concentration of 0.5 mM each), 1 M 
random hexanucleotide (n6NTP) primers (or oligo-dT primer), 10 units of RNase inhibitor 
(Promega, Southampton, UK), 4 units of Omniscript reverse transcriptase enzyme, and total 
RNA template (typically 0.5-2 g total RNA, eluted in water) made up to 20 l with RNase 
free water. 
RNase free water, RNA and n6NTP primers were incubated for 10 minutes at 65 °C and 
then placed on ice for 2 minutes to denature the RNA. The remaining reagents were added 
and incubated at 37 °C for 1 h to allow for synthesis of cDNA, followed by an incubation of 
3 minutes at 95 °C to inactivate any remaining enzyme, before proceeding directly to a PCR 
reaction. Incubations were carried out in a thermal cycler (Hybaid, UK). Negative controls 
omitted either RNA, or RT enzyme to ensure no genomic DNA contamination. All reactions 





The polymerase chain reaction (PCR) allows rapid and exponential amplification of a 
specific piece of DNA in vitro. The HotStarTaq PCR kits (Qiagen) included a Taq DNA 
polymerase that has been modified to prevent activity and hence formation of misprimed 
products and primer dimers at low temperatures. A 25 l PCR reaction mix was prepared, 
comprising final concentrations of 1 x PCR reaction buffer, 1.5 mM MgCl2 (contained in 
PCR buffer), 100 M of each dNTP, 0.1 - 0.5 M forward primer, 0.1 - 0.5 M reverse 
primer, 2.5 units HotStarTaq DNA polymerase,  1 g cDNA template from the RT 
reaction and molecular biology grade water to the final reaction volume. Negative controls 
were set up in parallel in which the cDNA template was replaced with either an equal 
volume of the RT negative controls, or an equal volume of molecular biology grade water 
(PCR negative control). All reactions were performed in 0.2 ml microfuge tubes 
(Eppendorf, supplied by VWR International Ltd.). 
The reaction tubes were placed in a thermal cycler (Hybaid) and heated to 95 °C for 15 
minutes allowing activation of the HotStarTaq polymerase. The three step process of 
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denaturation, annealing and extension involved in PCR was then initiated. The reaction mix 
was heated for 30 seconds at 94 °C in order to denature the DNA template strands. The 
temperature was then lowered to a specific optimum annealing temperate for 30 seconds to 
allow the pair of oligonucleotide primers to bind to their complementary DNA sequences on 
the single target strands (annealing). Finally, the temperature was raised to 72 °C for 1 
minute to allow the DNA polymerase enzyme to extend the primers, using the target strand 
as template (extension), producing a new complementary DNA strand of the original strand. 
This three step process was carried out for 35-40 cycles generating an exponential increase 
in the number of copies of target sequence. At the end of the reaction, the extension time 
was lengthened to 10 min.  
, 	
Gene-specific oligonucleotide primers were designed to allow PCR amplification of either 
sections (Figure 2.1) or the full-length of ANK(H). Amplified products were then used for 
cloning, sequencing and cRNA synthesis. Oligonucleotide primers were either designed or 
were included with cloning kits. A full list is included in Table 2.1. 
Primer pairs were designed using Primer3 software1 from available database sequences 
(Ensembl) according to the following guidelines: a similar adenine (A) / thymine (T) to 
guanine (G) / cytosine (C) ratio, with one or two G or C residues at the 3’ end for extension 
stability; avoidance of internal homology and homology between primer pairs to prevent 
binding to self or primer dimerisation; and similar melting temperature (Tm) of each 
member of the pair. Primer sequences were verified for specificity using the Basic Local 
Alignment Search Tool2 (BLAST). For example, the primer pair JS 600F and 601R was 
originally designed for an internal mouse ANK product spanning exon-exon boundaries. 
BLAST search of the human genome confirmed that this sequence uniquely matched exons 
2, 3 and 4 of ANKH. Designed primers were custom made by VHBio Limited (Gateshead, 
UK) and supplied as a dried pellet. Prior to use, oligonucleotides were resuspended in 
molecular biology grade water to a concentration of 100 M, which were diluted further to a 
working concentration of 10 M and stored at -20 °C. 
                                                
1 http://frodo.wi.mit.edu/primer3 
2 www.ncbi.nlm.nih.gov/blast 





Primer sequences (forward / reverse, 








JS 600F CATCACCAACATAGCCATCG 490 58 Detection of internal product of mouse 
ANK or human ANKH 
JS 601R CCAGGTGACTGTGAAGCAAA 
β-actin F TCCACGAAACTACCTTCAAC 682 52 Detection of β-actin in human tissue 
and mpkCCDcl4 cells  β-actin R TTTAGGATGGCAAGGGAC 
SM 201F AGATGTGTGTGGGGTCAGC 397 58 Primer combination to amplify 
contiguous sequences from ANKH 
coding sequence (see Figure 2.1) SM 202R CGTCCACATGGTGCAGTTTA 
SM 210F CTGCCGTCTTTCACACACTG    699 57 Primer combination to amplify 
contiguous sequences from ANKH 
coding sequence (see Figure 2.1) SM 211R CGAAGGTGAACTTCTTGATGTG 
SM 212F GTGAGCACGAGCAACACAGT    597 57 Primer combination to amplify 
contiguous sequences from ANKH 
coding sequence (see Figure 2.1) SM 213R GCCGAAGTGTCATCCTGACT    
GC 206F ATGGTGAAATTCCCGGCG 1479 60 Cloning using GFP Fusion TOPO TA 
Expression kit; Attempted 
amplification of full-length human 
ANKH 
GC 207R TTATTCATTCTCCTCTCTCATTTCCAC 
SM 401F CACCATGGACTACAAAGACC 1566 55 FLAG F and ANKH R  primers for 
blunt-ended amplification with proof 
reading polymerase of full length 
ANKH-NT-3XFLAG, allowing 
subcloning into T7-containing vector 
GC 207R TTATTCATTCTCCTCTCTCATTTCCAC 
GC 208F CGACATCATCCCTGACAGAAG - - Sequencing primer for full-length 
ANKH-NT-GFP 
T7EEV AAGGCTAGAGTACTTAATACGA - - T7 forward primer (Promega cat 
Q6700) designed for sequencing in 
pTNT vector (used for ligated ANKH-
pTNT construct with SM 202R) 
T7F TAATACGACTCACTATAGGG - - For sequencing ANK(H) cloned into 
pcDNA3.1 expression vector 
BGH R TAGAAGGCACAGTCGAGG 
SM 300F CACCATGGTGAAATTCCCGGCG - - Amplification of full length ANKH for 
directional cloning into pcDNA3.1 Dir 
vector. The initiation codon 
(underlined) falls within a Kozak 
sequence for optimum translation 
Table 2.1 Oligonucleotide primers. Primer names prefixed with two letter codes were designed; 
others were bought or included with kits. Primer pairs designed specifically for amplification of 
contiguous portions of ANKH coding sequence are shown on the map in Figure 2.1. 
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Figure 2.1 Map of primer combinations designed to amplify contiguous sequences from ANKH 
coding sequence 
(Carr et al., 2007) 
(Pendleton et al., 2002; Canales et al., 2006) 
(Korkmaz et al., 2005; Sayer et al., 2008) 
(Wang et al., 2009) 




PCR products were separated by electrophoresis through an agarose gel. Typically, 
following PCR amplification, 10 l of each reaction was removed and mixed with 2 l 5x 
gel electrophoresis loading buffer (Promega). The samples were then loaded into the wells 
of a 1-2% agarose gel in 1x TBE buffer containing a final concentration of 0.5 g/ml 
ethidium bromide. PCR products were electrophoresed alongside an appropriate DNA size 
marker (O’Generuler, Fermentas) at 80 V for up to 60 minutes in 1x TBE buffer. Gels were 
viewed using a UV transilluminator (Alpha Innotech Corporation), and the digitised image 
was processed with an AlphaImager 1200 software analysis system. 
PCR products required for subsequent cloning and sequence analysis were excised under 
UV light using a clean scalpel, and DNA extracted and purified using a gel extraction kit 
(Sigma). Extracted DNA was eluted into 30 l of molecular biology grade water and 
quantified by spectrophotometry. 




Attempts at making a full length ANKH expression clone from human mRNA were 
unsuccessful (section 3.2.3) so an IMAGE clone (IMAGE: 3927236; MGC: 15102; 
corresponding RefSeq mRNA: NM_054027.3) containing the full length ANKH coding 
sequence in a pOTB7 (drosophila) plasmid expression vector in E. coli was obtained from 
Geneservice (Cambridge, UK). The pOTB7 plasmid also contained a gene conferring 
chloramphenicol resistance. This clone is cDNA and therefore contains no introns. 
However, previous work on ANK using the Xenopus oocyte expression system used 
amphibian (pOX) and mammalian (pcDNA3) expression vectors (Gurley et al., 2006b), the 
former containing 5’ and 3’ UTR sequences from frog β-globin. Subcloning was therefore 
performed from pOTB7 to other vectors, by amplification of the ANKH coding sequence 
(ATG to stop codon), gel extraction and recloning into the new vector (supplied linearised) 
to enable expression of mammalian protein in Xenopus oocytes.  














The cloning reaction consisted of 3 l fresh PCR product, 1 l of salt solution, 1 l of 
pcDNA3.1 vector (±NT-GFP) and 1 l molecular biology grade water. The reactants were 
mixed gently, incubated for 10 minutes at room temperature then placed on ice. The product 




2 l of the plasmid was added to a vial of either TOP10TM chemically competent E.coli
(Invitrogen) or to NEBTM 5-alpha F´Iq High Efficiency Competent E. coli (New England 
Biosciences, cat C2992), mixed gently and incubated on ice for 30 minutes. The cells were 
‘heat shocked’ for 30 s at 42 °C, without shaking in a heat block. The tubes were 
immediately transferred to ice and incubated for 5 minutes, then 950 l of room temperature 
SOC outgrowth medium (provided in kit) was added and the tube shaken horizontally at 250 
rpm in an incubator for 60 minutes at 37 °C. A 50 l aliquot from the transformation was 
spread on a pre-warmed Luria-Bertani (LB) agar plate containing ampicillin (125 g/ml) 






Colonies were selected to inoculate a duplicate LB plate containing ampicillin and allowed 
to grow for a further 12-24 h, to allow expansion of the clone before screening directly 
using PCR. A standard PCR reaction using internal ANK primers (Table) was set up, with 
the initial 95 °C incubation step allowing release of bacterial DNA. Colonies wire-looped 
directly from the duplicate plate provided DNA template. Products were analysed using 2% 
agarose gel electrophoresis. 
$ #
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Positive recombinant colonies identified by PCR screening were cultured overnight in 1 ml 
LB broth containing ampicillin 125 g/ml, in aerobic eppendorf tubes on a benchtop vial 
shaker (Eppendorf) at 200 rpm at 37 °C. Glycerol stocks were prepared by mixing 200 l of 
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cultured broth with 800 l of 50% sterile glycerol, and stored at -80 °C. This stock could be 
defrosted and used to inoculate further LB broth. The plasmid DNA was isolated and 
purified using the QIAprep miniprep protocol with the use of a microcentrifuge (Qiagen 










The NT-GFP Fusion TOPO™ TA Expression Kit was utilised to allow insertion of the PCR 
DNA into the vector pcDNA3.1/NT-GFP (Invitrogen), allowing expression of the cloned 
ANKH product with GFP fused to the N-terminus of ANKH. This vector incorporates a 
gene conferring ampicillin resistance. This ‘TA’ cloning method exploits the addition by 
Taq DNA polymerase of a single deoxyadenosine to the 3’ ends of the PCR product. These 
3’ A overhangs are used to insert the PCR product into the expression vector which has 
complementary T overhangs at the insertion site, so that restriction digestion is not required. 
Transformation was into TOP10 cells. 
The sequenced ANKH-NT-GFP contig (Figure 2.2) was checked for reading frame3 then 
BLAST search was performed4. This showed 100% identity with the amino acid sequence 








The pcDNA™3.1 Directional TOPO® Expression Kit (Invitrogen, cat. no. K4900-01) was 
used. This vector has the advantage of ensuring cloning of the PCR product in the correct 
orientation by the addition of four bases (CACC) to the forward primer which are 
complementary to the overhang in the cloning vector (GTGG). This overhang invades the 5’ 
end of the PCR product, annealing to the CACC of the insert, resulting in correct orientation 
efficiencies of > 90%. Attempted transformation into TOP10 cells resulted in no colonies 
(although colonies were obtained with the kit’s positive transformation control), 
necessitating use of NEB 5-alpha F´Iq High Efficiency cells. The protocol was otherwise as 
described above, and sequencing confirmed correct orientation of the insert into the vector 
(Figure 2.3). 
                                                
3 www.ncbi.nlm.nih.gov/projects/gorf/ 
4 http://blast.ncbi.nlm.nih.gov/Blast.cgi 
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Figure 2.2 Sequencing of ANKH-NT-GFP construct 
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Figure 2.3 Sequencing of ANKH-pcDNA3.1 construct 






The pTNT vector (Promega, aliquot kindly donated by Prof F Karet, Cambridge) has been 
previously used in Xenopus experiments (Edashige et al., 2007; Fronius et al., 2010) and 
contains a 5’ β-globin leader sequence which can enhance gene expression (Falcone & 
Andrews, 1991).   
In two separate reactions, 1 g of closed pTNT vector and 1 g of ANKH-pcDNA3.1 were 
double-digested in order to obtain a linearised vector with “sticky ends” and an insert with 
appropriate restriction sites, respectively. Reactions consisted of: 5 l of 10x NEB Buffer 2, 
0.5 l of 100x BSA, 1 l of each of the restriction enzymes NotI and KpnI, and 1 g of 
DNA, made up to 50 l with molecular grade water. These were incubated at 37 °C for 90 
min, then run on a PCR clean-up column (Qiagen) and eluted in water to concentrate and 
purify the DNA. The cut DNA was separated from supercoiled DNA on a 1% agarose gel, 
then cut out from the gel and gel purified to obtain pure linearised DNA; the vector being 
5249 bp and the insert 1538 bp.  
Vector and insert were ligated at “sticky ends” using T4 DNA ligase (NEB, cat. no. 
M0202S), as follows: 1 l of 10x buffer, 0.5 l of T4 DNA ligase, and 0.5-3 l of vector 
and insert such that they were each present in separate reactions as vector:insert molar ratios 
of 1:1, 3:1 and 1:3. The reaction was made up to 10 l with molecular grade water, and 
incubated at room temperature for 40 minutes. Negative controls omitted insert (causing 
religation of the vector) or omitted both insert and T4 DNA ligase (double digested vector 
only, giving rise to very few colonies). All five ligation reactions were terminated by 
heating at 65 °C for 10 min, followed by transformation of each DNA into NEB 5-alpha 
F´Iq High Efficiency Competent E. coli. PCR screening of duplicate plates was performed 
using T7EEV as forward (T7 EEV Promoter primer, Promega cat Q6700) and SM 202R as 
reverse primers (Table 2.1). Sequencing confirmed β-globin upstream and in-frame with 











2.3.3.4.1 The FLAG tag 
The FLAG® (Sigma) tag is a hydrophilic antigenic epitope consisting of only eight amino 
acids (DYKDDDDK), synthetically-designed for minimal size but maximum exposure on 
the surface of the folded protein (Einhauer & Jungbauer, 2001). The 3XFLAG® tandem 
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repeat (DYKDHDGDYKDHDIDYKDDDK; ~3 kDa) enhances the sensitivity of FLAG by 
10-fold, making it particularly useful for detection of proteins that are low-abundance or 
difficult to express. The tag is preferably inserted at the 5' end of the gene of interest to 
promote good initiation of translation (Einhauer & Jungbauer, 2001).  
2.3.3.4.2 Method of subcloning 
ANKH-NT-3XFLAG in pReceiver-M12 vector was obtained from GeneCopoeia (product 
Mm01188). This product corresponded to NM_020332.2, but direct sequencing in our 
laboratory revealed the coding sequence to exactly correspond to human ANKH. In order to 
make cRNA for injection into oocytes, subcloning into a T7-containing expression vector 
was necessary.  
The strategy was as follows. The original clone was single-digested using NotI restriction 
enzyme and digestion verified on a 1% gel. This band was then cut out and gel purified in 
order to prevent carryover of old vector in the subsequent PCR reaction. PCR was 
performed using a proofreading DNA polymerase (Phusion, Finnzymes) as follows: 10 l of 
5xPhusion buffer HF, 1 l of 10mM dNTP, 2.5 l each of SM 401F and GC 207R full-
length primers, 0.5 l of Phusion DNA polymerase, and 8 ng of single-digested DNA 
template. PCR conditions were modified as follows: activation , 98 °C for 30 s; and 35 
cycles comprising denaturation,  98 °C for 20 s, annealing,  55 °C for 30 s, extension 72 °C 
for 30 s. The amplified ANKH-NT-3XFLAG insert was verified for size and a single band 
on a 1% gel, and was then cloned into pcDNA3.1 TOPO vector and transformed into NEB 
5-alpha F´Iq High Efficiency cells using the protocols above. Sequencing of plasmid DNA 
using SM 202R confirmed that T7 was upstream and in-frame with ANKH-NT-3XFLAG 
(Figure 2.5).   
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Figure 2.4 Sequencing of ANKH-pTNT construct  
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Figure 2.5 Sequencing of ANKH-NT-3XFLAG construct subcloned into a T7-containing mammalian 
expression vector 
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2.4 Preparation of capped RNA for oocyte micro-injection 
$ '""
Protein synthesis in the Xenopus oocyte expression system is best achieved by micro-
injection of capped RNA (cRNA) making the RNA analogous to mRNA. The 7-
methylguanosine cap is a modified nucleotide at the 5’ end of the molecule allowing it to 
maintain stability during protein synthesis and acting as the start point for transcription by 
RNA polymerase. The mMESSAGE mMACHINE T7 Ultra kit (Ambion) modifies this by 
altering a nearby hydroxyl group in order to ensure transcription initiation by T7 RNA 
polymerase in the correct orientation. The kit incorporates other ways of maximising cRNA 
yield such as high nucleotide concentrations and an RNase inhibitor. Linearised plasmid 
DNA that contains a T7 RNA polymerase promoter site is used as template for in vitro
transcription. The cloning strategies and preparation techniques described in section 2.3 





Plasmid DNA was first linearised using a restriction enzyme as follows. NEBcutter V2.05
was used to identify a restriction enzyme that would cleave each vector only once, 
downstream of the insert, and without cleaving the insert itself (see Table 2.2). The 
following reaction was assembled on ice: 5 l of 10x NEB Buffer 2, 0.5 l of 100x BSA, 1 
l of restriction enzyme and 1 g of DNA, made up to 50 l with molecular grade water. 
This was incubated at 37 °C for 2 h then put on ice to stop the reaction. An aliquot of 1 l 






Ethanol precipitation was employed to recover pure DNA as well as increasing its 
concentration. To the ~50 l sample, 0.1 volumes of 3 M sodium acetate and 2.5 volumes of 
95% ethanol were added, which terminated the digest. The sample was frozen at -80 °C for 
                                                
5 http://tools.neb.com/NEBcutter2 
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10 min, then centrifuged at 14000x g for 20 min at 4 °C to pellet the DNA. Supernatant was 
aspirated using a sterile freshly pulled fine glass pipette, and the pellet rinsed in 100 l of 
70% ethanol at -20 °C, pipetted gently down the opposite side to the pellet. The tube was 
centrifuged again for 10 min as above, then re-aspirated and left to dry in air at room 
temperature for a few minutes to remove any traces of ethanol. The DNA was then 
resuspended in 5 l of molecular grade water. 
$ +
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RNase-free consumables were used, other equipment and benches were decontaminated 
with RNase AWAY™ (Sigma) and pipettes subjected to UV crosslinking (Stratalinker®, 
Stratagene). The following were added to the pure linearised DNA in water at room 
temperature: 10 l of T7 2x NTP/ARCA, 2 l of 10x T7 reaction buffer, 2 l of T7 RNA 
polymerase enzyme mix, 1 l of RNaseI inhibitor. The reaction was gently mixed, briefly 
microfuged and incubated at 37 °C for 2 h. Post-reaction DNase treatment to remove 
template, and poly(A)-tailing to increase mRNA proportion, are not usually required for 
oocyte microinjection applications. The cRNA end product was diluted with molecular 
grade RNase-free water, quantified by spectrophotometry, and stored as single-use aliquots 
at -80 °C.  
$ #	
Using these methods, cRNA was made for constructs as shown in Table 2.2. This was 
complemented by total RNA extracted from mouse cell lines and human renal tissue (Table 
2.3). 

















NotI or XbaI IF, 
Flux 
NaPi-IIb pSPORT1 Flounder NaPi-IIb Kindly gifted 





















Mouse mANK-GFP Kindly 
obtained from 






























Table 2.2 Summary of constructs used for synthesis of cRNA, and their usage in downstream 
applications. All vectors contained a T7 promoter and were ampicillin-resistant. IF, 
immunofluorescence.  
Total RNA type Species Origin of construct Usage 
CCD control Mouse Extracted from mpkCCDcl4 cells Flux 
CCD forskolin- 
treated 
Mouse Extracted from forskolin-treated 
mpkCCDcl4 cells 
Flux 
Human kidney Human Extracted from human tissue Flux
Table 2.3 Total RNA types extracted from cells and tissues for co-injection in flux 
experiments.  





Membrane proteins present in human renal tissue sections, in cells grown on permeable 
filters and in Xenopus oocytes were detected by immunofluorescent staining using primary 
and secondary antibodies, with visualisation of localisation using a confocal microscope. 
, 4*

Fixation and permeabilisation was performed using methanol for 15 minutes at -20 °C (4 h 
at 4 °C for oocytes). Tissue due to be treated with anti-CD98 antibody required fixation 
using 2% paraformaldehyde in PBS for 1 h (4 h for oocytes) on ice (4 °C), with or without 
subsequent permeabilisation by 0.1% Triton X100. Similarity of results with and without 
permeabilisation would only be expected of proteins at the membrane. 
, 	
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Specific details of antibody use are given in the Results chapters. General details of the 
primary antibodies used are given in Table 2.4. 
















P Ab3 Meth Rabbit 1:250 4°C, 
overnight 
Generous 
gift from Dr 
Kingsley, 
Stanford 
















AQP2 Human P  Meth Goat 1:250 Room 
temp, 1 h 
Santa Cruz 
sc-28629 








hAE1 Human M  Meth Mouse 1:10 4°C, 
overnight 
Generous 
gift from Dr 
A Toye, 
Bristol 
GFP - M Conjugated 
to HRP 








Human P  Meth Sheep  Room 






Human P  Meth Goat 1:100 Room 
temp, 1 h 
Santa Cruz 
sc-7691 





FLAG - M Anti-FLAG 
M2 








Table 2.4 Primary antibodies used for immunofluorescence studies. P = polyclonal, M = 
monoclonal, Conc = concentration. 






Secondary antibodies appropriate to the primary antibody (Alexa Fluor®, Molecular 
Probes), corresponding to the wavelengths for either FITC (488) or TRITC (568), were used 
at 1:100 at room temperature for 1 h.   
,, 3
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Non-specific binding sites were blocked by incubating fixed material with 3% normal horse 
serum (Sigma; diluted in PBS) for 30 – 60 minutes at room temperature on a glass slide. 
The primary antibody/antibodies was diluted in blocking solution, applied to the specimen 
on the slide and incubated. The specimen was washed three times with PBS then incubated 
with secondary block (3% normal goat or donkey serum) at room temperature for 30-60 
minutes. Bound primary antibody was detected by incubation with secondary antibody 
diluted in secondary blocking solution and incubated for 1 h at room temperature. Following 
rinsing in PBS, slides were prepared by applying a tiny drop of Vectashield fluorescence 
mounting medium (Vector Laboratories, Peterborough, UK) between a coverslip and the 





Unfixed tissue blocks (section 2.1.2) were removed from storage at -80 °C and were cut into 
10-12 m sections on a cryotome and immediately transferred onto poly-L-lysine coated 
glass slides (Histobond). Sections were then fixed, permeabilised, and stained using the 
protocol above. 
Predominantly cortical tissue was used; the area below the capsule consisting of medullary 
rays (tubules perpendicular to the capsule, extending into the medulla) and cortical labyrinth 
(containing glomeruli, proximal and distal tubules).  
,1 &
Cells were grown on sterile filters (Transwell cat. no. 3401; 12 mm diameter, 0.4 m pore 
size). Six days after seeding, resistance of the cell layers was confirmed before and after any 
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agonist treatment. Filters were washed in PBS, fixed with ice-cold methanol for 15 min, 
then removed from the plastic Transwell insert and divided into four portions to enable 
control experiments to be performed on the same cell layer. Primary block was performed 
on each filter segment while on an orbital shaker at 100 rpm. Antibody solutions were then 
applied by inverting individual filter segments onto the appropriate drop of solution.  
,1 '
Injected oocytes were incubated for at least 72 h to allow maximum expression (Manoharan
et al., 2006) then fixed for 4 h at 4 °C in either methanol (Rungroj et al., 2004) or 2% 
paraformaldehyde in PBS. They were transferred to 30% w/v sucrose in PBS at 4 °C 
overnight, then embedded in OCT compound on a block of cork, having first drained all 
sucrose media by temporarily placing the oocyte on top of another drop of OCT. Such 
oocytes were fragile, and the least traumatic way of handling them was found to be with a 
plastic Pasteur pipette. The embedded oocyte was flash frozen in liquid nitrogen and a 
cryotome used to cut 15-20 m sections onto poly-L-lysine coated glass slides (Histobond). 
Blocks could be stored for up to 4 weeks at -80 °C, and sections for up to 24 h at -20 °C. 
Sections were stained using the protocol in section 2.5.5. 
,5 &
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Optical sections of stained tissue were obtained using a confocal laser scanning microscopy 
(CLSM) system (Leica TCS-NT). Fluorescent antibodies and GFP fusion proteins were 
excited by focused krypton-argon laser light, allowing very thin (micrometre) sections to be 
visualised. Filter sets for FITC (excitation 488 nm, emission 519 nm), TRITC (excitation 
568 nm, emission 572 nm) and transmitted light were used to image series in x-y or x-z
planes, using x40 (numerical aperture (NA) 0.70) lens, or x63 (NA 1.32) or x100 (NA 1.40) 
oil immersion lens.  Within an experiment, identical imaging, illumination intensity and 
photo-multiplier settings were maintained.  
Pixel quantification (in arbitrary units) of mid-cell xy sections was performed using Leica 
TCS-NT analysis software in order to compare the intensity of two simultaneous stains in 
one section.  
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Protein samples were analysed by sodium dodecyl sulphate (SDS) polyacrylamide gel 
electrophoresis (PAGE). The detergent SDS denatures proteins which then become 
negatively charged and migrate according to size when electrophoresed. Following 
separation, proteins were transferred to a PVDF membrane to allow probing with a specific 
antibody. A secondary antibody conjugated to the enzyme horseradish peroxidase (HRP) 








Protein lysate from renal cortex of each of three human subjects (H, J, K) was prepared 
from tissue previously stored in RNA later. Diced tissue was homogenised using 30 strokes 
of a glass homogeniser on ice in sucrose/Tris lysis buffer, followed by centrifugation at 
10,000x g for 10 min at 4 °C to pellet debris. The supernatant protein lysate was quantified 
by Bradford assay and stored at -80 °C.  
1 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Oocytes microinjected with cRNA or water three days earlier (allowing time for protein 
expression) were lysed in order to isolate total oocyte membranes. The lysis buffer was 
freshly made and resembled the composition of ORII (see section 2.8.1): 10 mM HEPES 
and 83 mM NaCl buffered to pH 7.9 and made up to 100 ml with water before adding a 
protease inhibitor cocktail tablet (‘Complete’, Roche). 20-50 oocytes were added to this 
buffer (20 l /oocyte), and membranes ruptured in a glass homogeniser using 20 strokes on 
ice. The mixture was centrifuged initially at 500x g for 5 min at 4 °C to remove debris. The 
surface fat layer was gently skimmed off using a cut P1000 pipette tip and the supernatant 
gently aspirated from the debris layer at the bottom. The supernatant was ultra-centrifuged 
at 100 000x g for 1 h at 4 °C (Beckman Coulter Optima with TLS55 rotor). The resulting 
membrane pellet was washed with ice-cold lysis buffer, resuspended in fresh lysis buffer (1 
l /oocyte), quantified by Bradford assay and stored at -80 °C.  





Protein lysate (10-50 g per lane) was heated for 10 min at 85 °C with sample buffer 
containing -mercaptoethanol; these reducing conditions causing protein denaturation. Each 
sample was loaded and run on a 4% (stacking)-10% (running) SDS-polyacrylamide gel at 
30 mA for 1 h with MOPS (3-(N-morpholino) propane sulfonic acid) running buffer to 




Separated proteins on the gel were then transferred onto a PVDF membrane (Hybond-P, 
Pharmacia Biotech, UK). Filter paper was pre-soaked in transfer buffer (10% CAPS [Sigma 
C2632], 10% methanol, 80% water), and a sandwich assembled (from anode to cathode) of: 
sponge pad, filter paper x2, PVDF membrane, gel, filter paper x2, sponge pad. Transfer was 
carried out overnight in a cassette with a current of 50 mA running through the transfer 
buffer. 









Conc. Incubation Source 
Primary antibodies 
C-terminal ANK (Ab3) Rabbit 1:250 4 °C, overnight Generous gift from Dr 
Kingsley, Stanford 
N-terminal ANKH Rabbit 1:200 4 °C, overnight Santa Cruz sc-67242 
CD98 Goat 1:500 4 °C, overnight Santa Cruz sc-7095 
β-actin Mouse 1:1000 Room temp, 2 h Abcam ab6276 
Pre-immune serum Rabbit 1:500 4 °C, overnight Davids Biotechnologie, 
Germany 
Secondary antibodies 
anti-goat IgG-HRP  1:2500 Room temp, 1 h Dako P0160
anti-rabbit IgG-HRP  1:10,000 Room temp, 1 h Amersham  NA9340 
Conjugated antibodies 
anti-FLAG (M2)- HRP 
(monoclonal) 
Mouse 1:200 Room temp, 1 h Sigma A8592 
Table 2.5 Antibodies used in Western blotting experiments. Conc., concentration
PVDF membranes were probed for proteins using antibodies as shown in Table 2.5. Non-
specific antibody binding sites were blocked by incubation in 5% w/v skimmed milk 
powder in TBS/0.1% Tween (20 mM Tris buffer, 137 mM NaCl, 0.1% Tween-20, pH 7.6) 
for 1 h at room temperature on a rocking table. The membrane was then incubated overnight 
at 4 °C in primary antibody diluted at the required concentration in milk protein-
TBS/Tween using a rotary swirler. Controls omitted primary antibody. The membrane was 
washed three times with TBS/Tween then incubated with appropriate diluted secondary 
antibody conjugated to HRP for 1 h at room temperature, followed by another series of 
washes. 
The membrane was incubated for 5 minutes with a chemiluminescent substrate detection kit 
(ECL Plus, Amersham Biosciences), generating photons in the presence of HRP which were 
detected with autoradiography film (Kodak) after exposure for 1-10 minutes. If required, the 
membrane was then stripped (Restore Western Stripping Buffer, Pierce) with confirmation 
of antibody removal and reprobed with another primary antibody. Finally, the membrane 
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was stained with copper phthalocyanine to demonstrate adequate and equal protein transfer 
across the membrane. 
2.7 Tissue culture procedures 
Tissue culture procedures were performed in class II vertical laminar flow hoods (Jouan 
MSC12, Jouan Ltd, Herts UK) with sterile handling techniques. Culture media, media 
supplements and consumables were obtained sterile or sterilised before use by high pressure 
and temperature autoclave, overnight baking at 162 °C in a hot air oven, or filter 
sterilisation, as appropriate. 
5 &

In order to study nephron-specific localisation in vitro, oncogene-transfected cell lines have 
been developed in order to enhance cell proliferation. Advantages over primary culture 
include the availability of a continuous source of cells, improved phenotypic 
reproducibility, ability to alter the cellular environment over the medium-term, and often 
greater purity of the population of cells of a particular type.  
5 !0 7
The HEK293 cell-line was established from primary cultures of human embryonic kidney 
which were transformed by sheared human adenovirus type 5 DNA (Graham et al., 1977) 
and retain some features of tubular epithelial cells (Simmons, 1990). Cells were grown in 
Modified Essential Medium Eagle’s (MEME), supplemented by glutamine (2 mM), non-
essential amino acids 10% v/v, fetal bovine serum and 100 g / 500 ml penicillin 
/streptomycin. Passages 71-74 were used.  
5 	#&&2$
The murine cortical collecting duct clone 4 (mpkCCDcl4) cell line is a clonal epithelial cell 
line known to be sodium transporting and responsive to aldosterone and vasopressin 
(Robert-Nicoud et al., 2001). The line was microdissected from kidneys of a transgenic 
mouse carrying the simian virus 40 large T antigen gene under the regulatory control of the 
L-type pyruvate kinase promoter (SV-PK/Tag; (Bens et al., 1999)). Cells were generously 
gifted by Professor Alain Vandewalle (INSERM, Paris). 
mpkCCDcl4 was cultured in Ham’s F12/Dulbecco’s Modified Eagle’s Medium (DMEM) 1:1 
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v/v with: 60 nM sodium selenate; 5 g/ml transferrin; 2 mM glutamine; 50 nM 
dexamethasone; 1 nM triidothyronine; 10 ng/ml epidermal growth factor; 5 g/ml insulin; 
20 mM D-glucose; 2% fetal calf serum; 20 mM HEPES at pH 7.4; 100 U/ml penicillin and 
100 g/ml streptomycin. Passages 38-47 were used. 
5 &
Cells were incubated at 37 °C, with a humidified atmosphere of 5 % CO2 in air. Cells were 
passaged weekly and media replaced as necessary.  
Permeable TranswellTM filter supports (12 mm diameter, 0.4 m pore size; Corning Inc Life 
Sciences, USA) were employed to grow confluent polarised epithelial layers of mpkCCDcl4
cells. Cells were seeded onto the filters at 2 x 105 cells / cm2 and incubated for 6-10 days in 
supplemented DMEM/F12 medium, with medium replacement every 2 - 3 days. By day 6 a 
significant transepithelial resistance (2.9 ± 0.3 kcm2, n=140) and spontaneous p.d. (6-13 
mV basal solution electropositive) were observed that was associated with transepithelial 
Na+ absorption. The basal epithelial surface was incubated with arginine vasopressin (AVP; 
10 nM), forskolin (10 M, Sigma F6886) or control media for 24 h. RNA was then 
extracted or monolayers were fixed for immunofluorescence by methanol immersion as 
described in section 2.5.6.2. 
5 +#
Cells were subcultured when confluent as determined by light microscopy. Media was 
removed and cells washed three times with sterile PBS and incubated with 0.05 % v/v 
trypsin and 0.02 % ethylenediaminetetraacetic acid (EDTA) in Earle’s balanced salt solution 
at 37 °C until cells were detached (20-30 minutes). The trypsinised cells were then decanted 
into a universal container and cell culture media was added to deactivate the trypsinisation 
reaction. Centrifugation of the cell suspension was not performed in order to avoid the 
possibility of cell damage. Cells were resuspended by passing through a wide bore needle 
several times and cell number determined using an electronic cell counter (Coulter). Cells 
were used to seed new flasks (approximately 2.5 x 105 cells in 75 cm2 flask) or coverslips (2 
x 105 cells per 13 mm-diameter coverslip), culturing with the appropriate media. 
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Mature female Xenopus laevis frogs (Xenopus Express, France) were housed in the 
Comparative Biology Centre at Newcastle University. The frogs were killed by an approved 
Schedule 1 method and the ovaries removed. Ovaries were cut into small clumps and 
digested with collagenase A (2 mg/ml) (Roche Diagnostics GmbH, Manheim, Germany) in 
ORII solution (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, 10 mM HEPES, pH 7.5) for 60-
120 min. Collagenase treatment was stopped by washing the oocytes six times, first in ORII 
solution and then in Barth’s solution (88 mM NaCl, 1 mM KCl, 0.82 mM MgSO4, 0.41 mM 
CaCl2, 0.33 mM Ca(NO3)2, 2.4 mM NaHCO3, 10 mM HEPES, pH 7.5 plus 0.02 mg/ml 
gentamicin).  Healthy stage V/VI oocytes (those with defined vegetal and animal poles) 




A glass cannula was heated and stretched to produce a needle of small diameter for 
microinjection of oocytes (PUL-1 micropipette puller, World Precision Instruments Ltd., 
Stevenage, UK). The needle was filled with paraffin oil dyed with Oil Red O (BDH, VWR 
International) and attached to a micro-injector (Drummond ‘nanoject’, Drummond 
Scientific Company, Pennsylvania, USA). Needles were backfilled with either cRNA 
diluted in RNase-free water or RNase-free water alone. Oocytes were placed on to a plastic 
mesh and bathed in Barth’s solution. Using a light microscope, oocytes were injected in the 
centre of the vegetal pole (yellow hemisphere) with a volume of 50.6 nl of either cRNA or 
water. The injected oocytes were maintained at 18 ºC for 3 days in Barth’s solution to allow 
expression of the protein encoded by the injected cRNA (Figure 2.12). To compensate for 
the death of some oocytes over the incubation period, 150-200% of the required number of 
oocytes were injected. In experiments involving co-injection of ANKH cRNA and human 
kidney total RNA, the former was used in excess, as used by Kowalczuk (Kowalczuk et al., 
2008). Oocytes were re-injected after 3-day incubation with labelled substrate for efflux 
experiments.  
8 
Substrates (listed in Table 2.6) were labelled with the high-energy β-emitting isotope 32P 
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(Perkin-Elmer, USA). As a result, intra-oocyte activity could be accurately quantified, even 
if the cell had not been completely lysed. In addition, detection would occur even if the 
substrate is subsequently metabolised. 
Radiolabelled 
tracer & product 
code 










05081F8 96.6 88.58 3.28 
05081F8 96.6 88.58 3.28 
08081J7 81.7 88.37 3.27 
10081K7 97.3 107.28 3.97 
01091H7 85.6 84.13 3.11 





09118/1 5 3000 111 
01229/1 5 3000 111 
05149/1 5 3000 111 
ATP-[α-32P]
BLU003X
07318/1 10 800 29.6 
Pi
NEX063001MC




080723 0.1 0.055 0.002 
Table 2.6 Radiolabelled substrates. All were obtained from PerkinElmer; catalogue numbers are 
shown. 





Radioactivity was dispensed according to the laboratory safety protocol in a dedicated 
room. 200 l aliquots of each radiolabelled solution were prepared for each experimental 
condition, along with a little extra to enable calculation of standards.  
Usually ten oocytes per experimental condition were aimed for; this allowed for variation 
between oocytes and loss of some oocytes through rupture. The oocytes were washed in 
groups in 2 x 500 ml volumes of wash buffer (100 mM NaCl or choline chloride, 2 mM 
KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, pH adjusted to 7.4 with Tris base) then 
transferred to a 5 ml polystyrene tube. Residual wash buffer was removed using a Pasteur 
pipette (to avoid damage to the oocytes) and replaced at timed intervals with 200 l of 
appropriate uptake solution. Uptake solutions comprised the radiolabelled substrate diluted 
in wash buffer. Experiments were incubated in the climate-controlled oocyte room (18 °C) 
usually over 40 min.   
Following incubation, uptake solution was removed using a pipette and the oocytes were 
washed by addition of 5 ml ice-cold (to prevent further ion flux) wash buffer to the test tube.  
The wash buffer was removed by aspiration and the oocytes were washed a further three 
times. Individual oocytes were then placed into scintillation vials. 2 ml of scintillation 
cocktail (Optiphase Hisafe 2, Perkin Elmer) was added to each vial, which was then 
vortexed for a few seconds. 4 x 10l samples were taken from each radiolabelled uptake 
solution and counted alongside the oocyte samples to provide a standard reference for each 
experiment. Uptake of [32P]-substrate was measured by scintillation counting over 5 minutes 
per sample using standard settings for 32P isotope, and the results expressed as fmol per 
oocyte per hour.  
An influx experiment at zero-time was performed by immersing oocytes into uptake 
solution then immediately removing, washing and counting the activity in the usual way 
(Table 5.3, ANKH-FLAG, influx time =0). There was no increase in influx into the ANKH-





The principle was to pre-inject the radiolabelled substrate into each previously cRNA- or 
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water-injected oocyte immediately before the start of the efflux experiment. As the 
functions of relevant transporters were unknown, preloading by incubation (as in (Scott & 
Karniski, 2000)) was not possible.  
Radioactivity was dispensed as above, either undiluted or diluted into either potassium 
chloride 150 mM or unlabelled PPi as required. 24 oocytes in each cRNA-injected group 
were aimed for, requiring ~30 healthy oocytes. This included a few standards to calibrate 
the initial labelled activity and concentration (section 2.8.6.3.3). Oocytes were injected 
using the micro-injector behind suitable shielding. Substrate-injected oocytes were washed 
twice by transferring into two beakers of wash buffer at room temperature using a Pasteur 
pipette, to remove any surface-bound 32P.  
8, 
To start the efflux measurement, oocytes were transferred individually into 1 ml of ordinary 
wash buffer (time = 0) in separate wells in a 24-well plate. Unlabelled PPi was added to the 
room temperature wash buffer if needed for trans-stimulation experiments. A cut-off and 
sanded P1000 filter pipette tip was used to pick up individual oocytes while minimising 
trauma. A minimal setting on the Gilson pipette meant that a constant extra 50 l of wash 
buffer was also transferred with the oocyte, but was necessary in order to keep the 
membrane intact during transfer. Oocytes were left at 18 °C to efflux for the desired time 
period (usually 2-4 hours), and the plate was gently shaken periodically to dissipate any 
gradient surrounding the oocyte (as suggested in Chapter 3 of (Baldwin, 2000)).
After incubation, each oocyte was again individually transferred into a scintillation vial, and 
the buffer solution for that oocyte was transferred into a separate paired scintillation vial. 
This allowed calculation of the efflux as a percentage of the total activity in the system 
(oocyte plus buffer solution), a measure that other groups have used (Jutabha et al., 2003). 
Standard oocytes (which were injected with labelled substrate but did not participate in 
efflux) for each cRNA-type were also placed individually into vials, as well as a blank vial 
(to estimate background) and some 0.5-1 l samples of the labelled substrate solution. Any 
damage to oocytes during pipetting was noted prospectively.  
8, 
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As a result of technique refinement, an alternative method was used for efflux in later 
experiments. Six oocytes were used, with injection and surface washing as above. An initial 
Chapter 2 – Materials and Methods 
__________________________________________________________________________________________________________________________________________ 
56
15-minute “recovery” efflux experiment was performed in a 96-well plate, by placing each 
oocyte into 200 l of buffer solution for 15 minutes. After this incubation, 100 l of this 
solution was drawn off for counting, and the oocyte was transferred (with ~50 l of 
remaining buffer) to a polythene tube. Remaining buffer was carefully removed and 
replaced with 100 l of fresh buffer. After the experimental incubation period, an 80 l 
buffer aliquot was collected for counting, and the oocyte washed/aspirated three times in 
ice-cold buffer before activity was counted. This technique had the advantages of: (a) a 
smaller volume of buffer into which substrate could efflux, allowing a higher concentration 
for counting, (b) intra-oocyte control measurement of any post-injection leak of labelled 
substrate in the first 15 minutes, and (c) further surface wash after efflux solution collection, 




Variations in experimental conditions were made as follows. Unlabelled sodium 
pyrophosphate (Sigma) was added to the room temperature buffer solution for trans-
stimulation experiments. Proton dependence of 32PPi efflux was investigated by varying the 
buffer pH using MES (4-morpholineethanesulfonic acid) for pH 5.5 buffer, HEPES for pH 
7.0 and Tris for pH 8.0. Each additive had a pKa (or pKb) of approximately the final desired 
pH of the buffer.  
8,, 9
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Experiments in which oocyte quality was poor, usually manifested as a significant death rate 
during the three-day incubation, were omitted. Only visibly undamaged oocytes were 
transferred into scintillation vials. Individual data points were only subsequently removed 
from the analysis if there was clear evidence of total or partial oocyte rupture (scintillation 
counts being higher in buffer than intra-oocyte) or non-injection of tracer into an oocyte 









Transport at different substrate concentrations can be resolved into two components: a 
saturable component reflecting Michaelis-Menten kinetics of an expressed transporter, and a 
linear component that is directly proportional to the substrate concentration (Figure 2.6). 
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Water-injected oocytes are used as controls to demonstrate the linear component, which is 
likely to be a combination of: 
- flux occurring due to membrane damage such as trauma caused by oocyte 
injection (this damage is worsened by poor quality oocytes) 
- non-specific binding (mostly removed by washing) 
- simple diffusion (< 2% of the total flux) 
- minor saturable components resulting from the presence of multiple or 
endogenous transporters for the substrate (Baldwin, 2000).  
When substrate concentration is much higher than the Km, the transporters are saturated, and 
the limiting factor is the rate of substrate transport of the transporter-substrate complex. The 
maximal rate of transport (capacity) can thus be determined under these conditions. 
However, at very high substrate concentrations, the linear component is proportionately 
much higher, and non-specific mass effects can result. When substrate concentration is less 
than the Km, then binding of the transporter with its substrate is more important, and the 
substrate concentration itself becomes the limiting factor. Competition with non-labelled 




The rate of flux (gradient of the curve) is greatest at substrate concentrations less than the 
Km. Due to the large size of oocytes there is relatively slow equilibration of transport, 
allowing the initial rate of flux to be sustained for long periods (minutes to hours) (Baldwin, 
2000)), allowing initial flux rates to be determined by experiments conducted over this time 
period. On the other hand, excessively long incubation times can introduce inaccuracies due 
to metabolism/breakdown of substrates over time, inhibitory effects on the transporter, and 
also intra-experiment oocyte death. It is normally not possible to distinguish these from the 
transported component, and so they constitute a source of error in the rate of flux calculated 
from the experiment. In the case of labelled PPi, surface hydrolysis over similar time 
periods (in influx experiments; section 5.2.4) or intracellular hydrolysis (in efflux 
experiments) would result in overestimation of flux due to transport via inorganic phosphate 
transporters.  
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Figure 2.6 Diagram illustrating effect on flux (rate of radiolabel transport) of increasing substrate 
concentration.  




2.8.6.3.1 Problem of cis-inhibition due to decay 
The 32P isotope has a decay half life of 14.3 days. The specific activity (activity per unit 
mass or activity per mole) of the 32P containing isotope therefore decreased markedly over 
only a few weeks, whereas new batches were available only every three months (see 
PerkinElmer website for schedule). At low activity:concentration ratio, the radiolabelled 
tracer molecules are diluted by non-radioactive tracer molecules. This reduces counts per 
minute for any given amount of tracer, which depending on the Km, effectively results in a 
cis-inhibition. This might account for misleadingly low flux results, which may be difficult 
to distinguish from background especially in experiments involving transporters that have 
low transport capacity (Vmax).  
2.8.6.3.2 Optimum specific activity 
The optimum conditions for detection of flux would be high specific activity (SA) of the 
tracer as well as a high enough PPi concentration to activate the transporter, but not so high 
as to result in a significant linear component (see diagram above). In fact, the highest usable 
SA of tracer per oocyte was obtained when the radiolabelled tracer stock was a few weeks 
old. In contrast, fresh stock had very high activity necessitating dilution in either KCl or 
unlabelled PPi. In practice, the actual activity and concentration of labelled substrate used in 
each experiment was variable (see results tables).   
2.8.6.3.3 Calculation of tracer activity 
The decay corrected specific activity (SA) of the undiluted tracer was obtained using a 
decay correction chart (Perkin Elmer datasheets). The SA (in Bq/pmol) was adjusted for 
dilution with wash buffer (influx) or with an excess of either cold PPi or KCl (efflux). The 
total amount of labelled PPi present in the diluted uptake solution (influx) or in the 50 nl of 
diluted stock injected into each oocyte (efflux) was then calculated. In the case of influx 
experiments incorporating experimental conditions aiming to investigate the effect of 
competitive inhibition of labelled substrate (“knockdown”), only the amount of 
radiolabelled substrate was considered. Multiplying the latter two values gives the total 
radioactivity in the uptake solution (influx) or injected into each oocyte (column D in Table 
5.4 -Table 5.6 for efflux). This activity is representative of the total labelled PPi 
concentration available for subsequent flux, but values in column D (Bq) were very 




2.8.6.3.4 Estimation of initial substrate concentration 
In efflux experiments, the initial substrate concentration was corrected for dilution after 
injection into the oocyte. Assuming a diameter of 1 mm, oocyte volume is 5x10-10 m3, so an 
injection of 50nl (5x10-11 m3) of PPi substrate represents a dilution of 10-fold assuming it 
distributes evenly throughout the oocyte. This value is given in column E in Table 5.4 -








Mannitol is an osmotic agent that does not pass through cell membranes. Six previously-
uninjected oocytes were injected with 50 nl of 14C-mannitol and were then either washed 
twice in fresh buffer or not washed before transferring into a well on a 96-well plate. Excess 
buffer was removed and 100 l of oocyte buffer was added. Oocytes were incubated for 
varying time periods, following which the activity of an 80 l aliquot of each incubation 
buffer was counted. This count was adjusted for 100 l and the oocyte’s activity (after three 
ice-cold washes) also counted in order to measure the total activity in each single-oocyte 
system.  
Figure 5.7 A shows that only 1-2% of the initially injected labelled substrate was detected in 
the extracellular buffer solution for time periods up to 2 h, confirming that 14C-mannitol is 
impermeable to the undamaged oocyte membrane. The lack of increase in time suggests that 
the oocyte membrane was intact over this time period. There was no clear difference 
between washed and unwashed oocytes, suggesting that surface binding of 14C-mannitol is 
unimportant (but see section 2.8.7.4 for results with PPi). However, experiments with 32PPi 
may differ in that PPi may be metabolised, oocytes were previously injected with water or 
cRNA, and even a 1% extracellular detection rate may be significant in relation to measured 
32PPi efflux. The second graph (Figure 5.7 B) suggests that for injected 14C-mannitol, post-
injection leakage of isotope is likely to account for the extracellularly detected tracer, rather 
than an effect of surface binding of tracer requiring extensive washing.  
85 "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Though tested as an intended impermeant intracellular marker, Lucifer Yellow proved to be 
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a useful control for injection, intra-oocyte equilibration and efflux. Lucifer Yellow is an 
actively secreted fluorescent organic anion in renal tubules (Masereeuw et al., 1999) 
allowing it to be used as a positive control of the efflux protocol. Lucifer Yellow (di-lithium 
salt, Sigma L0259) was diluted in 50% w/w in water to 400 g /ml final concentration. A 50 
nl aliquot was diluted into 100 l of Barth’s solution and subsequent 1:1 serial dilution 
series made in triplicate. The fluorescence of 50 ul aliquots of each dilution was detected 
using a Tecan Infinite plate reader (section 2.9.1; excitation 425 nm, emission 520 nm). The 
mean fluorescence value of the three separate dilution series was used to generate a standard 
curve (Figure 5.8 A), showing that fluorescence over this range of Lucifer Yellow dilutions 
is proportional to the concentration. 
To measure the time course of Lucifer Yellow exit from oocytes, groups of oocytes were 
injected two days earlier with water, ANKH-pcDNA3.1 cRNA or not-injected. They were 
then re-injected in duplicate with 50 nl of Lucifer Yellow diluted in water as above, briefly 
washed by transfer via Barth’s solution, and incubated for varying lengths of time in 100 l 
of Barth’s, up to 120 min. Following incubation, 50 nl aliquots were removed for 
fluorescence counting, and the mean value obtained. Lucifer Yellow exit was expressed as 
the fluorescence of dye detectable extracellularly after each incubation period, as a 
percentage of that detectable after 120 min incubation. Figure 5.8 shows that there is an 
increase in extracellular fluorescence over time with all three oocyte types, suggesting that 
efflux of dye is occurring at constant rate over 100 min. Efflux (or diffusion) is more likely 
to account for this constant rate of exit than leakage due to membrane puncture. These 
results are in direct contrast to the radiolabelled mannitol efflux data. There is no difference 
between water-injected or ANKH-injected oocytes showing that no non-specific action of 
ANKH protein is evident. It may be concluded that an endogenous transporter is present in 






The modified efflux method outlined in section 2.8.5.3 included a count of bathing buffer 
after 15 minutes, allowing detection of any post-injection leak of labelled substrate prior to 
the main experiment. This leak tended to be less than 5% of the calculated injected 
substrate, and was usually closer to 1-2% (Figure 2.7). 
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Figure 2.7 Effect of prior water-injection on subsequent detection of 
32
P activity in oocytes. 
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Figure 2.8 Contamination of non-injected oocytes with activity acquired from 
surrounding buffer.  
(A) Effect of exposure to surrounding buffer on detectable activity. Oocytes were 
injected 3 days earlier with either water (left pair of bars) or ANKH-pTNT (right pair). 
In each batch, ~50 oocytes were each re-injected with 23 pmol of labelled sodium 
pyrophosphate. Six non-injected oocytes were collected from the buffer solution at 
the end of each injection session, and their mean 32P activity measured (red bars). 
Mean activity of six oocytes which had not been present during injections was 
measured as a control (blue bars). Error bars represent SEM for n = 6 oocytes, p < 
0.01 between pairs of bars.  
(B) Effect of washing on detectable activity.  Oocytes were injected 3 days earlier 
with human kidney cRNA. 6-11 oocytes were collected from each buffer solution at 
the end of injection sessions ("exposed"; left pair of bars) or non-present controls 
as above ("non-exposed"; right pair of bars). In each group, oocytes were either 
washed three times with fresh buffer (pink bars) or not washed (red bars). Errors 
bars represent SEM for n = 2-6 oocytes, * denotes p = 0.02.  
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Fig 2.8 goes here 







It was noted that the radioactive content of the buffer increased during the injection of 
oocytes with radiolabel, and it was important to determine whether this may result in an 
increase in surface binding of activity and if so, whether this was adequately removed by the 
washing protocol. During radiolabel injections of ~50 oocytes bathed in one aliquot of 
oocyte buffer, the activity of six non-injected oocytes was counted at the end of the 
procedure. Figure 2.8 A shows that non-injected oocytes in the same dish become 
contaminated in this way.  
Oocytes treated in this way then underwent three washing/aspiration cycles. This procedure 
significantly reduced (p = 0.02) their activity (Figure 2.8 B). In practice, the oocyte buffer 
was changed frequently during radiolabel injections.  
The equivalent experiment for the influx protocol was performed using water-injected 
oocytes at influx time = 0 (i.e. tracer-labelled buffer added and immediately removed). After 
three washing cycles, the final count was ~10% of that obtained for water-injected oocytes 
at time = 80 min.  








Uninjected control oocytes were used alongside water-injected oocytes as controls, and all 
were injected three days later with labelled substrate. There was no significant difference in 
the amount of 32P detected extracellularly between these conditions (Figure 2.7), during 





Results were obtained as dpm per oocyte. From this, pmol substrate per oocyte (influx 
experiments) or % efflux of the total counts in the system (oocyte + bathing buffer)(efflux 
experiments) were calculated. Obvious instances of partially or totally ruptured oocytes 
were excluded from analysis, e.g. intra-oocyte count lower or similar to extra-oocyte count, 
or >5% loss of counts during the 15-minute recovery period post-injection. However, most 
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exclusions occurred after visually confirming rupture during the experiment. Oocyte quality 
is a very important factor which is known to vary seasonally, with poorer quality over the 
summer months (Baldwin, 2000; Weber 1999). 
The standard error of the mean was calculated. Significance testing against values obtained 
using water-injected oocytes in each experiment was performed using one-tailed t-tests, on 
the grounds that the hypothesis predicted that cRNA-injected oocytes were likely to 




Using Minitab 15® statistical software, tests for variances were performed using Bartlett’s 
(parametric) test rather than an F test, as there were usually more than two levels for each 
factor. In all cases, p was less than 0.05, rejecting the null hypothesis and demonstrating that 
variances were unlikely to be equal. In addition, datasets were unbalanced due to differing 
numbers of oocytes not surviving each experimental condition. This precluded use of two-
way ANOVA. Since flux was the only response variable, a regression method called the 
General Linear Model was used, with Tukey’s method to examine pairwise comparisons 
between means. Significance was accepted at 95%.  
2.9 Pyrophosphate assay 
7 /
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In order to determine endogenous pyrophosphatase activity on the surface of Xenopus
oocytes, measurement was made of the reduction in PPi concentration of a known amount 
of PPi-containing buffer in the presence of oocytes for varying lengths of time. Initial 
attempts employed a coupled enzyme assay using fructose-6-phosphate kinase to convert 
fructose-6-phosphate with PPi to fructose-1,6-diphosphate, followed by D-glyceraldehyde-
3-phosphate and then dihydroxyacetone phosphate. The resulting oxidation of two moles of 
NADH to NAD+ per mole of PPi present are detectable spectrophotometrically (Sigma cat 
no P7275), but attempts were unsuccessful since no difference in PPi was measurable over 
time in the detectable range of this assay (1 mM). To allow lower PPi concentrations to be 
studied, a recently introduced highly sensitive assay kit was used (PhosphoWorks™ 
Fluorimetric Pyrophosphate Assay Kit, ABD Bioquest, California, USA, cat no 21611) in 
which the fluorescence of the proprietary PPi ‘sensor’ compound is proportional to the PPi 
concentration. 50 l samples were analysed for PPi by detection of fluorescence (excitation 
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368 nm, emission 415 nm) using a Tecan Infinite M200 fluorescence plate reader after 30 
minutes incubation with the sensor at room temperature in a UV-range 96-well plate 
(Corning) according to the manufacturer's instructions. Testing by the manufacturers shows 
no interference even in the presence of up to 20 mM of calcium and/or magnesium 
(personal communication).  
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Buffer solutions based on Barth’s solution (section 2.8.1) were made with and without 
calcium and magnesium. A standard dilution series from the 50 mM PPi kit component was 
made using these buffers, and 50 l aliquots were taken from each dilution (in duplicate) to 
allow generation of a standard curve for PPi assay (Figure 5.5). A further 50 l aliquot was 
taken and added to 1 l of PPase enzyme already present in the 96-well plate, and mixed 
carefully. Inorganic PPase (cat I1643, Sigma) was previously diluted in molecular grade 
water to 0.25 units/ l (equating to formation of ~15 mol Pi per hour), so that the enzyme 
was in a large excess compared to PPi. This allowed confirmation of the effect of PPase 
enzyme activity on PPi of varying concentrations. Analysis with the assay kit confirmed that 
PPi activity was reduced to zero in the presence of this amount of PPase except at very high 
PPi concentration (Figure 5.5), confirming specificity of the assay for PPi. 
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Oocyte experiments were performed in the 3.6 M dilution with normal (calcium and 
magnesium-containing) buffer, this dilution being in the middle of the detectable range. 
Storage buffer was carefully aspirated from groups of 7-10 healthy uninjected oocytes in a 
PPi-free eppendorf tube, to which 70 l of 3.6 M PPi-containing buffer was added. 
Oocytes were incubated at 18 °C for varying time periods, including zero time. At the end 
of the incubation timer period, 50 l of experimental buffer was collected, as well as 
simultaneous collection of 50 l of unused 3.6 M PPi buffer. The latter acted as a “no-
oocyte” control to investigate any changes in the buffer over time, e.g. precipitation of PPi.  
Attempts to estimate intracellular PPase by performing PPi assays in the presence of 
centrifuged oocyte lysates were unsuccessful, as the mild turbidity present even after 
lengthy centrifugation caused major interference and failure of the fluorescence assay.  
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Protein complexes, rather than individual proteins, are increasingly recognised as the 
molecular basis of cellular fluxes (Bruckner et al., 2009). However, standard gel 
electrophoresis would cause these complexes to denature. Protein complexes can be purified 
by tagging an epitope, then either immunoprecipitating with a specific antibody or using 
affinity columns which recognise the tag, followed by analysis of the complex using mass 
spectrometry. This method is expensive and time consuming, is not suitable for high 
throughput, and requires detergents to prevent dissociation of membrane protein complexes 
(such as might be important for ANKH function) when the lipid bilayer is disrupted 
(Hooker et al., 2007). In contrast, the yeast two-hybrid system, developed by Fields and 
Song in 1989 (Fields & Song, 1989) allows in vivo detection of interacting protein pairs in 
living yeast cells. Positive interactions activate reporter genes that enable growth on specific 
media (see Figure 2.10 for method and terminology). Since the identity of potential 
interactors (prey) with ANK (bait) was unknown, a mouse kidney cDNA library was used. 
These cDNA fragments aim to cover the entire transcriptome of mouse kidney so increasing 
the sensitivity of the screen (Bruckner et al., 2009) but at the expense of specificity, causing 
a false positive rate of up to 50% (Hooker et al., 2007). 
=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The mouse ANK clone NP_065065 was used. It is highly likely that the fully folded 492-
amino acid ANK protein would not be able to enter the nucleus of the yeast cell, so to 
reduce false negatives it is standard practice to use a representative fragment of the protein, 
although there is an inherent risk of misfolding due to a protein fragment being used and its 
fusion to the DNA-binding domain of the transcription factor. TMHMM6/SMART14
transmembrane domain prediction software predicts eight transmembrane segments in 
ANK, and the N- and C-terminals are both cytoplasmic (Ho et al., 2000). No part of ANK 
corresponds to any known motif/domain as predicted by InterPro7. To our knowledge, there 
is no published work which has used ANK in a yeast two-hybrid system. The screening 
company (see section 2.10.3.1) had neither previously screened ANK nor found it as prey in 
                                                
6 www.cbs.dtu.dk/services/TMHMM 
7 www.ebi.ac.uk/interpro/ 
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a screen. For these reasons, there was little guidance on the choice of optimum ANK 
fragment suitable for a yeast two-hybrid experiment.  
The bait was chosen to be intracellular and avoid transmembrane segments. Since we were 
using a C-terminal anti-ANK antibody (Ab3), we have previously made fusion constructs at 
the N-terminal (ANKH-NT-GFP and ANKH-NT-3XFLAG). Staining and membrane 
localisation of both constructs has been confirmed with Ab3 as well as anti-GFP (Carr et al., 
2007) and anti-FLAG (Chapter 4) antibodies respectively. C-terminal truncation (Carr et al., 
2007) stopped trafficking from the endoplasmic reticulum to the Golgi. Wang et al. (2009) 
showed that the ANK N-terminal M48T mutation abolished interaction between ANK and 
the basolateral sodium/phosphate transporter PiT-1, suggesting that the N-terminal 
contained an interacting site. Hence an N-terminal ANK fragment encompassing this 






Yeast two-hybrid screening was performed by Hybrigenics SA, Paris, France 
(www.hybrigenics-services.com). The coding sequence for amino acids 24-85 of mouse 
ANK (GenBank accession number gi: 157951667) was PCR-amplified generating a product 
with amino acid translation NIAIDFGEQALNRGIAAVKEDAVEMLASYGLAYSL 
MKFFTGPMSDFKNVGLVFVNSKRDRAK. This cDNA fragment was fused to the C-
terminal of the DNA-binding domain (BD) of the transcription factor LexA for optimum 
folding of the bait. This bait construct (N-LexA-Ank(24-85)-C; one of the “hybrids”) was 
cloned into the vector pB27. The construct was checked by sequencing the entire insert and 
using it as bait to screen a random-primed mouse kidney cDNA library containing 10 
million independent fragments constructed into the pP6 vector. Since the library is random, 
each possible kidney DNA could be represented by one or more unique prey fragments or 
even multiple identical fragments. Additionally, only about a third of clones will have the 
correct reading frame, and half of these are likely to be antisense. This initial screen of the 
bait construct allowed identification of the most appropriate selection medium, and 
excluded any autoactivating or toxic effect of the bait itself (the latter leading to no positive 
interacting clones). 
Chapter 2 – Materials and Methods 
__________________________________________________________________________________________________________________________________________ 
70
Figure 2.9 Location of the ANK N-terminal fragment (residues 24-85, in 
orange) used for the bait fusion construct. Transmembrane domain predictions 
were obtained from SMART and the graphics were created using TOPO2 
Transmembrane protein display software (Johns S.J., www.sacs.ucsf.edu/ 
TOPO2/). 
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Figure 2.10 Classical yeast two-hybrid system with ANK as the protein of 
interest.  
A C-terminal fragment of ANK (green) was fused to a DNA binding domain (BD; 
light blue) of a transcription factor, forming a construct called the “bait” (1). Plasmid 
cDNAs coding for potentially interacting proteins P,Q,R,S are each fused to the 
activation domain (AD; yellow) of the same transcription factor – this forms 
constructs called “prey” (2). Once translated, the BD protein binds to the upstream 
activator sequence (dark blue line) of the transcription factor (3). Interaction of the 
“two hybrids” (i.e. bait with prey) allows the BD and AD to function together as a 
transcription factor (4). This allows RNA polymerase II to initiate transcription of the 
reporter gene, in this case His3, within the yeast cell. Its protein product, imidazole 
glycerol phosphate dehydratase, allows yeast cells to grow on a selective medium 
lacking histidine (5). In this way, the process selects out only those cells that 
contained a cDNA plasmid whose protein product directly interacted with ANK.   










An ULTImate Y2H screen (Hybrigenics) was performed, in which the bait construct was 
transformed into yeast cells each containing random fragments from the cDNA library. An 
outline of the experiment is shown in Figure 2.10. This yielded 55.3 million interactions 
(5.5-fold the complexity of the library). After selection on medium lacking histidine, 
growing yeasts represented positive interacting clones, these originally containing two 
hybrid transcription factors which directly interacted, causing activation of the reporter 
gene. The plasmid DNA in these positive yeast colonies was extracted, and the 






The sequences were analysed for reading frame (all F2), submitted as a BLAST query 
against the mouse genome to identify the interacting prey, and the amino acid sequences 
aligned using Multalin8 (Corpet, 1988). The minimum common amino acid domain shared 
by all prey fragments corresponding to the same protein was deduced to be the interacting 
domain. As a post-screening check, the bait construct was also extracted from yeast cells 
and sequenced to verify the integrity of the bait fragment. Bioinformatics software 











The in vivo nature of the technique, specifically overexpression of bait, potential post-
translational deficiencies in the host yeast cell, and necessity to cross the nuclear membrane, 
all contribute to the large number of false positives and negatives in the yeast two-hybrid 
technique. The accuracy of a classic yeast two-hybrid screen such as the present study may 
be only 10% compared to data sets obtained using other techniques (Bruckner et al., 2009). 
It is therefore essential to re-interpret any output from a physiological point of view, and 
then to verify putative interactions experimentally using colocalisation in cell lines or 
functionally using co-immunoprecipitation or functional overexpression (Chapter 5).  
                                                
8 http://multalin.toulouse.inra.fr/multalin/multalin.html 







False positives, which can be up to 50% of putative interactions (Hooker et al., 2007) can 
arise from overexpression of bait and prey, especially if they are in a non-physiological 
subcellular compartment. The possibility of auto-activation of the reporter gene by the bait 
was excluded. Techniques to limit false positives include: selection for more than one 
reporter gene in parallel (increases specificity at the cost of sensitivity), and reconfirmation 
of positive interactions by direct yeast two-hybrid interaction experiments between bait and 
positive preys. An alternative might be to repeat the experiment after swapping DNA 
binding domain-Bait and AD-prey constructs, so that each fuses with the other. 
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False negatives may occur when the bait used does not contain the interacting domain of the 
protein. Other reasons include the inability of yeasts to perform all the post-translational 
modifications or glycosylation necessary for interaction of mammalian proteins. Expression 
levels of bait and prey depend on the yeast promoter used. The protein-protein interaction in 
a yeast two-hybrid experiment occurs in the cytosol, but if the bait-prey membrane protein 
complex is unable to move into the nucleus, transcription of the reporter gene will not 
occur.  









The transcriptome of a cell or cell type can vary over short periods of time and changes with 
the cell's function or environment (e.g. response to hormones), as compared to the genome 
which is stable over time in cells (unless mutations occur). It is a surrogate for the proteome 
which is more difficult to characterise either by protein microarrays or by Western blotting. 
The expression profile of the transcriptome is the pattern of gene expression produced when 
an ANK-expressing tissue of interest is subjected to a physiological intervention. This 
allows functional insights, such as potential molecules involved in the regulation of ANK. 
Since ANK and AQP2 were found to colocalise in human tissue (Chapter 3), mouse tissue 
and mouse cell lines, with clear evidence of co-ordinated regulation ANK and AQP2 in 
AVP-stimulated filter layers of mpkCCDcl4 cells (Chapter 6), AVP was selected as agonist. 
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mpkCCDcl4 cells have previously been shown  to respond to AVP treatment by increased 





Microarray experiments offer the major advantage of being able to study the effects on 
many genes of a single intervention at a point in time without knowing in advance which 
genes might change (Kurella et al., 2001). Negative aspects include: the relatively high cost, 
only one physiological intervention is possible per experiment, the altered transcriptome 
does not necessarily reflect equivalent protein expression, and a large and sometimes 
unwieldy dataset may include false positives. These features render the microarray a 
screening tool, the results of which require subsequent confirmation by other techniques 
such as RT-PCR or immunocytochemistry. 
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Total RNA was extracted from mpkCCDCl4 cells grown on filters under control (non-
treated) and AVP-treated (10-8 M for 24 hours) conditions, using a Qiagen RNeasy Midi kit, 
and was stored at –80 °C or transported on dry ice. A small portion of the filter was retained 
for immunofluorescent confirmation of ANK and AQP2. The concentration and quality of 
the RNA was assessed using spectrophotometry and by cDNA synthesis of an aliquot of 
each sample using an Agilent Bioanalyzer 2100 (Figure 2.11; Medical Solutions Ltd, 
Nottingham; www.medical-solutions.co.uk).  
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A DNA oligonucleotide microarray (“gene chip”) is a matrix of thousands of cDNA probes 
bound to a solid support (Kurella et al., 2001). The Affymetrix GeneChip® Mouse Genome 
430 2.0 Array (Affymetrix, Santa Clara, CA) is a very high-density array, containing 
~12000 synthesized oligonucleotide probes. Each of these probes corresponds to a separate 
gene (Kurella et al., 2001), but many probes exist per gene. mRNA is extracted and purified 
from cells (section 2.11.2), reverse-transcribed using nucleotides labelled with a fluorophore 
and fragmented. Each labelled fragment was allowed to hybridise over 16 hours to its 
complementary sequence on the array. The array is then washed and stained, and the bound 
probe detected with a confocal laser. Each RNA (three control, three treated) was hybridised 
to a separate array. 
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Figure 2.11 Validation of total RNA quality 
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The raw data produced as a confocal microscope image is transformed into the names of the 
probes, by correlation to the location of probes on the array, and can be output as a text file. 
These can then be converted into GenBank gene names.  Specialised software analyses the 
images and text files and performs statistics, resulting in data such as the magnitude of gene 
expression. More sophisticated downstream analyses can then be performed, such as 
overlaps with other published datasets, to look for patterns of gene expression and attempts 
to identify potentially related biological functions.  
$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The large dataset generated by the microarray requires a number of analyses to be 
performed in sequence. First, the data must be normalised, which is the process used to 
remove non-biological variation between the samples. This is followed by quality control 
checks and finally tests for differential expression (t-tests, fold changes).  
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The raw data as Affymetrix text (CEL) files were imported into GeneSpring GX 10 
(Agilent, Palo Alto, CA, USA), and the six microarrays used were identified to the software 
as being either “control” or “treated”. A “probeset” is a collection of oligonucleotide probes 
(there are 45101 probesets in total per array), and there are sometimes multiple probesets 
per gene. Two normalisation methods were used. Initial quality control was achieved by 
analysis of the hybridisation of groups of probes (MAS5 software, Affymetrix, USA (Liu et 
al., 2002)), and by the use of Affymetrix control probesets containing deliberate mismatches 
which should prevent hybridisation of DNA fragments. Probesets that were present or 
marginal in at least two out of the six samples were deemed to be significant above 
background. The final quality controlled list of non-treated and treated probesets contained 
25343 probesets (Figure 6.7).  
The second normalisation method (Robust Multi-Array Average, (Irizarry et al., 2003)) 
provides a “normalised intensity value” (NIV) for each probeset, which is calculated by 
subtracting from each probe the median of the log summarized values for each probe across 
all six samples (both AVP-treated and controls). Positive NIV values occur when the result 
is above the median for all samples, and negative values occur when the result is below the 
median for all samples. The NIVs were plotted for each array (Figure 2.12). The “whiskers” 
on the figure indicate that the spread and distribution of the values from each array were 
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The quality controlled NIV results were grouped hierarchically using the Pearson 
correlation coefficient with average linkage as a similarity measure. This clustering was 
performed two-dimensionally in order to gather information about co-regulation. Clustering 
between arrays determined which arrays were similar to which other arrays (shown in the 
six columns in Figure 2.13) hence attempting to group arrays into control versus treated 
conditions. Clustering was also performed between probesets, showing which probesets 
were similar to which other probesets (shown as many individual rows in Figure 2.13). The 
colours represent the NIVs of each probeset, with expression values maximally above the 
median expression for that particular probeset being coloured in red, and values maximally 
below the median expression in blue. For example, the probeset for AQP2 can be seen 
(arrowed on Figure 2.13) as either very red or very blue, indicating a large degree of change 
of each array with respect to the median AQP2 expression for all arrays. These results 
showed at an early stage that the biological replicates segregated into control and treatment 
groups. This can be seen more clearly in Figure 6.5 where significance testing has been 




A further technical quality control to check for adequate hybridisation was performed on the 
final quality controlled probe set list (25343 probesets). Four additional RNA transcripts 
had previously been artificially introduced into the experimental RNA samples. These are 
known to hybridise and express at varying levels, and are used to check the hybridisation 
reaction and subsequent washing and staining steps. Figure 2.14 shows the four control 
probesets on the x-axis, each with increasing signal values, followed by sister probesets 
representing the same four transcripts. The trend line connecting these eight data points 
therefore gives rise to two ‘spikes’. The resulting “spike” of the chips with respect to 
controls had similar profiles across all chips in the experiment. 
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Figure 2.12 Normalisation of raw data 
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Figure 2.13 Hierarchical clustering of normalised microarray data 
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Figure 2.14 Hybridisation controls forming a ‘spike’ plot 
(Davidson & Halestrap, 1988) 
(Pendleton et al., 2002) 
(Reichenberger et al., 2001) 









The normalised, quality controlled probesets were used to generate a list of genes expressed 
differentially between control and AVP-treated samples, after removing the 60 control 
probesets, giving a total of 25283 probesets. Since these two groups were parametric and the 
hypothesis of the experiment made a difference between means the expected result, 
significant changes were tested for using an unpaired t-test with significance at p value 
<0.05 (Genespring GX 10 software). Since 5% of 25283 samples is 1264, this could 
represent a relatively large type I error (false positive rate) in the final gene list. This was 
further reduced by performing a multiple testing correction known as the Benjamini-
Hochberg False Discovery Rate (Benjamini & Hochberg, 1995), which ensured that <5% of 
the genes in the final list were false positives. 
The t-tested list was then further selected for a fold change in the NIV of each probeset 
(gene) of greater than 1.18 in the treated condition with respect to the control condition. 
Although this particular value is arbitrarily chosen, it allows a robust minimum level of 







The CREB targets database list (Zhang et al., 2005) consists of 16242 probesets. This list 
was refined by CRE/TATA box (to ~12000) then sorted by “full site” to ~600. The overlap 
between this list and our final list of differentially expressed genes in the microarray was 
computed (see section 6.3.3.4). In order to determine if this overlap was more or less than 
expected by chance, a representation factor score (defined in (Kim et al., 2001)) can be 
calculated as follows:  
(number of genes in common between both lists)(number of genes in the mouse 
genome)/(number of differentially expressed genes in microarray)(number of genes in 
CREB target list) 
    256 x 35661 
= ________________ 
    364 x 16242 




This indicates more overlap than expected by chance between these two independent groups 
of genes. Using the same figures, an exact hypergeometric probability of random overlap9
was calculated to be 7 x 10-25, indicating that the overlap is highly significant, and thus 
likely to be relevant.  
2.12  Quantitative RT-PCR 
'
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Total RNA extracted from mpkCCDcl4 cells for use in microarray experiments was reverse 
transcribed to cDNA and PCR-amplified using gene-specific primers. Amplification 
products were identified by comparing their melting temperatures to those obtained from 
previously prepared standards. These standards were specific PCR products of known 
concentration, from which a standard curve could be obtained to allow interpolation of 
concentration of amplified samples. The increase in the concentration of cDNAs by gene-
specific primers is proportional to the initial expression level of transcripts. These results 
were normalised by comparison to the expression of the reference gene GAPDH.  
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Using a Promega DNase kit the following were added on ice, for each of the six RNA 
samples: 1 g RNA, 4.5 l DNase, 2 ul START buffer RQ, made up to 20 l with molecular 
grade water. The reaction was incubated at 37 °C for 30 min, then terminated using 4 l of 




RT was performed using random hexamer primers, in order to capture all target sequences. 
1 l of 0.5 g/l random hexamer primers were added to each DNase-treated 1 g RNA 
aliquot or to water alone (RNA-ve control). Samples were made up to the same volume with 
molecular grade water, denatured at 65 °C for 5 min then cooled on ice for 2 min. A mix 
                                                
9 stattrek.com/tables/hypergeometric.aspx 
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containing 5x buffer, 2 mM dNTPs, 0.5 l RT enzyme and 0.25 l HPRI (RNaseA) per 
sample was added to each reaction. RT enzyme was omitted in RT negative reactions. 
Reactions were incubated at 42 °C for 1 h, followed by 70 °C for 3 min to destroy the RT 
enzyme.  
 	
Primers optimised for use with SYBR-green systems were supplied (Tebu-bio) as pre-mixed 
pairs each at 10 M. Primers for SLC27A2 were designed using D-LUXTM software10 and 













PDE4B NM_019840.2 4062-4080 60  98 
AQP2  NM_009699.3 1271-1291 60  138 
ANK NM_020332.4 1086-1104 60  89 
GAPDH NM_008084 309-329 60  140 
SLC27A1 NM_011977.3 507-527 60  136 
SLC27A2  NM_011978.2 GTACATTGGTGAACTGCTTCG 57.9 4 74 
CTTTGTGGTCCCGGTCATTTG 59.8 5 
Table 2.7 Primer sequences used in quantitative RT-PCR experiments. Since Tms for all primers 
were ~60 °C, experiments could be run simultaneousl y for all primer sets. 
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Clones were available for ANK (ANK-GFP construct, (Carr et al., 2007)) and SLC27A2 
(mouse IMAGE clone 30348317). These were diluted 1:100,000 before further 1:10 serial 
dilutions. For the other target genes, template DNA from section 2.12.2.2 was amplified 
using the primer sets above, and 1:10 serial dilutions made of the amplified products. All 
dilutions were performed in duplicate, with the range covering all likely concentration 
ranges encountered in the target gene. The first step of the qPCR reaction (below) denatures 
any coiled DNA present in the clones. 
                                                
10 http://escience.invitrogen.com/lux/index.jsp 




All experiments were performed from the same batch of original cDNA samples (in order to 
exclude inter-batch RT variations) in a LightCycler® 480 Instrument with a SYBR Green 
Master Mix kit (Roche Diagnostics, UK). cDNAs were diluted 1:8 to reduce the effects of 
pipetting errors. 10 l reactions were set up in a 96-well plate as follows: 5 l SYBR Green 
I Master Mix (containing SYBR green I dye, FastStart Taq DNA polymerase, reaction 
buffer, dNTP mix and MgCl2), 0.5 l of 20x primer and 4.5 l of diluted cDNA (the latter 
replaced by water for no-template controls). The programme was: denaturation for 10 min at 
95°C, then amplification through 45 cycles of 95 °C (15 s), 60 °C (60 s), 72 °C (1 s, during 
which fluorescence was acquired). This was followed by a melt curve programme of 95 °C 







Results were obtained using Roche LightCycler 480 Software. The “crossing point” (Cp) is 
the amplification cycle number at which a sample’s fluorescence first rises above 
background fluorescence. This is calculated as the point at which the rate of increase of the 
already increasing fluorescence (hence “second derivative”) is maximal.  Samples with less 
initial DNA thus require more amplification cycles to become visible above background 
noise, resulting in a higher Cp. Standard curves are plotted as the Cp for each dilution (y
axis) against the logarithm of the sample’s initial DNA concentration (x axis), from which a 
linear regression is calculated (Figure 6.8). The slope of each standard curve indicates the 
rate at which amplification of the initial DNA template proceeds. This can also be expressed 
as efficiency, where efficiency = 10(-1/slope). The perfect amplification would result in a 
doubling of the initial DNA, giving an efficiency of 2 (corresponding to a slope of -3.3). 
The mean squared error of each data point’s fit to the regression line was < 0.03 in all cases 




Determination of expression of each gene transcript was carried out on three sample pairs of 
untreated and AVP-treated samples. Since only the change in levels between untreated and 
treated samples was desired, quantification of expression was performed relative to the 
reference gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) which did not 
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change recognisably between experimental conditions. Results were expressed relative to 
the expression of GAPDH in the same sample, enabling normalisation of differences 
between individual samples.  
Evidence for the validity of using GAPDH as a reference gene included: the efficiencies of 
the GAPDH standards and the test samples were all 2.00 – 2.01 (to 2 decimal places); test 
samples were all extracted and reverse transcribed under the same conditions; and GAPDH
expression has previously been used as a control in qPCR experiments involving forskolin 






Fold changes in expression were calculated using the method of Pfaffl (Pfaffl, 2001). This 
method accounts for efficiency and allows normalisation to a reference gene. Results are 
expressed as a proportion of the reference gene to normalise for inter-experimental 
variations. The fold change for each target gene is calculated thus: 
change in expression = efficiencyCp (untreated) - Cp (treated) 
Calculation of errors in this analysis is not usually undertaken. Here, experiments were 
performed on multiple occasions and the mean Cp calculated. A standard error could be 
calculated from this but may not be meaningful as the total number of repeats was quite 
small in the present experiments.  
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3 Results (I): Expression and localisation of ANKH in 
human kidney 
3.1 Introduction 
Using Northern analysis of ANK transcripts, Ho et al. (2000) found that ANK mRNA is 
expressed in many mouse tissues including brain, liver, spleen, lung, muscle and kidney.
Two transcripts of ~3500 bp and ~4000 bp were detected in each tissue, suggesting usage of 
different polyadenylation sites. Carr et al. (2007) have confirmed expression of ANK at 
mRNA level using RT-PCR in native murine kidney and in the mouse inner medullary 




An anti-ANK antibody (Ab3) has been raised against residues 477-492 of the protein 
sequence at the intracellular C-terminal (Ho et al., 2000), and was kindly gifted to us by the 
Kingsley laboratory. This C-terminal peptide sequence (PTEEVTDIVEMREENE) is 
identical in both mouse and humans (Figure 3.1). Work in our own laboratory has shown 
that immunofluorescent detection of ANK by Ab3 has been shown to parallel that of an 
ANK-NT-GFP fusion protein when expressed in fixed and permeabilised IMCD-3 cells 
(Carr et al., 2007), and Ab3 fails to recognise a C-terminal deletion mutant R480X ANK-
NT-GFP fusion protein expressed in these cells. Although Ab3 (Ho et al., 2000) has 
previously been shown in mouse cell lines, mouse tissue and monkey cell lines to detect 
ANK on Western blotting and immunofluorescence, it has never so far been used to detect 
ANK in human kidney tissue. A commercially available anti-ANK antibody raised against 
residues 1-300 of the N-terminal human protein sequence was also available (Table 2.4). 
Both antibodies are polyclonal and raised in rabbit. 
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The main aim of this section was to clarify whether ANKH mRNA is expressed in human 
kidney. The specific expression of ANKH protein in human kidney tissue could then be 
investigated. In order to implicate ANKH in a crystal inhibitory role, localisation of 
expression to the more distal nephron segments and collecting duct would be expected. The 
specificity of the two available anti-ANK antibodies, each directed against different peptide 
sequences, was tested using Western blotting and immunofluorescence studies in human 
renal tissue in order to validate their use in protein expression studies. 
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Figure 3.1 Evolutionary conservation of ANK (amino acid sequences) 
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Figure 3.2 Evolutionary conservation of ANK (nucleotide sequences) 








Ho et al. (2000) found that there is significant conservation of the ANK gene across 
vertebrates and the human homologue ANKH is virtually identical to that in mouse. Figure 
3.2 shows a remarkable conservation of ANK at the nucleotide level in four vertebrate 
species. 
For protein sequences (Figure 3.1) there is 83% amino acid identity of the human sequence 
with the zebrafish ANK homologue, and 98% identity with the mouse homologue. 
Differences between substitutions are often conservative e.g. residue 21 (alanine/glycine) 
and residue 130 (arginine/lysine). Although bacterial species do have some small conserved 
domains, these are unlikely to code for the whole functional protein. A search of the NCBI 
Protein database revealed only four bacterial species in which hypothetical proteins with 
similarity to ANKH exist. One such occurs in Desulfuromonas acetoxidans (ZP_01311818) 
which has 84/428 identities with ANKH (19%). A prediction of the transmembrane 











Total RNA from human kidney, human embryonic kidney (HEK) cells and mpkCCDcl4 cells 
was extracted (section 2.2.2.1), reverse transcribed and amplified using internal ANK 
primers. ANK human IMAGE clone (3927236; Geneservice) was used as a positive control. 
Results obtained with the mouse collecting duct cell line mpkCCDCl4 and with mouse 
kidney tissue are also shown as further positive controls (Carr et al., 2009). Direct 
sequencing of gel-extracted PCR products confirmed the identity of the 490 bp products as 
ANK in all positive samples (Figure 3.4).  
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Figure 3.3 Putative domains of the ANKH protein  
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Figure 3.4 Expression of an ANK amplification product in human kidney cell line and tissue 











In order to investigate the expressed nucleotide sequence of ANKH mRNA in human 
kidney, including the possible existence of polymorphisms and splice variants, it was 
necessary to verify the expression in kidney from normal human subjects of full length 
ANKH mRNA representing the coding sequence.  
Attempts to use long-range PCR with primers designed for full-length ANKH coding 
sequence were unsuccessful, so primers were instead designed to amplify overlapping 
regions of the ANKH gene. It was not possible to amplify products greater than about 800 
base pairs. Three primer pairs (see section 2.2.5) were successfully used to amplify 
overlapping products (Figure 3.5). -actin controls showed product only in RT positive 
samples, excluding genomic DNA contamination. Contigs of the complete nucleotide 
sequence were then assembled (Figure 3.6) after gel extraction and direct sequencing of 





Contiguous sequences showed that ANKH residue 294 was determined as either a cytosine, 
thymine or heterozygous (‘N’) by the sequencing reaction (corresponding to position 317 in 
Figure 3.6). The sequencing chromatograms (Figure 3.7) confirmed that three subjects had a 
cytosine in this position, one had a thymine, and two were heterozygous for both C and T. 
Both possible codons, GCC and GCT, are synonymous for alanine at amino acid position 
97. The SNP in ANKH at this position is annotated as RS17251667 in exon 2 (SNP 
database on NCBI), and has a quoted heterozygosity index across all populations of 0.111 ± 
0.208.   
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Figure 3.5 RT-PCR of ANKH products from human renal cortex.  
Total RNA extracted from the renal cortex of three normal human subjects (H, J, K) 
was reverse transcribed. ANKH mRNA expression was observed by separation on 
a 2% agarose gel of amplified overlapping products using three different ANKH-
specific primer pairs. The first (201F/202R) produced a 397 bp product, the second 
(210F/211R) a 699 bp product, and the third (212F/213R) a 597 bp product. No 
alternative splice variants were detected. Results from β-actin primer pairs are 
shown in the lower figure. RT negative controls are shown for each human subject 
(lanes h, j, k). Negative controls for 210F/211R were run over two gels. The no-
RNA control is in lane c; PCR negative control is in lane x. Similar results were 
obtained in three further human subjects.  
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Fig 3.5 goes here 
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Figure 3.6 Example of full length ANKH sequence from a human subject. 
Contiguous sequences were obtained by amplification of RT products from patient 
E using three primer combinations: 201F/202R (E1), 210F/211R (E2), 212F/213R 
(E3). These were aligned using Multalin software (Corpet, 1988). The coding 
sequence (CDS) obtained from NCBI (NM_054027) is shown in red. Similar results 
were obtained in five other human subjects. In three subjects, an SNP was 
detected at position 317 (highlighted in green).  
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Fig 3.6 goes here 
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Figure 3.7 Detection of a single nucleotide polymorphism in ANKH coding sequence in six 
human subjects 












Probing a protein lysate obtained from human kidney cortex using the N-terminal ANK 
antibody revealed two prominent bands at 50 kDa and ~60 kDa with a less distinct band at 
~55 kDa (Figure 3.8). In contrast, using the C-terminal ANK antibody (Ab3), a single band 
was obtained at 50 kDa. The Kingsley group had previously found that a single protein band 
of ~50 kDa is recognised by Ab3 when ANK was transfected into COS-7 monkey kidney 
cells (Ho et al., 2000) and when heterologously expressed in Xenopus oocytes (Figure 
4.3E). The question of antibody specificity under the latter conditions is investigated further 
in Chapter 4. Copper phthalocyanine staining of the membranes as controls for protein 
loading and transfer were satisfactory. 
Control experiments included a no-primary antibody control which yielded no bands 
(Figure 3.9A), with detection of actin protein at 42 kDa in each lane after stripping (Figure 
3.9B). Separately, rabbit pre-immune serum revealed only a faint band at ~40 kDa (Figure 
3.9D) despite adequate protein loading and transfer (Figure 3.9E), and no band was 
observed at 50 kDa. 
These data suggest that Ab3 is capable of recognising a single polypeptide of the correct 
predicted size in human kidney, and therefore provides a more specific reagent for 
immunolocalisation of ANKH in this tissue than the N-terminal ANK antibody. 
Chapter 3 – Expression and localisation of ANKH in human kidney 
__________________________________________________________________________________________________________________________________________ 
100
Figure 3.8 Western blot analysis of human renal cortex, probed with ANK N- 
and C-terminal antibodies. 
Protein lysate (50 g per lane for N-terminal ANK staining, 10 g per lane for C-
terminal) from three human subjects (H, J, K) was size fractionated on a 4-10% 
SDS-polyacrylamide gel and transferred to a PVDF membrane. The membrane 
was stained with anti-N-terminal-ANK antibody (Santa Cruz) at 1:100 at room 
temperature for 2 hours (A; n=3) or Ab3 1:500 overnight at 4°C (B). Detection was 
by anti-rabbit IgG-HRP and visualisation was with a chemiluminescent substrate 
detection kit.  
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Fig 3.8 goes here 
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Figure 3.9 Western blot controls for ANK detection in human renal tissue. 
Protein lysate (50 g per lane) from three human subjects (H, J, K) was size 
fractionated on a 4-10% SDS-polyacrylamide gel and transferred to a PVDF 
membrane. The membrane was incubated for two hours or overnight (in separate 
experiments) with milk protein-TBS/Tween without any primary antibody (A; n=2), 
followed by anti-rabbit IgG-HRP (1:10,000) after washing. The membrane was then 
stripped and reprobed with mouse anti-actin antibody at 1:1000 for 2 hours at room 
temperature (B). Copper phthalocyanine membrane staining is shown (C). 
15g of protein lysate per lane was treated in the same way, and the membrane 
incubated with rabbit pre-immune serum at 1:500 overnight at 4°C (D), followed by 
secondary antibody and detection as above. Copper phthalocyanine membrane 
staining is shown (E). 
Western blot data from mouse kidney cell lines and tissue, probed with anti-
ANK antibodies. Protein lysates (50 g per lane) from mouse cell lines mpkCCDcl4
(CCD), M1 (M1), and whole mouse kidney (MK) were probed with anti-N-terminal-
ANKH antibody (Santa Cruz) at 1:100 at room temperature for 2 hours (F; n=4) or 
Ab3 at 1:500 overnight at 4ºC (G) (experiment performed by Dr Georgina Carr (Carr
et al., 2009)).  
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Fig 3.9 goes here 









Ab3 immunofluorescence is strongest in a small subset of renal tubules, which are identified 
morphologically from their location and cobblestone appearance as cortical collecting ducts 
(Figure 3.10). A weaker, more generalised, immunofluorescent signal is observed in other 
renal tubules. Using a rabbit pre-immune serum as the primary antibody under the same 
conditions revealed much lower staining intensity (Figure 3.10 C). No staining was 
observed using secondary antibody alone (Figure 3.10 D). Preadsorption of Ab3 antibody 
by its immunising peptide showed decreasing staining as the peptide concentration 






Aquaporin-2 is a marker of the principal cells of the collecting duct (Nielsen et al., 2002) 
and traffics to the apical membrane allowing regulated water reabsorption from the tubule 
lumen. ANK reliably co-localised with AQP2 in four experiments, each using kidney tissue 
obtained from separate normal human subjects. Similar findings were observed in both 
cortical and medullary sections. Cortical sections often contained prominent medullary rays 
adjacent to the glomerulus-containing cortical labyrinth (Figure 3.12 B), and medullary 
sections were characterised by medullary collecting ducts and loops of Henle, as seen in 
cross-section in Figure 3.12 A. AQP2 staining was always observed to be concentrated at 
the apical (luminal) pole of the cells (Figure 3.12). ANK staining is seen to outline the 
tubular cells, suggesting plasma membrane staining at both apical and basolateral 
membranes. In addition, all cells within the collecting duct stain positively for ANK. This 
was further investigated by staining with a primary antibody against human AE1 (kindly 
provided by Dr A Toye, University of Bristol); this basolateral Cl-/HCO3
- exchanger occurs 
only in -intercalated cells. Basolateral AE1 staining was found to colocalise with Ab3 







On morphological grounds, proximal tubules were found to stain only faintly with Ab3, by 
comparison to distal segments (Figure 3.14 A). This was confirmed by using an antibody to 
CD98, a marker of the proximal tubule (Rossier et al., 1999) (discussed further in section 
4.3.1). Tubules that were CD98-positive did not stain brightly for ANK. The single tubule in 
Figure 3.14 C that stains brightest with ANK antibody is neither CD98 positive nor a 
proximal tubule on the basis of morphology. Staining with CD98 required PFA fixation and 
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Triton X100 permeabilisation. Ab3 clearly detects ANK in collecting ducts of PFA-fixed 
mouse tissue (Dr G Carr, unpublished results).  
Some tubules were noted to stain moderately brightly with Ab3 but were AQP2-negative 
despite being similar in appearance. These segments could be either early distal tubule or 
Loop of Henle. Tamm Horsfall protein (Phillips et al., 2004) is a marker of both apical and 
basolateral membranes of the thick ascending limb of the Loop of Henle and also the early 
distal convoluted tubule (Chakraborty et al., 2004); (Ronco et al., 1987). Figure 3.15 (A) 
shows two large tubules staining with Ab3, but only the left one shows obvious co-staining 
with anti-Tamm Horsfall antibody, giving a slightly yellow colour in the overlay image. In 
(B) many tubules stain moderately brightly with Ab3, and all but the largest, brightest 







The ectoenzymes nucleotide pyrophosphatase phosphodiesterase-1 and -3 (NPP1, NPP3) 
generate PPi from ATP or other nucleotide triphosphates (Vekaria et al., 2006a). NPP1 is 
expressed basolaterally in murine distal tubule (Harahap & Goding, 1988). Our results show 
NPP1 expression basolaterally in AQP2-positive cells in human kidney (Figure 3.16 B). 
NPP1 staining alone (Figure 3.16 C) and co-staining with Ab3 (Figure 3.16 A) confirmed 
some interstitial staining.  
NPP3 was found to localise to the apical membrane of proximal tubules (identified 
morphologically; Figure 3.17 A), as was seen in mouse kidney (Vekaria et al., 2006a); 
(Goding et al., 2003). Staining was present but more limited in distal segments (Figure 3.17 
B).  
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Figure 3.10 ANK immunofluorescence using the Ab3 antibody in human kidney 
. 
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Figure 3.11 Preadsorption of Ab3 antibody by its immunising peptide. 
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Figure 3.12 Colocalisation of ANK with AQP2 in human kidney.  
Chapter 3 – Expression and localisation of ANKH in human kidney 
__________________________________________________________________________________________________________________________________________ 
109
Figure 3.13 Colocalisation of ANK with AE1 in human kidney. 
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Figure 3.14 ANK is minimally expressed in human proximal tubule.  
CLSM images showing: 
(A) x20 image of human renal cortex. Parallel medullary rays are seen in the 
centre, top and top-right, and stain brightly with anti-C-terminal ANK antibody, Ab3. 
Proximal tubules are seen to the left and bottom of the image, and stain very poorly 
with Ab3. Scale bar = 40 m. 
(B) No-primary antibody control from the same experiment.  
(C) Human renal cortex fixed with PFA and permeabilised with Triton X100 0.1%. 
Staining was with Ab3 (green channel), anti-CD98 antibody (red channel) and 
overlay image. Scale bar = 20 m. 
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Fig 3.14 here 
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Figure 3.15 ANK is expressed to a limited extent in Loop of Henle/distal convoluted tubule.  
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Figure 3.16 Expression of NPP1 in the collecting duct of human kidney.  
CLSM images showing immunofluorescence in human renal cortex. Scale bar = 20 
m for all images.
(A) Anti-C-terminal ANK antibody (Ab3; green channel), anti-NPP1 antibody (red 
channel), and overlay of images 
(B) Anti-AQP2 antibody (green channel), anti-NPP1 antibody (red channel), and 
overlay of images 
(C) No-primary control and anti-NPP1 antibody staining alone.  
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Fig 3.16 here 
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Figure 3.17 Expression of NPP3 in the proximal tubule of human kidney.  








ANK is highly conserved throughout evolution. This applies to some other membrane 
transporters such as AE1 (Jarolim et al., 1998) and the vacuolar H+-ATPase (Gogarten et 
al., 1989), but the ANKH domain is unique in the human and mouse genomes (Figure 3.18). 
Prediction of transmembrane domains using 11 different programs showed that between 7 
and 12 domains are likely (Williams et al., 2002); (Wang et al., 2009). Although no further 
structural experiments are available in the literature, Ho et al. (2000) demonstrated that the 
C-terminal, to which Ab3 is raised, is likely to be intracellular. 
Results of the RT-PCR of internal ANK products show that ANK is endogenously 
expressed in a human renal cell line (HEK) and, importantly, in human kidney. The primers 
detected the identical product in mouse collecting duct cell line and mouse kidney tissue, 
since mouse and human sequences are almost identical in the region between these primers. 
However attempts using RT-PCR to amplify the entire 1479 bp ANK coding sequence 
using two separate primer pairs each flanking the whole sequence were unsuccessful. Using 
three contiguous sequences, we have sequenced for the first time the full length ANKH 
coding sequence from the kidneys of six normal human subjects (not known to have 
chondrocalcinosis or CMD). Sequence analysis revealed a synonymously coding SNP, 
which has an average heterozygosity frequency of 11 ± 21% 11, suggesting that it occurs in 
up to ~30% of subjects. 
Figure 3.18 ANKH transcript and protein summaries from Ensembl.
Upper: There is only one known ANKH transcript (number ENST00000284268), which is encoded 
on the reverse strand. Vertical lines are exons (coding sequence) and horizontal lines are introns. 
Unfilled boxes are UTR (untranslated region) exons. Lower: Parts of the ANKH protein coded for by 
the 12 ANKH exons are shown in alternating pink and purple colours, followed by the predicted 
transmembrane segments in green. The Pfam database of protein domains shows ANKH as a 
single unique domain (pfam07260; grey line). The positions of four known SNPs are marked 
(coloured dots); the first is rs17251667 which was detected in three of the six human subjects in this 
study. Figures were downloaded from www.ensembl.org
                                                
11 www.ncbi.nlm.nih.gov/SNP 












Detection of endogenous ANKH protein on Western blot in human kidney tissue has been 
confirmed. Findings using a C-terminal antibody (Ab3) are consistent with those of the 
Kingsley group (Ho et al., 2000) who obtained a major band at 50 kDa in ANK-pCMV-
transfected monkey kidney cells, although no data are given for any minor bands they 
obtained. Yet the Kingsley group were never able to detect endogenous ANK in tissues 
using Ab3 (Dr KA Gurley, personal communication). This band compares favourably with 
the predicted protein size of 54.3 kDa based on the coding sequence for ANKH. We have 
also confirmed that Ab3 detects ANK-FLAG overexpressed in Xenopus oocytes (section 
4.2.6) at 50 kDa, in agreement with Kingsley et al (Figure 4.3E), as well as Ab3’s detection 
of both endogenous and overexpressed ANK in HEK293 cells (Carr et al., 2009) and CCD 
cells (Figure 6.1).  
In human tissue, the N-terminal antibody (Santa Cruz; Table 2.4) consistently gave a band 
at ~50 kDa but also a further band at ~60 kDa. This additional band is unlikely to represent 
the formation of a hetero-oligomer as experiments were performed under reducing 
conditions. N-terminal anti-ANK antibody detection was reconfirmed in ANK-
overexpressing Xenopus oocytes (Figure 4.7), in the endogenously ANKH mRNA-
expressing mouse cell lines mpkCCDCl4 (Figure 3.4 A) and M1 (Carr et al., 2009), and in 
mouse kidney tissue. In Xenopus oocyte expression studies using FLAG-tagged ANK, the 
N-terminal antibody failed to detect it. In addition a 60-65 kDa band was observed in both 
water and ANKH-injected oocytes (Figure 4.3 A). In mouse cell lines and tissue a single 
band of ~60 kDa is seen with N-terminal ANK antibody, compared to a band size of 50 kDa 
with Ab3 in cell lines together with additional bands of smaller size seen in the mouse tissue 
sample (Figure 3.9 F&G). Santa Cruz’s datasheet12 shows product sizes of either ~50 kDa 
or ~60 kDa with N-terminal ANK antibody in separate experiments in transfected HEK293 
cells. This antibody is raised against amino acids 1-300 of human ANKH, a very large 
epitope which contains two amino acid differences from the mouse sequence. These 
discrepancies in expected band size in our experiments and the company’s own data, as well 
as the very large epitope, suggest that the Santa Cruz N-terminal antibody is less specific 
than Ab3 and does not recognise ANKH specifically. 
                                                
12 www.scbt.com 
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Rabbit pre-immune serum was used since both N- and C-terminal antibodies were raised in 
rabbit. This together with the no-primary antibody control demonstrated that bands arising 
with Ab3 after detection by the secondary antibody are specifically due to binding of Ab3.  
Taken together, these results confirm that human kidney tissue expresses the ANKH 
protein. The weight of evidence from the present study as well as published data, and the 
calculated protein size, favours a band size of ~50 kDa. Given the inconsistency of results 
obtained in human tissue between N- and C-terminal anti-ANK antibodies, all tissue 










Previous results (Carr et al., 2007) have shown that ANK is expressed in the cortical 
collecting ducts of mouse kidney tissue. The present study confirms expression of ANKH in 
the human kidney with localisation to the collecting ducts. It offers some evidence of 
limited expression in the preceding nephron segments (thick ascending limb of the Loop of 
Henle or early distal convoluted tubule). This is the first time that ANKH has been localised 
in human renal tissue. The data also suggest that there is very little expression in the 
proximal tubule. 
All sections show that ANK staining occurs on both membranes of human collecting duct 
cells in situ. This is similar to findings in non-polarised cell lines such as HEK293 and in 
polarised cell lines such as mIMCD-3 (Carr et al., 2007) and mpkCCDcl4 cells (Chapter 6). 
In many cases, staining was noted to be particularly marked on the apical aspect (Figure 
3.10 A). Given its predominant expression in the collecting duct, this places ANK in the 
same physiological location as AQP2. This suggests that there may be a functional 
relationship between these two proteins, supporting the hypothesis that transport of PPi to 
the tubule lumen may be involved in the inhibition of calcium crystal formation. This is 
investigated further in Chapter 6.  The AE1 antibody studies show that ANK also localises 
to the basolateral membrane. This suggests a possible role in the inhibition of interstitial 
calcification, perhaps complementing the role of the ectoenzyme NPP1.  
Validation of the Ab3 antibody using appropriate controls for immunofluorescent staining 
in human tissue is important, particularly since the pattern of staining may be different to 
that observed for Ab3 in Western blotting. The reduction of immunofluorescence by pre-
adsorption with the C-terminal peptide to which Ab3 is raised provides support for its 
specificity in human renal tissue. Ab3 has been previously validated for 
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immunofluorescence in mouse tissue and cells using a Glu440X C-terminal deletion mutant 
(Carr et al., 2007). Unfortunately human patients with ANKH C-terminal deletions have not 
been described, and tissue from the mutant ANKank/ank mouse (Jackson Laboratory, Maine, 
USA) was not available to us. Results in Chapter 4 using a FLAG-tagged ANK construct 
and CD98 membrane marker show that human ANKH expressed after cRNA was injected 
into Xenopus oocytes is indeed localised to the plasma membrane, and that Ab3 can detect 
plasma membrane-expressed ANKH.  
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Since active calcium regulation occurs in the distal tubule (Bindels, 1993), and the final 
urinary concentration is regulated via AQP2 in the collecting duct, the localisation of 
ANKH to these nephron segments places it in the most useful anatomical position to 
function in the limitation of calcium crystal formation. This is supported by the finding that 
the PPi-producing ectoenzyme NPP1 is localised to the distal nephron in human kidney. 
ANKH expression was particularly marked on the apical membrane, which would be 
structurally consistent with PPi transport into the lumen in support of this theory. However 
ANKH was expressed on both membranes and is also present in the medullary collecting 
ducts. There may also be a role for basolateral ANKH transport into the medullary 
interstitium, this area also being recognised in the pathogenesis of renal stones (Sayer et al., 
2004). 
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4 Results (II): Intracellular and plasma membrane 








Having confirmed ANKH expression and membrane localisation in human renal collecting 
ducts, ANKH function may now be investigated by overexpressing heterologous ANKH 
constructs in Xenopus oocytes. 
Unlike epithelial cell lines, oocytes do not exhibit tight junctions and membrane polarity, 
and hence act as a single membrane separating cytosol and extracellular compartments. The 
major advantage of oocytes is that rather than transfecting with DNA as in cell lines, the 
vast protein manufacturing ability and quality-control mechanisms of the oocyte can be 
utilised to produce huge numbers of expressed protein molecules from a few ng of 
heterologous cRNA. Since overexpression in this way results in 1010-1011 transporters in the 
membrane per oocyte, etc (Zampighi et al., 1995), and very few endogenous oocyte 
membrane transporters exist (Weber, 1999), it should in theory be easy to determine 
positive membrane expression by immunofluorescent staining (IF) or Western blotting. In 
reality, these techniques presented many technical problems; for IF these included: method 
of fixation, preservation of morphology, delineation of the membrane itself and 
autofluorescence of the oocyte. As a result, there are numerous different protocols for 
oocyte IF available in the literature, and although oocyte IF is sometimes performed e.g. 
(Kohl et al., 1998), it is often omitted if the flux results are convincing (e.g. (Bröer et al., 
1998); (Wagner et al., 2000).  
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The aim of this section is to confirm expression of the heterologous ANKH-constructs in the 
oocyte and localisation to the plasma membrane. These constructs would thus be validated 
for use in functional experiments. Experiments were performed on oocytes from a batch 
which was then used in subsequent functional experiments. In tissue, a discrepancy was 
observed between results obtained with the N- and C-terminal anti-ANK antibodies, with 
the latter found to be most consistent. To avoid any doubt in oocytes, a FLAG-tagged 
ANKH construct was made and staining results checked with both anti-ANK antibodies. 
Localisation to the plasma membrane was confirmed using the specific marker CD98.  
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Oocytes were injected with human CD98 cRNA. The anti-CD98 antibody used detects the 
extracellular C-terminal of the dimer at ~120 kDa 13 (Rossier et al., 1999). A band was seen 
at ~120 kDa in the membrane fraction only of CD98-injected oocytes (Figure 4.1 A). The 
lack of a band in water-injected oocytes showed that CD98 does not occur endogenously in 
oocytes. No bands were seen in the cytoplasmic protein fraction. Bands of approximately 
the same size were obtained from the protein lysate of kidney from three normal human 





To verify detection of ANK by the anti-ANK antibodies, an ANKH-NT-3XFLAG fusion 
construct was obtained and cRNA made. Oocytes were injected with ANKH-FLAG and 
membrane fractions were prepared in the same way as for CD98. A very strong band was 
seen at ~50 kDa in the membrane fractions, consistent with detection of the construct 
(Figure 4.2 A). The copper stained membrane confirms that increased transfer of ANKH-
FLAG protein compared to water-injected protein was not the cause (Figure 4.2 B). A 
lighter band of the same size was seen in the cytoplasmic fraction of experiment ‘2’ only. 
Non specific bands were seen at 37 kDa.  
Using 0.6 g of protein also resulted in a strong band at 50 kDa, showing that detection of 
FLAG is highly sensitive using this technique (Figure 4.2 C). Boiling in SDS did not affect 
the results, confirming the efficacy of the protocol used (section 2.6.2.2). Protein from 









The same fractions as those used in experiment 1 in Figure 4.2 A were used to investigate 
detection of anti-ANK antibodies. Anti-N-terminal ANK antibody was unable to detect the 
ANKH-FLAG protein at the expected size in the membrane fraction, giving only non-
specific bands (Figure 4.3 A). This confirms the lack of detection observed with this 
antibody in human tissue. The anti-C-terminal Ab3 antibody gave a convincing band at 50 
                                                
13 http://datasheets.scbt.com/sc-7095.pdf 
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kDa in the ANKH-FLAG membrane fraction only (Figure 4.3 B), agreeing with the result of 
anti-FLAG immunodetection. Non-specific bands were seen at ~40-42 kDa in all lanes. 
Omission of primary antibody resulted in no bands (Figure 4.3 D).  
Ab3 was then used to confirm expression of ANKH-pcDNA3.1 construct, i.e. without the 
FLAG tag. Although the protein lysate was not fractionated, clear bands at ~50 kDa are seen 
in lanes from ANKH-injected oocytes, with no difference between the bands for 85 ng and 
175 ng of initially injected cRNA (Figure 4.4). The slight reduction in band size may be due 







The mouse ANK-NT-GFP construct has been shown to localise to plasma membrane, 
endoplasmic reticulum, acidic endosomes and mitochondria in IMCD-3 cells (Carr et al., 
2007). Attempts to detect mouse and human ANK-GFP constructs in oocytes by visualising 
GFP fluorescence were unsuccessful partly due to autofluorescence of the oocytes, and use 
of anti-GFP antibodies was also unsuccessful. Since Ab3 was found to stain ANK on 
Western blotting, localisation was attempted with Ab3 in injected oocytes. Representative 
images in Figure 4.5 show that ANKH-pcDNA3.1, mouse ANK-GFP and ANKH-pTNT 
constructs gave an outer rim of positive staining compared to water, which was brightest in 
the image for mouse ANK-GFP. There was marked intracellular staining, seen also on 
water-injected oocytes but not on the no-primary control, which may indicate either non-







Anti-FLAG staining in both Figure 4.6 and Figure 4.7 showed a bright outer rim of staining 
in ANKH-FLAG sections compared to much dimmer or no staining of water controls. 
Appearances of positive and control oocytes are the same as those shown in Figure 5 of 
(Wagner et al., 2000). This pattern was mirrored by Ab3 staining (Figure 4.6) but there was 
very little staining with anti-N-terminal ANK antibody (Figure 4.7). Overlay images 
confirmed colocalisation of staining due to Ab3 and anti-FLAG. 
As seen above, diffuse intracellular staining was noted on both water-injected and ANKH-
FLAG-injected sections, but not on the no-primary control. However the sub-membrane 
area was noticeably brighter on Ab3 and anti-FLAG staining of the ANKH-FLAG injected 
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sections compared to water-injected sections. All results were consistent over experiments 
performed on separate batches of oocytes on two separate occasions. In a parallel 
experiment, anti-FLAG antibody raised in rabbit rather than mouse was used separately as 
primary antibody, and was detected with anti-rabbit FITC. This produced similar results to 






Having established CD98 overexpressed in oocytes as only detectable in the membrane 
fraction, these oocytes were sectioned and stained with anti-CD98. Staining was observed 
along the outer rim of the oocyte (Figure 4.8). No staining was seen in water-injected 
controls, or no-primary controls with either injected type. This confirms that the outer rim of 
the oocyte is the plasma membrane. 
Oocytes were injected with either water, ANKH-FLAG or co-injected with both ANKH-
FLAG and CD98. Anti-FLAG antibody detected ANKH-FLAG at the membrane in oocyte 
sections that contained this construct (Figure 4.9 rows 3 and 4), giving rise to the green 
spikes on the profile plot of pixel intensity. Similarly, anti-CD98 antibody detected CD98 at 
the membrane in CD98-injected oocyte sections. This is different to the background 
fluorescence seen with water-injected controls. Colocalisation of ANKH-FLAG and CD98 
at the plasma membrane is confirmed, indicated by a yellow colour on the overlay image 
and an arrow showing the merging red and green peaks on the pixel quantification (Figure 
4.9 row 4). Experiments were performed on separate batches of ANKH-FLAG-injected 
oocytes on four separate occasions, and on two occasions with CD98 co-injection.  
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Figure 4.1 Detection of CD98 expressed in oocyte membrane by probing with 
anti-CD98 antibody 
Western blot analysis of oocytes injected three days earlier with water (W) or CD98 
(CD) cRNA fractionated into membrane (m) and cytosolic (c) components, and 
whole human kidney cortex lysate. 
(A) Protein lysate (40 g/lane for membrane fraction, 10 g/lane for cytoplasmic 
fraction) was loaded with sample buffer containing -mercaptoethanol at room 
temperature (as Halestrap protocol), size fractionated on a SDS-polyacrylamide gel 
and transferred to a PVDF membrane before probing with polyclonal goat anti-
human CD98 antibody (Santa Cruz sc-7095) at 1:500 (3 hours, room temp), with 
HRP-anti-goat at 1:2500 as secondary.  
(B) Protein lysate (40 g/lane) from whole renal cortex of three normal human 
subjects (H, J, K) was loaded, run and probed as above. 
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Fig 4.1 here 
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Figure 4.2 Expression of ANKH-FLAG construct in oocytes, detected by anti-
FLAG antibody 
Western blot analysis of oocytes injected three days earlier with water (W), CD98 
(CD) cRNA or ANKH-FLAG (AF) cRNA, fractionated into membrane (m) and 
cytosolic (c) components. 
(A) Protein lysate (10 g/lane) was loaded with sample buffer containing -
mercaptoethanol at room temperature (as Halestrap protocol), size fractionated on 
a SDS-polyacrylamide gel and transferred to a PVDF membrane before probing 
with anti-FLAG M2-HRP conjugated antibody at 1:200 (1 hour, room temp). Two 
separate experiments are shown (labelled 1 and 2); total n=3. 
(B) The PVDF membrane from experiment 2 was stained with copper 
phthalocyanine for 30 min, then washed for 30 min with 12 mM hydrochloric acid. 
(C) Protein lysate (0.6 g/lane) was loaded with sample buffer containing -
mercaptoethanol, then either boiled for 10 min at 95°C (left three lanes) or kept for 
10 min at room temperature (right three lanes). They were then run and probed as 
above. The results are similar regardless of whether samples were first boiled or 
not.  
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Fig 4.2 here 
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Figure 4.3 Confirmation of ANKH-FLAG expression in oocytes by detection 
with Ab3 antibody 
Western blot analysis of oocytes injected three days earlier with water (W) or 
ANKH-FLAG (AF) cRNA, fractionated into membrane (m) and cytosolic (c) 
components. 
(A) Protein lysate (40 g/lane for membrane fraction, 10 g/lane for cytoplasmic 
fraction) as used in experiment 1 in Figure 4.2 A was loaded and run as above. The 
membrane was probed with anti-N-terminal-ANKH antibody at 1:200 (Santa Cruz) 
overnight at 4°C, with detection by anti-rabbit IgG -HRP (1:10,000) as secondary.  
(B) Protein lysate (50 g/lane for membrane fraction, 25 g/lane for cytoplasmic 
fraction) as used in experiment 1 in Figure 4.2 A was loaded and run as above. The 
membrane was probed with anti-C-terminal-ANKH antibody (Ab3) at 1:500 
overnight at 4°C, with detection by anti-rabbit HRP  as above (n=2). 
(C) The membrane from (B) was stripped for 8 minutes according to manufacturer’s 
protocol and lack of detection of bands was confirmed after incubation with a 
chemiluminescent substrate detection kit (data not shown). The membrane was 
washed in TBS/Tween and reprobed with anti-alpha tubulin 1:1000 overnight at 
4°C. Bands of expected size of 50 kDa can be seen m uch more prominently in the 
cytosolic fractions (c) than in the membrane fractions (m).  
(D) Protein lysate (50 g/lane for membrane fraction, 25 g/lane for cytoplasmic 
fraction) as used in Figure 4.2 A was loaded and run as above. The membrane was 
incubated overnight with milk protein-TBS/Tween without any primary antibody, 
followed by anti-rabbit HRP after washing, and visualisation with a 
chemiluminescent substrate detection kit. No bands are visible despite adequate 
protein loading and transfer as confirmed on the adjacent copper phthalocyanine 
membrane staining. 
(E) Data from the Kingsley group, confirming detection of a band at 50 kDa using 
Ab3 in frog oocytes injected with ANK (left lane). This band was not seen in oocytes 
injected with an ANK mutant missing the C-terminal epitope against which Ab3 was 
raised (right lane). Non-specific bands are seen in both lanes, notably at ~35 kDa. 
Data kindly provided by Dr Kyle Gurley, Kingsley lab, Stanford, USA. 
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Fig 4.3 here 
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Figure 4.4 Detection of ANKH-pcDNA3.1 expression in oocytes using Ab3 antibody 
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Figure 4.5 ANK constructs localise to the oocyte plasma membrane  
CLSM images of oocyte sections (10-15 m thickness) fixed with methanol 5 d after 
injection with either water (row 1) or cRNA of ANKH-pcDNA3.1 (row 2), mouse 
ANK-GFP (row 3), ANKH-pTNT (row 4).  
Overnight staining at 4°C with Ab3 is shown (column  1), except where primary 
antibody was omitted as stated. Secondary staining in all sections was with anti-
rabbit FITC. Transmitted light appearances are shown in column 2, and an overlay 
of Ab3 staining onto transmitted light (column 3). Scale bar = 50 m (applies to all 
images). 
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Fig 4.5 here 
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Figure 4.6 Identical and enhanced staining in ANKH-FLAG-injected oocytes 
using both Ab3 and anti-FLAG antibodies 
CLSM images of oocyte sections (10-15 m thickness) fixed for 4 h with methanol 3 
d after injection with either water (upper row) or ANKH-NT-3XFLAG cRNA (lower 
row).  
Overnight staining at 4°C was simultaneously perfor med with Ab3 (second column), 
mouse anti-FLAG (third column), or primary antibody was omitted (first column). 
Secondary staining in all sections was with anti-rabbit FITC and anti-mouse TRITC. 
Overlay of staining with both antibodies onto a transmitted light image is shown in 
the fourth column. Scale bars = 50 m, n = 2 separate experiments. 
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Fig 4.6 here 
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Figure 4.7 Non-identical staining of ANKH-FLAG-injected oocytes using anti-
N-terminal ANK and anti-FLAG antibodies 
CLSM images of oocyte sections (10-15 m thickness) fixed for 4 h with methanol 3 
d after injection with either water (upper row) or ANKH-NT-3XFLAG cRNA (lower 
row).  
Overnight staining at 4°C was simultaneously perfor med with rabbit anti-N-terminal 
ANK (second column), mouse anti-FLAG (third column), or primary antibody was 
omitted (first column). Secondary staining in all sections was with anti-rabbit FITC 
and anti-mouse TRITC. Overlay of staining with both antibodies onto a transmitted 
light image is shown in the fourth column. Scale bars = 50 m, n = 2 separate 
experiments. 
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Fig 4.7 here 
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Figure 4.8 CD98 marks the plasma membrane of Xenopus oocytes 
CLSM images of oocyte sections (10-13 m thickness) fixed with 2% PFA 3 d after 
injection with either water (top row) or human CD98 cRNA (other rows). Staining 
was performed with mouse anti-human CD98, with primary antibody omitted as a 
control (example in bottom row). Secondary staining was with anti-mouse TRITC in 
all sections. Overlay onto a transmitted light image is shown opposite each 
corresponding section. Anti-rabbit FITC was used separately as a further secondary 
antibody control, but no staining was observed. In all sections, results were the 
same regardless of whether (second row) or not (third row) permeabilisation with 
0.1% Triton X100 had been performed. 
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Fig 4.8 here 
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Figure 4.9 Confirmation of ANKH-FLAG localisation to the oocyte plasma 
membrane 
CLSM images of oocyte sections (10-15 m thickness) 2% PFA-fixed 3 d after 
injection with either water (row 2), ANKH-NT-3XFLAG (row 3) or ANKH-NT-
3XFLAG with CD98 (rows 1 and 4).  
Staining was simultaneously performed with rabbit anti-FLAG (green; column 1) 
and mouse anti-CD98 (red; column 2) as primary antibodies. Overlay of anti-FLAG 
and anti-CD98 images (column 3), and transmitted light views (column 4) are 
shown. No-primary antibody controls (row 1) were similar for all injected oocyte 
types. Secondary staining was with donkey anti-rabbit FITC and donkey anti-mouse 
TRITC in all sections. All sections were stained with and without 0.1% Triton X100 
permeabilisation for 15 min after fixation; results were indistinguishable from each 
other. Scale bars represent 50 m and apply to all images. 
Pixel intensity quantification for each channel using Leica software along a transect 
(marked with blue line; arbitrary units) for each overlay image is shown in column 5. 
Plasma membrane staining is marked by the asterisk.  
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Fig 4.9 here 













Endogenous oocyte membrane proteins may not be present in sufficient quantities to allow 
robust detection, so the specific membrane protein CD98 was overexpressed. CD98 (also 
known as 4F2) is composed of two subunits; a heavy chain membrane glycoprotein 
(SLC3A2) and a non-glycosylated light chain (SLC7A5), which dimerise to form a 
functional amino acid transporter as demonstrated by overexpression in Xenopus oocytes 
(Rossier et al., 1999). CD98 is expressed in many cell types but only on plasma membranes 
(Kanai et al., 2000). In kidney CD98 is a subunit of the LAT2 amino acid transporter which 
localises to the basolateral membrane of the renal proximal tubule (Rossier et al., 1999). 
Our results confirm expression and detection of the endogenous CD98-light chain complex 
in human kidney. Since CD98 is only expressed on the plasma membrane, it can be 
concluded that membrane and cytosol extracts are each reasonably pure. A pure membrane 
fraction will contain minimal cytoskeleton, and the much reduced alpha tubulin detection in 
the membrane fraction of oocytes also confirms this (Figure 4.3 C).  
CD98 staining experiments were performed on the same batch of oocytes as was used for 
CD98 detection by Western blotting. The results of staining (Figure 4.8) indicate that the 
red outer band seen on staining must be the membrane of the oocytes and not the vitelline 
layer. The similarity of appearances regardless of permeabilisation with detergent also 






The results confirm that ANKH-FLAG is expressed in the oocyte membrane. The lighter 
band seen on only one of the cytoplasmic fractions indicates the presence of cytoplasmic 
ANKH-FLAG, or more likely that there is contamination of the cytoplasmic preparation. 
Although immunofluorescence showed staining of intracellular membranes with all 
antibodies except anti-CD98, some of this may be non-specific given that it also occurs in 
water-injected oocytes. There is a brighter sub-membrane band in Ab3 and FLAG-stained 
ANKH-FLAG-injected oocytes (Figure 4.6) which may be due to massive overexpression 
of the protein resulting from injection of ~50 ng cRNA. Membrane proteins are transported 
in vesicles from the endoplasmic reticulum to the membrane, causing excess protein to 
simply collect below the membrane (Hirsch et al., 1996); (Forster et al., 1999). Cytoplasmic 
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staining was much reduced when only 5 ng of cRNA was used (Fernandes et al., 2007). 
Figure 4.4 confirms ANKH expression with injection of the non-FLAG tagged construct, 
which is probably maximal given the large amount of cRNA injected. 
Ab3 paralleled anti-FLAG’s immunodetection, hence validating Ab3 and supporting results 
obtained in Chapter 3 with this antibody in human tissue. It also agrees with results obtained 
by the Kingsley group (Figure 4.3 E), who also showed loss of the band when a C-terminal 
epitope deletion mutant (E440X) was probed with Ab3 (Figure 1a in (Gurley et al., 2006b)). 
None of the additional bands with either anti-FLAG or Ab3 immunodetection were 
consistent, suggesting that these are non-specific rather than representing detection of 






Staining of the outer rim of oocytes injected with ANKH-containing constructs was 
observed using Ab3. This appearance was confirmed with anti-FLAG staining, which 
exactly reflected staining with Ab3 in ANKH-FLAG-expressing oocytes. Finally, CD98 
was established as a precise marker of the oocyte membrane, seen in our experiments at the 
outer rim. Colocalisation of ANKH-FLAG and CD98 was seen in oocytes expressing both 









Cytosolic staining was noted on immunofluorescence using all antibodies.  Massive protein 
overexpression can lead to insertion into heterotopic membranes, which could include 
intracellular membranes (Wagner et al., 2000), and localisation of ANK in intracellular 
organelles is known (Carr et al., 2007). No immunodetection was observed in the 
cytoplasmic fraction of oocyte protein lysates, suggesting that the cytosolic staining may be 
artefactual. Oocyte autofluorescence (Manoharan et al., 2006) is unlikely to be a cause 
given the negative results of no-primary antibody controls. 
The outer rim of staining was more pronounced with methanol-fixed (Figure 4.6 and Figure 
4.7) compared to PFA-fixed sections (Figure 4.8). Methanol is a coagulating protein fixative 
causing dehydration which results in up to 50% shrinkage of cell volume (Bacallao et al., 
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2006). But staining of the outer rim was consistent with membrane localisation even in 
PFA-fixed oocytes (Kunchaparty et al., 1999). The apparent gap is likely due to a layer of 
dark sub-membranous cortical granules (Figure 4.10; and (Dumont, 1972)), as seen in 
transmitted light images (Figure 4.6 to Figure 4.8). 
4.4 Conclusions 
Expression of heterologous ANKH-constructs in the Xenopus oocyte has now been 
confirmed, with definite localisation to the plasma membrane. The purity of the membrane 
fraction of protein lysate, and definition of the oocyte plasma membrane were verified. Ab3 
was validated using a FLAG-tagged construct as suitable for confirming expression and 
detecting localisation of ANK(H) in oocytes using both immunofluorescence and Western 
blotting. On the other hand, the commercially available anti-N-terminal ANK antibody was 
found not to reliably detect ANK on either Western blot or immunofluorescence. 
ANKH-FLAG was constructed in the pcDNA3.1 mammalian expression vector. These 
results demonstrate that ANKH cloned into the pcDNA3.1 vector, as used in many of the 
functional experiments, is capable of expression of a membrane protein in oocytes, without 
modification or addition to the vector such as the -globin gene, as previously suggested by 
Gurley et al. (2006b). 
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Figure 4.10 Schematic diagram of ultrastructure of the vegetal pole of a Stage VI Xenopus
oocyte 
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The original paper by the Kingsley group (Ho et al., 2000) identified ank as the defective 
gene causing hereditary ankylosis in mice. Evidence relating to the physiological function 
of ANK was derived from experiments using primary fibroblast cultures from wild type and 
mutant ANKank/ank mice, where no increase in extracellular PPi concentration was observed 
in the latter, and from the observed abolition of abnormalities in mutant ANKank/ank mice 
when transfected with pCMV-ANK. They concluded that ANK functioned directly in PPi 
export. A second paper from this group (Gurley et al., 2006b) overexpressed the mouse 
ANK protein in Xenopus oocytes, using the isotope 33PPi to measure uptake of PPi, 
specificity being gauged by increased uptake of PPi relative to water injected oocytes. This 
technique, pioneered by Gurdon et al. (1971), has been widely used, as the oocytes can 
efficiently translate RNA for many membrane transporters and membrane receptor systems 
(Wagner et al., 2000). Many effects of disease-causing mutations are similar between 
oocytes and mammalian cells (Kamsteeg & Deen, 2001) even though oocytes are non-polar 
cells. Gurley et al. (2006b) demonstrated apparent specificity for their data regarding ANK-
mediated 33PPi uptake by demonstrating that expression of the E440X truncation mutation 
effectively eliminated 33PPi uptake. 
Gurley et al. (2006b) also showed saturation by external pyrophosphate (PPi) of 33PPi influx 
into ANK-expressing oocytes with an apparent Km of ~1.3 M, suggesting that ANK shows 
transporter rather than channel characteristics. This low Km for influx suggests high affinity 
but low capacity for extracellular PPi. As noted by these authors, the physiological direction 
of PPi transport is export rather than import, however, they were unable to perform this key 
experiment for unspecified “technical reasons”.  
The data presented in Chapters 3 and 4 have shown that transcription of ANKH cRNA can 
occur from various template constructs, and is efficiently translated to protein which traffics 
to the plasma membrane of oocytes. It is now possible to address the physiological mode of 
action of ANKH with radiolabelled tracer studies. The isotope 32PPi is readily available 
from PerkinElmer for studies of biosynthetic pathways and is of a high enough specific 
activity for flux determinations. The main advantage of 33PPi is its radio-stability compared 
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to the short half-life of 32PPi (14.7 days).  
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The objectives of this section are firstly to validate the experiments of Gurley et al. (2006b), 
then to investigate PPi transport in the physiologically relevant efflux mode. Given the data 
that emerged, it was considered important to revisit several aspects of the original work 
performed by Gurley, namely in control experiments for the stability of PPi against external 
phosphatase activity (so potentially releasing radiolabelled Pi) and the specificity of 
endogenous or overexpressed transport by NaPi (SLC34) for both Pi and PPi. Since ANKH-
mediated PPi transport (either in influx or efflux modes) could not be convincingly 
demonstrated, alternative possibilities concerning the nature of ANKH function were 
hypothesised and tested. Some transporters require assembly of a protein complex for 
function, such as CD98 (see section 4.3.1) which requires oligomeric association of light 
and heavy chains. In order to identify binary protein interactions, the N-terminal of ANK 
was used as bait using a high-quality mouse kidney cDNA library to perform a genome-
wide screen using the yeast two-hybrid method. 



















An endogenous sodium-dependent influx of inorganic phosphate (Pi) was clearly discerned 
in water-injected oocytes (Figure 5.1 A), with a median value of 1.5 pmol/oocyte/hour 
(Figure 5.1 A and Table 5.1). This endogenous transporter is likely to represent either a 
Xenopus type II Na+/Pi cotransporter (SLC34) which preferentially transports divalent 
HPO4
2– or a type III Na+/Pi cotransporter (SLC20; e.g. PiT-1) which transports monovalent 
H2PO4
– (Virkki et al., 2007). In oocytes injected three days earlier with flounder NaPi-IIb 
cRNA there is a marked increase in the sodium-dependent component of Pi influx compared 
to that obtained with endogenous transporters (Figure 5.1 B). Calculated fold changes of 
this influx with respect to endogenous (water-injected) influx was 4, 11 and 110 in three 
separate experiments (Table 5.1), illustrating the inherent variability in expression levels 
achieved between batches of oocytes from different frogs. In the absence of sodium, Pi 
influx was negligible (Figure 5.1 B). 
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Table 5.1 Influx of 
32
P activity as sodium phosphate into Xenopus oocytes. 
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Figure 5.1 Mean influx of 32P as 20 M NaH2PO4 into Xenopus oocytes over 40 minutes. 













A key issue that arises in these experiments is the possibility that PPi transport may be 
mediated by Pi (or other anion) transporting systems independently of ANKH, especially 
given the finding above that an endogenous Pi transport is present in oocytes. Additionally 
the presence of extracellular pyrophosphatase activity will release Pi from PPi. In order to 
determine whether either possibility exists, Pi or PPi were used at 1.25 mM in the 
extracellular medium as competitive inhibitors of 32Pi uptake. The flounder NaPi-IIb used in 
this experiment has a Km for Pi of ~40 M and mouse kidney NaPi-IIa has a Km for Pi of 
~70 M (Nalbant et al., 1999), indicating that saturation and hence knock-down of 32Pi 
transport would be expected at an extracellular [Pi] of 1.25 mM, as was observed (Figure 
5.2: A vs C; hatched bars; p=0.0001). A similar cis-inhibition of the endogenous NaPi 






When extracellular PPi was present at 1.25 mM, 32Pi influx via flounder NaPi transporters 
was non-significantly inhibited by 43% (p = 0.26, Figure 5.2: A vs B; hatched bars). Thus 
there may be a component of either competition of PPi with Pi for uptake via the same 
transporter, or extracellular hydrolysis of PPi enabling generation of sufficient non-labelled 
Pi to dilute out the effect of 32Pi and cause competitive inhibition of NaPi-mediated 32Pi 
uptake. Further experiments to determine the level of surface pyrophosphatase activity 
present in oocytes are presented in section 5.2.4, and experiments to investigate possible PPi 






Both Ca2+ and Mg2+ can give rise to complexes with both Pi and PPi which could reduce 
free substrate availability, so the effect of removing these cations from the extracellular 
buffer was tested. 32Pi transport into NaPi-injected oocytes was reduced but non-
significantly (p = 0.14) in the absence of extracellular calcium and magnesium (Figure 5.2: 
A vs D; hatched bars), but this also applies to the corresponding result with water-injected 
oocytes. This non-specific effect may indicate an increased membrane permeability 
occurring in the absence of Ca2+/Mg2+ (Orlov et al., 2005) followed by increased loss of 
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intracellular label in the wash phases. A significant cis-inhibition of Pi uptake by 1.25 mM 
Pi was still observed with excess unlabelled Pi (Figure 5.2: D vs F; hatched bars; p < 0.001), 
and there was also reduction of 32Pi uptake with excess PPi but again this was not 










32PPi influx was tested in ANKH cRNA-injected oocytes, three or six days post-injection so 
that a direct comparison could be made with data obtained by Gurley et al. (2006b). Using 
an extracellular 32PPi concentration of ~10 M, the level of 32PPi uptake in ANKH-injected 
oocytes was 176 ± 41 fmol/oocyte/hour; Table 5.1), compared to uptake (or surface 
binding) of 40 ± 8 fmol/oocyte/hour in water-injected oocytes, giving a 4.4-fold increase 
that was statistically significant ((p = 0.002), Table 5.1 and Table 5.3). In a similar influx 
experiment with a separate oocyte preparation (Figure 5.3) but using a 1 M PPi external 
solution, only a 1.7-fold increase of ANKH- versus water-injected conditions was observed.  
These values compare favourably with the ~180 fmol/oocyte/hour reported by Gurley for 
ANKH-expressing oocytes at 7 M external PPi (Figure 1 in Gurley et al. (2006b)). 
However, this represents an increase of at least 20-fold over the rate for water-injected 
oocytes, since Gurley obtained values of just ~5 fmol/oocyte/hour for influx into water-
injected oocytes. Corresponding values in our experiments were much higher even at 
equivalent substrate concentrations (Table 5.3; section 5.2.3.2).  
The effect of omission of divalent cations (Ca2+ and Mg2+) on 32PPi influx was also tested 
(Figure 5.3). This gave similar suppression of radiolabel uptake as was seen with 32P influx 
(section 5.2.2.3), ruling out complex formation as a reason for the low signal relative to 
water-injected oocytes.  
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In subsequent experiments using cRNA prepared from the ANKH-pcDNA3.1 construct, a 
significant and reproducible increment in 32PPi uptake over water-injected oocytes was not 
observed (Table 5.3). The level of 32PPi uptake in water injected oocytes was in the range 8 
- 4530 fmol/oocyte/hour (over a 0.5 - 109 M external 32PPi range), yielding a fold change 
of ANKH cRNA-injected over water-injected oocytes in the present data of less than two 
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(except for the single measurement at 4.4-fold). Such small fold changes are likely to be too 
small to provide reliable evidence of an effect.  
Figure 5.4 shows an experiment where the difficulties associated with such a low fold 
change of increased flux due to ANKH are evident. Here the ability of unlabelled PPi or Pi 
to cis-inhibit 32PPi uptake was tested. The increment in 32PPi uptake was only 1.6-fold 
compared to water-injected oocytes, and whereas 0.25 mM PPi reduced 32PPi uptake to 
similar values compared to water-injected, 0.25 mM Pi also reduced 32PPi uptake to similar 




Given the ability of unlabelled PPi to suppress a component of 32Pi uptake via the flounder 
NaPi-IIb and the endogenous oocyte NaPi transporter (section 5.2.2.2), the ability of 32PPi 
to act as a substrate in NaPi-IIb-injected oocytes was directly tested (Table 5.1). The level 
of 32PPi uptake (from 10 M external 32PPi) into NaPi-IIb-injected oocytes was 615 ± 83 
fmol/oocyte/hour, which was significantly enhanced compared to water-injected controls 
(p<0.001); indeed it was also above the level of 32PPi uptake into ANKH-injected oocytes 
(p < 0.001; Table 5.1, see also Table 5.3). With 32PPi at 100 M (i.e. much higher than the 
Km of PPi for ANKH reported by (Gurley et al., 2006b)), the fold change of ANKH- over 
water-injected was 1.4 compared to 2.7 for NaPi-IIb:water. It may be concluded that PPi is a 
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P into variously cRNA-injected oocytes. 
Oocytes were injected three days earlier with either ANKH-pcDNA3.1 cRNA, flounder NaPi-IIb or 




P as substrate. Each horizontal line 
represents a set of experiments performed simultaneously. Statistical analysis was with Tukey’s test 
enabling pairwise comparisons (results in text). 
Chapter 5 – Functional studies of ANKH in Xenopus oocytes 
__________________________________________________________________________________________________________________________________________ 
152
Figure 5.2 Effect of varying external conditions on the influx of labelled Pi into NaPi-IIb 
and water-injected oocytes. 
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Figure 5.3 Influx of labelled PPi into ANKH-pcDNA3.1 injected oocytes. 
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Table 5.3 Influx of 
32
P activity as sodium pyrophosphate into Xenopus oocytes 
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Figure 5.4 Influx of labelled PPi into ANKH-pcDNA3.1-injected oocytes under 
conditions of excess unlabelled substrate.  








Table 5.3 summarises several strategies that were attempted to improve the functional 
expression of ANK(H). Of greatest concern was the stability and integrity of the cRNA that 
was injected for translation in oocytes. All constructs were fully sequenced (Figure 2.2 to 
Figure 2.5) with no coding sequence errors. Data are shown for the various constructs used 
including mouse ANK-GFP (N-terminal), ANKH-GFP (N-terminal) and ANKH-FLAG (N-
terminal). Variation of constructs, oocyte incubation over 2-6 days, influx time period, 
concentration and activity of the tracer (Table 5.3) were all attempted, but none allowed 
consistent improvement of the fold change for 32P influx with construct- over water-
injected. It should be noted that the amounts of cRNA that were injected allowed robust 
detection of ANK protein expression and plasma membrane location (see Chapter 4). The 
median fold-increase above water for all 22 experiments was 1.24, but in the majority of 
these experiments this increase was not significant.
,$ !
Surface hydrolysis of PPi was determined by incubation of oocytes in a PPi-containing 
standard influx buffer solution under standard conditions. PPi concentration was determined 
directly used a novel fluorescent chemical sensor for PPi (see section 2.9). A typical 
standard curve for PPi concentration in the buffer used for oocytes is shown in Figure 5.5. 
The linear part of the standard curve confirmed that the useful range of the sensor was 0.3 to 
~10 M PPi. Furthermore, addition of an excess of PPase showed that the sensor was 
sensitive for PPi over Pi. 
Figure 5.6 shows that in the absence of oocytes PPi concentration is well maintained in the 
oocyte influx buffer. In the presence of oocytes there is a time-dependent decrease in PPi, 
with a loss over 60 minutes of 18% of initial PPi. The y-intercepts confirm that the initial 
PPi concentrations were the same (3.6 M). Using the slope of the line, the amount of PPi in 
the 70 l aliquot lost due to oocytes at 60 minutes can be calculated, and adjusted for the 
doubling of molar amount of Pi formed (PPi2 Pi), giving a rate of Pi formation of ~13 
pmol/oocyte/h. This is within the range of many of the results obtained for PPi influx (Table 
5.3). These data provide direct evidence that PPi may be hydrolysed to form Pi in the 
presence of oocytes, and show that substrate hydrolysis followed by alternative transport is 
a very important issue in influx experiments.   
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Figure 5.5 Standard curves for PPi assays using a chemical PPi sensor. 
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Figure 5.6 Determination of pyrophosphatase activity on the surface of Xenopus
oocytes. 
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In order to measure the efflux of 32PPi from ANKH- or water-injected oocytes it was first 
necessary to establish a protocol that allowed injection, sealing and subsequent maintenance 
of oocyte integrity during the efflux measurements. The inert sugar mannitol was used as a 
non-transported marker of the intracellular space (Figure 5.7). [14C]-mannitol was injected 
into oocytes, followed by washing and transfer into unlabelled oocyte incubation buffer 
using the efflux protocol (section 2.8.5.2). Loss of intracellular [14C]-mannitol activity was 
minimal (1-2%, Figure 5.7 A) when expressed as a proportion of the total activity 
(extracellular medium plus oocyte activity). Post-injection washing of oocytes does not 
substantially alter extracellular activity suggesting that surface activity and leakage after 
injection are minimal. In addition, there was no change in detected extracellular activity up 
to 120 minutes of incubation. The small but constant difference between calculated and 
measured mannitol in the system supports expression of efflux as a percentage of the total, 
rather than as an absolute number (Figure 5.7 B). 
The fluorescent organic anion Lucifer Yellow is actively secreted by isolated killifish 
proximal tubules (Masereeuw et al., 1999). Water-injected, ANKH-injected and uninjected 
oocytes re-injected with Lucifer Yellow resulted in the loss of ~70% of the injected amount 
at one hour (Figure 5.8). This shows that an endogenous “active” efflux mechanism for this 







A significant increase in efflux of labelled PPi in ANK-injected over water-injected oocytes 
was detected in only five out of 19 experiments with a maximum fold change of 5.3. Since 
mannitol leakage of up to 2.5% was seen, % 32PPi efflux values of greater than 2.5% would 
give additional experimental confidence that an ANK(H)-mediated efflux was occurring. 
Applying this, six of the 19 experiments are positive. Table 5.4 summarises the use of 
differing vectors, post-injection incubation periods, times over which efflux was measured, 
and the concentration and activity of intracellular radiolabelled tracer. There is no apparent 
correlation with any of these factors. Attempts at varying the injected cRNA concentration 
over the range 1-8 g/l resulted in premature oocyte death by two days’ incubation for 
cRNA concentrations greater than 3 g/l. 
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Figure 5.7 Estimation of 14C-mannitol leakage after micro-injection into 
Xenopus oocytes 
(A) Post-injection extracellular detectability of 14C-mannitol. Previously uninjected 
oocytes at 4 days after harvesting were injected with 50.6 nl of 14C-mannitol and 
incubated individually for varying time periods in 100 l of oocyte buffer. Oocytes 
were either washed twice in fresh buffer between injection and start of incubation 
(red), or not washed (blue). After the required incubation time, 80 l of buffer was 
drawn off for counting of 14C activity. Oocytes were resuspended in fresh buffer, 
then washed three times in ice-cold buffer before counting 14C activity. Results are 
expressed as the percentage of total activity (oocyte + buffer) left remaining in the 
buffer after the incubation period. Error bars represent SEM for n=6 oocytes. 
(B) Comparison of measured versus calculated total 14C activity in system. The 
mean measured total activity in each individual oocyte/buffer system at end of each 
incubation was calculated as the sum of the activity in oocyte and in the buffer after 
the incubation period, for both washed (red) and unwashed (blue) oocytes. The 
calculated total amount of substrate injected per 50.6 nl aliquot is shown in green. 
Error bars represent SEM for n=6 oocytes. 
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(Fig 5.7 goes here) 
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Figure 5.8 Active efflux from Xenopus oocytes re-injected with Lucifer Yellow 
(A) Standard curve of fluorescence due to Lucifer Yellow in oocyte buffer solution. 
Lucifer Yellow (dilithium salt) was diluted into oocyte buffer solution, and 1:1 serial 
dilutions were made in this buffer, to a total volume of 100 l each on a 96-well 
plate. The mean values from three separate dilution series were used. 
Fluorescence was measured at 520 nm, after excitation at 425 nm. The trend line 
shows a linear fit when fluorescence is plotted as a function of the Lucifer Yellow 
dilution (log scale shown here), showing that fluorescence over this range of Lucifer 
Yellow dilutions in oocyte buffer is proportional to the concentration. 
(B) Time course of Lucifer Yellow efflux/leakage from Xenopus oocytes. Groups of 
oocytes, injected two days earlier with either water (light blue) or ANKH-pcDNA3.1 
cRNA (red), or not injected (dark blue) were re-injected with 50 nl of Lucifer Yellow 
diluted in water. Each oocyte was immediately incubated in 100 l of oocyte buffer 
for the required length of time, with a further oocyte in 100 l buffer for 2 h. After 
incubation, 50 l of buffer was removed to a separate 96 well plate and 
fluorescence at  = 520 nm (excitation at 425 nm) was measured. Mean values 
from two oocytes per time-point were used. Data are expressed as fluorescence in 
the buffer at the end of the incubation period as a percentage of the total 
fluorescence of the single oocyte system at 2 h incubation. 
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Fig 5.8 here 
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Table 5.4 Efflux of 
32
P activity as sodium pyrophosphate from Xenopus oocytes. 






Intracellular PPi hydrolysis may partially account for the lack of observed efflux. However, 
there was no correlation between the estimated intra-oocyte PPi concentration attained and 
the resulting flux (Table 5.4), suggesting that PPi hydrolysis is not the sole reason. Attempts 
to measure PPi stability within the cytosol using the fluorescent PPi assay (section 5.2.4) 
were unsuccessful due to interference of oocyte homogenate with the assay (not shown).  
Facilitated transport displays an acceleration of unidirectional (cis to trans) flux when the 
trans-concentration of unlabelled substrate accelerates re-orientation of the carrier, this 
phenomenon being known as “trans-stimulation”. Its potential effect on detection of 
mediated 32PPi exit was tested by raising the extracellular concentration of unlabelled PPi to 
1 mM (Table 5.5). A significant increase in % efflux over water-injected oocytes was 
observed in only two out of five experiments, with only one of these giving rise to an efflux 
above 2.5%, with a maximum fold change of 3.4 (Table 5.5).  
These data show that either “technical reasons”, such as intra-oocyte PPi hydrolysis, prevent 
detection of ANKH-mediated efflux of PPi, or that the results are consistent with PPi not 
being the substrate for ANKH.  
,,$ 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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Rather than direct transport of PPi, it is possible that ATP may act as the original substrate. 
ANKH might then be an “active” carrier, allowing ATP binding and subsequent hydrolysis 
to release PPi followed by export of PPi to the external medium. Therefore efflux 
experiments using [32P]ATP labelled at either  or -phosphate positions were undertaken. 
Since PPi release would be expected to occur after hydrolysis between the  and β-
phosphates of ATP (forming AMP + PPi, (Heinonen, 2001)), the [-32P]ATP acted as a 
negative control. Sufficient [32P]ATP was injected to give an estimated intracellular 
concentration over the range 9-167 M, ensuring that a significant proportion of the whole 
intracellular ATP pool (normally ~1 mM) would be labelled. A significant increase in the % 
of 32P efflux that also exceeded the 2.5% criterion (described in section 5.2.5.2) was 
recorded in only one of nine experiments (Table 5.6). Flounder NaPi-IIb is included as 
another negative control. On balance, these results do not provide compelling evidence that 
ANKH uses ATP directly in order to generate PPi export. 
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Table 5.5 Efflux of 
32
P activity as sodium pyrophosphate from Xenopus oocytes under 
trans-stimulation conditions. 
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Table 5.6 Efflux of 
32
P activity as ATP/ from Xenopus oocytes. 










The pH of urine can alter markedly even over a few hours, but calcium phosphate stones 
form only at high pH (Sayer et al., 2010), implying a potential role for increased PPi export 
under these conditions. Proton dependence of ANKH in two vectors was investigated by 
altering pH of the buffer (Figure 5.9). Statistical analysis with Tukey’s test showed a 
difference only between pH 7.0 and 8.0 (p=0.02) with efflux from ANKH-pcDNA3.1-
injected oocytes being significantly increased compared to water controls (p<0.001).  
The effect of acute stimulation of ANKH activity was investigated using the cAMP 
activator forskolin and the intracellular free calcium augmenter thapsigargin. No increase in 
32PPi efflux was observed with either forskolin (p=0.61) or thapsigargin (p=0.49) above the 





The transport function of some membrane proteins requires the formation of dimers or 
oligomers at the plasma membrane (e.g.(Rossier et al., 1999)), without which a protein 
subunit is non-functional. To investigate the effect on efflux of potential partner proteins, 
ANKH-pcDNA3.1 cRNA was co-injected with total RNA extracted from whole human 
kidney (Table 5.7 and Figure 5.11). All pairwise comparisons between all groups in all three 
experiments were non-significant, except for one significant comparison as shown in Figure 
5.11 which occurred at much higher tracer activity (Table 5.7; see section 2.8.6.3 for an 
explanation of the relevance of activity). Although suggestive, these data can only be 
regarded as preliminary at present.  
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Figure 5.9 Effect of pH on efflux of 
32
P as sodium pyrophosphate from Xenopus
oocytes. 
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Figure 5.10 Effect of acute stimulation of ANKH activity on efflux of 
32
P as sodium 
pyrophosphate from Xenopus oocytes. 
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Table 5.7 and Figure 5.11 Efflux of 
32
P activity as sodium pyrophosphate from 
Xenopus oocytes co-injected with ANKH-pcDNA3.1 cRNA and human kidney total 
RNA. 





In order to screen for potential interacting partner proteins for ANKH, a commercial yeast 
two-hybrid screen was conducted using an N-terminal ANK fragment (residues 24-85) of 
mouse ANK as bait against a mouse kidney library (section 2.10.2; Figure 2.9). The output 
of the yeast two-hybrid screen is a list of positively interacting cDNA clones (prey 
fragments) many of which are fragments of actual mouse genes (Table 5.8). The interacting 
domain is deduced after aligning the fragments, and is defined as the minimum common 
domain shared by all the prey fragments corresponding to the same protein (Figure 5.12). 
However, the extent of the true interaction may actually be only about 20 amino acids.  
Overall, 33% of all interactions were deemed “high” or “very high” confidence as scored by 
Hybrigenics’ bioinformatics software; this corresponded to six genes. The remainder were 
all of either “good” or “moderate” confidence, and corresponded to 12 genes. No post-
scored interactions were deemed to be low confidence or due to known artefacts. Due to the 
heterogeneity of the mouse kidney cDNA library, many fragments may correspond to the 
same gene, which serves to increase the confidence in the result, provided that the 
interacting domain is the same in all the fragments, e.g. as with the Slc27a2 result (Figure 
5.12). However two putative interacting domains were identified within the 26 positive 
fragments for Aldh6a1 (aldehyde dehydrogenase; Figure 5.13). Two such domains very 
close together but not overlapping on the same protein suggests that this may be a false 
positive. In contrast, clones positive for Eef1a1 showed tight alignment.  
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Table 5.8 Positive interacting clones obtained from a yeast two-hybrid screen 
of an N-terminal ANK fragment.  
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       77 
                  1.  PHKPFLLFRD ETLTYAQVDR RSNQVARALH DQLGLRQGDC VALFMGNEPA 
                  2.  PHKPFLLFRD ETLTYAQVDR RSNQVARALH DQLGLRQGDC VALFMGNEPA 
                  3.  ..KPFLLFRD ETLTYAQVDR RSNQVARALH DQLGLRQGDC VALFMGNEPA 
                  4.  ......LFRD ETLTYAQVDR RSNQVARALH DQLGLRQGDC VALFMGNEPA 
                  5.  ......LFRD ETLTYAQVDR RSNQVARALH DQLGLRQGDC VALFMGNEPA 
                  6.  .......... ETLTYAQVDR RSNQVARALH DQLGLRQGDC VALFMGNEPA 
           Consensus  ......lfrd ETLTYAQVDR RSNQVARALH DQLGLRQGDC VALFMGNEPA 
                      117                                                  
                  1.  YVWIWLGLLK LGCPMACLNY NIRAKSLLHC FQCCGAKVLL ASPDLQEAVE 
                  2.  YVWIWLGLLK LGCPMACLNY NIRAKSLLHC FQCCGAKVLL ASPDLQEAVE 
                  3.  YVWIWLGLLK LGCPMACLNY NIRAKSLLHC FQCCGAKVLL ASPDLQEAVE 
                  4.  YVWIWLGLLK LGCPMACLNY NIRAKSLLHC FQCCGAKVLL ASPDLQEAVE 
                  5.  YVWIWLGLLK LGCPMACLNY NIRAKSLLHC FQCCGAKVLL ASPDLQEAVE 
                  6.  YVWIWLGLLK LGCPMACLNY NIRAKSLLHC FQCCGAKVLL ASPDLQEAVE 
           Consensus  YVWIWLGLLK LGCPMACLNY NIRAKSLLHC FQCCGAKVLL ASPDLQEAVE 
                      167                                                 
                  1.  EVLPTLKKDA VSVFYVSRTS NTNGVDTILD KVDGVSAEPT PESWRSEVTF 
                  2.  EVLPTLKKDA VSVFYVSRTS NTNGVDTILD KVDGVSAEPT PESWRSEVTF 
                  3.  EVLPTLKKDA VSVFYVSRTS NTNGVDTILD KVDGVSAEPT PESWRSEVTF 
                  4.  EVLPTLKKDA VSVFYVSRTS NTNGVDTILD KVDGVSAEPT PESWRSEVTF 
                  5.  EVLPTLKKDA VSVFYVSRTS NTNGVDTILD KVDGVSAEPT PESWRSEVTF 
                  6.  EVLPTLKKDA VSVFYVSRTS NTNGVDTILD KVDGVSAEPT PESWRSEVTF 
           Consensus  EVLPTLKKDA VSVFYVSRTS NTNGVDTILD KVDGVSAEPT PESWRSEVTF 
                      217              
                  1.  TTPAVYIYTS GG...... 
                  2.  TTPAVYIYTS GTTGLPK. 
                  3.  TTPAVYIYTS GTTGLPK. 
                  4.  TTPAVYIYTS GTTGLPKA 
                  5.  TTPAVYIYTS GTTGLPKA 
                  6.  TTPAVYIYTS ........ 
           Consensus  TTPAVYIYTS gttglpk. 
ETLTYAQVDRRSNQVARALHDQLGLRQGDCVALFMGNEPAYVWIWLGLLKLGCPMACLNYNIRAKSLLHCFQCCGAKVLLASPDLQEAVEEV
LPTLKKDAVSVFYVSRTSNTNGVDTILDKVDGVSAEPTPESWRSEVTFTTPAVYIYTS 
Figure 5.12 Alignment of amino acid sequences for Slc27a2 clone fragments 
that interacted with N-terminal ANK bait in a yeast two-hybrid screen. 
Nucleotide sequences for six individual Slc27a2 cDNA prey hits that interacted with 
ANK were obtained from the raw data (Hybrigenics). These were translated to 
amino acid sequences (SHOWORF), which were then aligned (Multalin). The 
conserved domain (green) is likely to contain the interaction domain. The numbers 
indicate the residues from the start of the coding sequence. The transmembrane 
domains (calculated from SMART) are at positions 5-27 and 266-288, both of which 
are outside the interaction domain, although TMPRED suggests a possible further 
transmembrane domain at 118-134.  
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Figure 5.13 Mapping of consensus sequences of interacting Aldh6a1 clones 
to the coding sequence. Nucleotide sequences for the 26 individual Aldh6a1 
cDNA prey clones that interacted with C-terminal ANK bait in a yeast two-hybrid 
screen were obtained from the raw data (Hybrigenics). These were translated to 
amino acid sequences (SHOWORF), which were then aligned (Multalin). The 
sequences were found to segregate into two categories; shown as consensus 
sequences x and y, with mapping to the Aldh6a1 coding sequence. 21 clones 
mapped to one section (consensus sequence x; purple). The other five clones 
mapped to a separate section (consensus sequence y; green). 
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        1                                                   50 
             Aldh6a1  .......... .......... .......... .......... .......... 
                   x  QVSSKVNATW YPASSFSSSS VPTVKLFIDG KFVESKSDKW IDIHNPATNE 
                   y  .......... .......... .......... .......... .......... 
           Consensus  .......... .......... .......... .......... .......... 
                      51                                                 100 
             Aldh6a1  .......... ..MDAAVESC KRAFPAWADT SILSRQQVLL RYQQLIKENL 
                   x  VVGRVPQSTK AEMDAAVESC KRAFPAWADT SILSRQQVLL RYQQLIKENL 
                   y  .......... .......... .......... .......... .......... 
           Consensus  .......... ..mdaavesc krafpawadt silsrqqvll ryqqlikenl 
                      101                                                150 
             Aldh6a1  KEIARLITLE QGKTLADAEG DVFRGLQVVE HACSVTSLML GETMPSITKD 
                   x  KEIARLITLE QGKTLADAEG DVFRGLQVVE HACSVTSLML GETMPSITKD 
                   y  .......... .......... .......... .......... .......... 
           Consensus  keiarlitle qgktladaeg dvfrglqvve hacsvtslml getmpsitkd 
                      151                                                200 
             Aldh6a1  MDLYSYRLPL GVCAGIAPFN FPAMIPLWMF PMAMVCGNTF LMKPSERVPG 
                   x  MDLYSYRLPL GVCAGIAPFN FPAMIPLWMF PMAMVCGNTF LMKPSERVPG 
                   y  .......... .......... .......... .......... .......... 
           Consensus  mdlysyrlpl gvcagiapfn fpamiplwmf pmamvcgntf lmkpservpg 
                      201                                                250 
             Aldh6a1  ATMLLAKLLQ DSGAPDGTLN IIHGQHDAVN FICDHPDIKA ISFVGSNQAG 
                   x  ATMLLAKLLQ DSGAPDGTLN IIHGQHDAVN FICDHPDIKA ISFVGSNQAG 
                   y  .......... .......... .......... .......... .......... 
           Consensus  atmllakllq dsgapdgtln iihgqhdavn ficdhpdika isfvgsnqag 
                      251                                                300 
             Aldh6a1  EYIFERGSRN GKRVQANMGA KNHGVVMPDA NKENTLNQLV GAAFGAAGQR 
                   x  EYIFERGSRN GKRVQANM.. .......... .......... .......... 
                   y  .......... .......... .......... .......... .......... 
           Consensus  eyifergsrn gkrvqanm.. .......... .......... .......... 
                      301                                                350 
             Aldh6a1  CMALSTAILV GEAKKWLPEL VDRAKNLRVN AGDQPGADLG PLITPQAKER 
                   x  .......... .......... .......... .......... .......... 
                   y  .......... .......... .......... .......... .LITPQAKER 
           Consensus  .......... .......... .......... .......... .litpqaker 
                      351                                                400 
             Aldh6a1  VCNLIDSGTK EGASILLDGR RIKVKGYENG NFVGPTIISN VKPSMTCYKE 
                   x  .......... .......... .......... .......... .......... 
                   y  VCNLIDSGTK EGASILLDGR RIKVKGYENG NFVGPTIISN VKPSMTCYKE 
           Consensus  vcnlidsgtk egasilldgr rikvkgyeng nfvgptiisn vkpsmtcyke 
                      401                                                450 
             Aldh6a1  EIFGPVLVVL ETETLDEAIK IVNDNPYGNG TAIFTTNGAT ARKYAHMVDV 
                   x  .......... .......... .......... .......... .......... 
                   y  EIFGPVLVVL ETETLDEAIK IVNDNPYGNG TAIFTTNGAT ARKYAHMVDV 
           Consensus  eifgpvlvvl etetldeaik ivndnpygng taifttngat arkyahmvdv 
                      451                                                500 
             Aldh6a1  GQVGVNVPIP VPLPMFSFTG SRSSFRGDTN FYGKQGIQFY TQLKTITSQW 
                   x  .......... .......... .......... .......... .......... 
                   y  GQVGVNVPIP VPL....... .......... .......... .......... 
           Consensus  gqvgvnvpip vpl....... .......... .......... .......... 
                      501              519 
             Aldh6a1  KEEDATLSSP AVVMPTMGR 
                   x  .......... ......... 
                   y  .......... ......... 
           Consensus  .......... ......... 
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The mechanism of PPi transport is unknown. PPi is a polar molecule and would be unable 
to cross a lipid bilayer at a significant rate (Visser et al., 2005). Gurley et al. (2006b) 
quantified ANK functional activity by influx since efflux determinations were limited by 
“technical considerations”. Since the presumed role of ANK is the export of PPi to the 
extracellular medium (Ho et al., 2000) and since the majority of PPi production is 
intracellular (Heinonen, 2001), it is unclear what physiological role influx of PPi would 
serve. Even if influx occurred, PPi (P2O7
4-) would move against its electrochemical gradient 
(resting intracellular potential in oocytes is -40 to -80 mV (Dascal et al., 1984)).  
The present data replicate those of Gurley et al. (2006b) in the overall magnitude of PPi 
influx, but differ in both the consistency and nature of PPi influx in water-injected control 
oocytes. One unusual feature of the data of Gurley is that the high variability in oocyte 
fluxes caused the authors to omit both the highest and lowest influxes in replicate data sets. 
Although obvious contamination or bursting of oocytes would cause exclusion from data 
analysis, the systematic removal of such data suggests an actual variability not accounted 
for by the indicated variances. Since we have demonstrated (for the first time) membrane 
expression of ANKH due to translation from injected cRNAs in various vectors, our data 






Two families of phosphate transporters are known: type II Na+/Pi cotransporters (SLC34) 
which preferentially transport divalent HPO4
2– and type III Na+/Pi cotransporters (SLC20; 
e.g. PiT-1) which transport monovalent H2PO4
– (Virkki et al., 2007). Only the type II 
transporters have been shown to exist endogenously in oocytes (Weber, 1999), and transport 
has been previously well characterised (Bröer et al., 1998). We confirmed that endogenous 
sodium-dependent phosphate flux exists, using flounder NaPi-IIb-injected oocytes as a 
positive control. 
Flounder NaPi-IIb has a Km for Pi of 40 M and mouse kidney NaPi-IIa has a Km for Pi of 
70±30 M (Nalbant et al., 1999). We showed that cis-inhibition of 32Pi transport occurs at 
an extracellular non-labelled Pi concentration much higher than the Km, consistent with 
saturation of 32Pi transport. We found that excess extracellular PPi tended to inhibit 32Pi 
influx (by 43%). Possible explanations that were tested further include extracellular 
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hydrolysis of PPi giving rise to generation of non-labelled Pi and subsequent competition, 
and PPi itself being a substrate for NaPi.  
The magnitude of 32Pi influx was reduced (but not always significantly) where divalent 
cations were absent including endogenous Pi transport. The NaPi transporter is not known 
to require divalent cations, but the absence of divalent cations can increase membrane 
permeability (Orlov et al., 2005), allowing increased loss of intracellular label in the wash 
phases. Alternatively, phosphatase activity is much reduced under Mg-free conditions since 
many triphosphatases use Mg-ATP as substrate (see section 5.3.4). 
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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Apparent 32PPi influx into ANKH-injected oocytes was even smaller than that using 32PPi 
into NaPi-injected oocytes. Again a possible explanation is that extracellular hydrolysis to 
labelled phosphate allowed subsequent influx of Pi via NaPi. Tracer influx of 32Pi via 
ANKH was greater than endogenous (water-injected) 32Pi transport, and of a similar 
magnitude to tracer influx of 32PPi via ANKH, suggesting that ANKH may transport both Pi 
and PPi. Recently, (Wang et al., 2009) suggested that ANK may interact directly with the 
Na-Pi transporter PiT-1, supporting the idea of a physiological relationship between Pi and 
PPi transport. The strategy of blocking endogenous Pi transport by using NaPi inhibitors 
such as foscarnet (Wang et al., 2005) and/or phosphatases (e.g. fluoride (Kocinsky et al., 
2007) or levamisole (Lomashvili et al., 2008)) was rejected as the effect on ANKH function 









An enzymatic assay for PPi (Sigma reagent, section 2.9.1) was unable to accurately detect 
PPi at concentrations lower than 100 M. The fluorescent sensor system developed by 
(Dong Hoon et al., 2004) uses two oxygen atoms on the PPi ion (P2O7
4-) to form a bridge 
between two Zn2+ ions in the sensor molecule. It shows high selectivity for PPi over Pi and 
ATP. Our results confirm that the sensor is useful over a suitably low PPi concentration 
range, and that PPi is removed from solution by PPase except when divalent cations are 
absent and PPi concentration is high. PPase enzymes require a divalent metal ion, usually 
Mg, for function (Miro et al., 1989). Indeed Fleisch (Russell et al., 1971) detected slow 
hydrolysis of PPi in blood over >20 hrs, which was almost abolished by adding the divalent 
cation chelator EDTA. The Km of PPase ranges from 0.5 M (Miro et al., 1989) to 18.8 M 
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(ocean Thermococcus (Lee et al., 2009)) showing relatively high affinity for PPi. 
Surprisingly, the presence or absence of divalent cations in the incubation buffers made no 
difference to measured PPi detection over the linear part of the standard curve. Since the 
sensor recognises free PPi ions, our results suggest that PPi must be biologically available in 
ionised form over the detectable range at pH 7.4, regardless of the formation of insoluble 
complexes with divalents or dissociation of PPi. No chelator was used so low divalent 
cation concentrations (e.g. ~1 M) would have been present even in the Ca/Mg-free buffer. 
Pyrophosphoric acid is a polybasic acid, therefore PPi solutions are always partially 
dissociated depending on the pH of the solution and the dissociation constants (McGilvery 
& Crowther, 1954). The third acid dissociation constant (pK3) is 7 (p. 424 in (Cotton, 
1999)), hence PPi is mostly ionised at physiological pH and unlikely to spontaneously 
hydrolyse over the experimental time period. These facts support the conclusion that PPi 
exists in the buffer in mostly ionised form, with good bioavailability to the sensor over the 




The reduction in PPi concentration over time strongly suggests surface PPase activity on 
oocytes. This is sizeable compared to the small measured flux of 32PPi and means that the 
interpretation that PPi influx occurs solely via ANKH is implausible. It is also consistent 
with the results showing apparently increased influx using 32PPi in NaPi-injected oocytes 
compared to ANKH- or water-injected oocytes. The oocyte follicular layer has high 
Ca2+/Mg2+-dependent ATPase activity (Ziganshin et al., 1995) but since all oocytes used 
were defolliculated, the molecular nature of the extracellular pyrophosphatase in oocytes 
remains unknown.
Our results strongly conflict with those of Gurley et al. (2006b), who used thin-layer 
chromatography to claim that “no detectable hydrolysis of PPi to Pi occurred in transport 
buffer incubated with oocytes during the time periods used for PPi assays”, but provided no 
data in their paper. Numerous attempts to examine intracellular PPase activity using 
centrifuged oocyte (cytosolic) homogenates were unsuccessful due to turbidity affecting the 
fluorescence of the sensor.  













Using control experiments with mannitol and Lucifer yellow, we defined a protocol to 
measure efflux of possible substrates from ANKH-injected oocytes. Gurley et al. (2006b) 
failed in a similar attempt due to “technical limitations” despite acknowledging that the 
predicted direction of transport via ANK (Ho et al., 2000) required measurement of efflux 
rather than influx. They generalised the results of influx on the basis of likely 
bidirectionality of transport, although there is no evidence to support this and indeed it 
conflicts with the presumed physiological mode of transport and the prevailing 
electrochemical gradient.  
Our results show that a consistently significant efflux ratio compared to water-injected 
oocytes was not detectable despite testing different combinations of vectors, substrates, 
substrate activities and concentrations, incubation times, buffer pH, two possible acute 
regulators and two different experimental techniques. As already demonstrated in Chapter 4, 
cRNA transcribed from various constructs has been shown to be generate ANKH protein 
which is expressed in the oocyte membrane. Therefore either ANK does not transport PPi, 
or appropriate conditions for efflux have not yet been fulfilled; notably any intracellular 
hydrolysis of PPi may rapidly deplete the substrate at the plasma membrane.
This conclusion was supported by considering various technical issues. Enough free PPi 
must be available for export. We used intra-oocyte 32PPi concentrations of between 1 and 
100 M. At very high concentrations, non-specific transport effects may be observed, but 
the availability of PPi would still be maintained even if PPase activities are saturated (their 
Kms are likely to be low; see section 5.3.4), yet significant export of hydrolysed or non-
hydrolysed radiolabel was often not observed. Leakage via membrane damage from re-
injection was found not to be significant using the technique of retention of labelled 
mannitol (section 5.2.5.1). Finally, the possibility that ATP may directly interact with 
ANKH, with membrane protein-associated binding and hydrolysis of ATP releasing PPi for 
transport to the external medium was considered. Efflux experiments using injections of 
both  and -labelled [32P]ATP failed to show a robust increase in radiolabel of ANKH-
injected oocytes compared to water-injected oocytes. 





Domain analysis of the mouse ANK protein (Ensembl reference ENSMUSP00000022875) 
using SMART14 reveals eight transmembrane segments, giving N- and C-terminals that are 
intracellular (Figure 2.9), but otherwise there are no recognised domains. Therefore ANK is 
unusual in consisting of a single, unique domain. A yeast two-hybrid screen using an N-
terminal ANK bait with a mouse cDNA kidney library was used to identify possible 
interacting proteins. Of the several possible interacting proteins identified, notably no 
phosphate transporters are identified despite their relatively high abundance within the 
kidney and possible co-operative behaviour between ANK and phosphate transporters 
(Wang et al., 2009). The N-terminal bait peptide used would have incorporated the site of 
the known M48T mutation that interrupts the ANKH interaction with PiT-1 (Wang et al., 
2009).  
The possible biological significance of each of the interactions identified is now considered.  
,5 1
Aldh6a1 is the only CoA-dependent aldehyde dehydrogenase (Kedishvili et al., 2000); it 
localises to the mitochondrial matrix where it catalyses acetyl CoA production from 
malonate. ANK localises to the mitochondria in the mouse collecting duct cell-line 
mIMCD-3 (Carr et al., 2007), but is not present in mitochondrial DNA. It is conceivable 
that ANK therefore requires a chaperone such as Aldh6a1 to allow mitochondrial 
localisation. On the other hand, the present screen revealed apparently two consensus 
interacting domains of Aldh6a1, which map to different amino acid sequences (Figure 
5.13). Although these two domains are very close together, they do not overlap on the same 
protein sequence. Notably, sequence ‘x’ (Figure 5.13) maps partially to an area before the 
start of the Aldh6a1 coding sequence (5’ UTR). These factors may suggest a spurious 
interaction which has caused a false positive. In addition, reactions involving Aldh6a1 do 
not generate PPi (Kedishvili et al., 1992).  
,5 0
The ubiquitously expressed and highly conserved protein Eef1a1 (eukaryotic translation 
elongation factor 1 alpha 1) allows the delivery of aminoacyl tRNAs to ribosomes in the 
process of protein translation and elongation. PPi is a product of the overall reaction 
catalysed by aminoacyl-tRNA synthetase (amino acid + ATP + tRNA aminoacyl-tRNA + 
                                                
14 http://smart.embl-heidelberg.de/ 
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AMP + PPi). As components of this process, the cellular localisation of aminoacyl-tRNA 
synthetase, elongation factors and ribosomes is likely to be co-ordinated. Oocytes contain 
many ribosomes, and intra-oocyte ANKH staining was noted in confocal sections where 
ANKH protein was expressed (Figure 4.6 and Figure 4.7). Removal of PPi is necessary to 
maintain the equilibrium for aminoacyl-tRNA formation (Heinonen, 2001) in membrane-
bound ribosomal complexes. Enzymatic hydrolysis of PPi may account for its removal, but 
this may also occur by PPi transport to the endoplasmic reticulum lumen.  
However it should be noted that Eef1a1 has many other important functions relating to the 
cytoskeleton (Mansilla et al., 2008), such as directing mRNA translation (Condeelis, 1995), 
and regulation of transcript selection (Zhang et al., 2009). In fact Eef1a1 is the second most 
abundant protein after actin in most cells (Condeelis, 1995) and the ubiquitous nature of this 
protein means that this putative interaction may represent a false positive in yeast two-







Slc27a2 (also known as FATP2) which has 2-3 predicted transmembrane domains 
(SMART14/TMpred16) mediates transport of long chain fatty acids into cells (some diffuse 
through the lipid bilayer). Localisation is confined to kidney cortex and liver (Hirsch et al., 
1998). There is high homology between FATP2 and other family members. Richards 
(Richards et al., 2003) showed that FATP1 (Slc27a1) forms dimers and possibly larger 
complexes, most likely through interactions between amino acids 191 and 475, as deduced 
by co-immunoprecipitation of truncated FATP1 constructs tagged with different markers. 
The present screen showed that a convincing interaction domain with N-terminal ANK was 
highly conserved among six clones (Figure 5.12), and occurred between residues 77 and 
227.  
All FATPs have a highly conserved AMP-binding region at around position 250 (Hirsch et 
al., 1998), which mediates ATP binding, enabling metabolism of long chain fatty acids to 
occur. FATPs mediate both fatty acid transport and acyl CoA-synthetase activity, the latter 
catalysing the hydrolysis of ATP to AMP and PPi (shown in Figure 5.14). Since this 
reaction is reversible (p. 191 in (Ernster, 1992)), PPi must be rapidly removed to favour 
production of long-chain acyl CoA for beta-oxidation, and this must occur immediately at 
the site of PPi production. ANK is present in membranes of many cell compartments (Carr
                                                
15 www.fccc.edu/research/labs/golemis/InteractionTrapInWork.html 
16 www.ch.embnet.org/software/TMPRED_form.html 
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et al., 2007). A direct interaction between FATP and ANK would be energetically 
favourable in maintaining the forward reaction, and would allow a physiological role for PPi 
on the trans side of the membrane without wasting energy by uncoupled hydrolysis of PPi 
by a pyrophosphatase.  
FATP2 is found on the membranes of renal peroxisomes, allowing entry of fatty acids from 
the cytosol. Visser et al. (2005) demonstrated a renal peroxisomal membrane transporter 
that facilitates “phosphate and possibly pyrophosphate” export. They were able to 
distinguish phosphate transport activity from that in mitochondria by using specific 
inhibitors, and demonstrated inhibition of phosphate transport by unlabelled PPi. They 
found no detectable PPase activity in the renal peroxisome fractions; similar findings have 
been shown in rat liver cells (Shatton et al., 1981). Given the findings of intracellular 
localisation, kidney expression, interaction data and lack of membrane-associated PPase, we 








Since (a) ANKH has been implicated in PPi export, (b) ANKH protein can be expressed in 
the oocyte membrane, and finally (c) PPi transport across a plasma membrane almost 
certainly requires the presence of a transporter, the possibility of PPi transport across this 
membrane in both directions was directly investigated. Previous studies have not considered 
in detail factors such as stability and bioavailability of PPi, the possibility of other 
substrates, and substrate specificity for ANKH or phosphate transporters. Even accounting 
for these, our studies showed no convincing influx or efflux due to ANKH even with 
various combinations of these experimental variables. Apparent lack of transport could be 
due to: 
1. Substrate non-availability – Substrate microinjected into oocytes may become 
sequestered inside the oocyte e.g. by ANKH present in intracellular membranes; 
hydrolysed by intracellular pyrophosphatases; unable to diffuse through the large 
cell volume of the oocyte to the surface; or complexed with free calcium inside the 
cell. In addition, the specific activity/concentration ratio of the substrate may not 
have been high enough after accounting for these factors.  
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2. Hydrolysis at cell surface – this may reduce PPi availability for ANK-mediated 
influx, especially at low initial PPi concentration, although intracellular PPase 
activity could not be assayed. 
3. Incorrect hypothesis – PPi may not be transported by ANKH itself but by another 
unknown protein with ANKH acting as a co-factor or regulator. The oocyte system 
would not replicate a multi-component system as found in the intact cell or kidney 
tissue.  
4. Requirement for binding partner – Slc27a2 (FATP2) was the only positive 
interacting clone on the yeast two-hybrid screen that is directly involved in PPi 
generation. It localises to the peroxisome in kidney, where a physiological role exists 
for PPi transport out of the peroxisome. However this may not reflect the situation at 
the apical membrane of collecting duct cells, as FATP2 is not known to localise to 
the plasma membrane. Conversely FATP1 is present at the plasma membrane but is 
expressed at low levels in kidney and was not a positive interacting clone in the 








The localisation of ANKH expression to the cortical collecting duct of human kidney was 
shown in Chapter 3, and supports previous data obtained in mouse kidney collecting duct 
cells (Carr et al., 2007). An alternative way of investigating ANK function would be to 
study a model epithelial cell line which retains specific differentiation appropriate to this 
tubule segment, such as AVP (ADH) responsiveness. Reconstituted epithelial layers grown 
on filters are polar in nature, allowing aspects of vectorial transport to be determined. The 
mouse cell-line, mpkCCDcl4, meets these requirements and was therefore chosen for further 
investigation (Chapter 6). 
185
Figure 5.14 Possible interaction between FATP and ANKH. 
(Singh & Poulos, 1988); (Steinberg et al., 1999)). 
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6 Results (IV): Regulation of ANK using a mouse 






The principal cells of the cortical collecting duct (CCD) are AVP-sensitive, allowing AQP2 
to be expressed in the apical membrane under appropriate conditions (Nielsen et al., 2002). 
We have shown that ANK and AQP2 proteins are both expressed in the collecting duct in 
human kidney, with previously similar findings in mouse (Carr et al., 2007). Water 
reabsorption via AQP2 causes increased calcium concentration in the lumen, which creates 
a physiological requirement for the co-ordinated inhibition of crystallisation. Export of PPi 
into the lumen via ANK would serve this role. We therefore hypothesise that the surface 
membrane expression of ANK is regulated by AVP in a similar manner to that of AQP2. 
Screening using the yeast two-hybrid method identified SLC27A2 as a potential interacting 
partner with ANK that may form a biochemical couple. SLC27A2 is expressed only in liver 
and kidney (Hirsch et al., 1998). It localises to rat liver peroxisomes and microsomes but 
not to mitochondria (e.g. Singh & Poulos (1988); Steinberg et al. (1999)). The plasma 
membrane of liver cells was not examined in this study and no published studies have 
defined subcellular localisation in particular nephron segments17. Whether or not SLC27A2 
is expressed in the plasma membrane of CCD cells, and is therefore available for potential 







Obtaining pure mRNA specific to collecting duct cells is a key requirement in these 
experiments. Extraction of mRNA from principal cells isolated directly from microdissected 
CCDs would give rise to only small amounts of mRNA (Robert-Nicoud et al., 2001). Bulk 
isolation would risk contamination with other cell types as well as requiring the 
maintenance of animals in dehydrated, euvolaemic and overhydrated water states. 
Establishing primary cultures of cells from the normal pole of resected human kidney would 
present similar isolation problems and would require extensive testing. Human cell lines 
originating from renal carcinomas invariably lose key phenotypic features (Charlton, 1993). 
                                                
17 http://locate.imb.uq.edu.au 
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A well characterised clonal cell line, mpkCCDcl4, was used instead. This cell line is derived 
from CCD segments isolated from the kidney of a one month old SV-PK/Tag transgenic 
mouse (Bens et al., 1999). ANK expression in mpkCCDcl4 murine cortical collecting duct 
cells and in whole mouse kidney was confirmed by RT-PCR (Figure 3.4), and endogenous 
protein expression has previously been confirmed at the expected size (~50 kDa) using Ab3 
antibody (Carr et al., 2009). mpkCCDcl4 cells display a polarised epithelial phenotype with 
steroid-sensitive sodium transport (Bens et al., 1999). Importantly, they have also been 
shown to respond to AVP treatment by increased expression of AQP2 (Hasler et al., 2002). 
They have also been studied in microarray analyses (see section 6.3.3.3), and the mouse 
ANK protein is virtually identical to the human homologue (Figure 3.1).  
1 - 
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Short-term regulation of membrane proteins occurs via interactions with other proteins or 
subunits and by phosphorylation (Van Winkle, 1993). ANK contains multiple 
serine/threonine and tyrosine phosphorylation sites within its cytoplasmic loops (NetPhos2 
prediction18) indicating such potential. Regulation over the longer term by growth factors 
and phorbol esters has been reported, which up-regulate ANK mRNA and protein 
expression (Guo et al., 2001).
1$ 	

The aim of this section is to investigate whether the regulation of ANK is linked to that of 
AQP2, and whether SLC27A2 or other partner proteins are expressed and involved in this 
process. Elucidating control of ANK regulation may provide clues to its molecular 
physiology and the identity of alternative partner proteins. The objectives were to examine 
the effects of AVP stimulation of a collecting duct cell line on expression of ANK and 
AQP2 proteins by immunofluorescence and on the pattern of gene expression, with 
confirmation of results using quantitative PCR. 





Cell monolayers were grown on filters allowing measurements of resistance and 
transepithelial potential difference to be made to confirm the integrity and differentiation of 
                                                
18 www.cbs.dtu.dk/services/NetPhos/ 
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the CCD layers. Under non-stimulated conditions, there was no AQP2-specific 
immunofluorescence. Using Ab3 antibody, ANK immunofluorescence of cilia was seen at 
the apical surface (top row in Figure 6.1 A), with subsequent confocal sections in a more 
basolateral direction showing plasma membrane outlines of ANK immunofluorescence in 
all cells (top row in Figure 6.1 B). This positive immunofluorescence in both apical and 
basolateral membrane areas was confirmed by co-staining using anti-ZO1 secondary 
immunofluorescence to identify tight junctions (Dr G Carr, unpublished results).  
After incubation with AVP in the basal bathing media for 24 h, an average of 6.6% of cells 
in random fields of view across four separate experiments showed marked upregulation of 
AQP2, with strong secondary immunofluorescence now present at the apical membrane. In 
similar analysis 1.8% of cells showed upregulation and apical secondary 
immunofluorescence for ANK (Figure 6.1). Surprisingly, after AVP exposure, the AQP2-
positive cell population was quite distinct from the ANK-positive population, with only 
very isolated instances of colocalisation of upregulated ANK and AQP2 at the apical 
membrane (not shown). Similar data were obtained after 24 h treatment with 10 M 








The unexpected results obtained in section 6.2.1.1 above, showing heterogeneity between 
cells in their response, suggests that the clonal nature of the cell line had not been 
maintained. An alternative possibility is that several phenotypes arising from the cortical 
collecting duct are represented. Since active calcium reabsorption occurs only in the 
adjacent distal tubule and connecting tubule segments (Hoenderop et al., 2002), the 
possibility that an unexpected calcium-transporting phenotype was represented was tested 
by investigating expression of calbindin-D28K. No anti-calbindin secondary 
immunofluorescence was seen in any section under non-stimulated conditions (Figure 6.2). 
In contrast, AVP treatment resulted in upregulation of both ANK and calbindin staining, 
with co-localisation in all positive cells to the apical plasma membrane. Unlike AQP2 
immunofluorescence above, only one population of positively stained cells was revealed. 
Three-channel confocal microscopy was not available, but similar immunofluorescence was 
seen when anti-calbindin antibody was used alone. A cytofluorogram of pixel intensity over 
the whole field showed that fluorescence of green (ANK) and red (calbindin) channels 
overlapped considerably producing a yellow colour, with evidence of separate green and red 
pixels, though green predominated in the peripheries.  
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Figure 6.1 (next two pages) CLSM images of methanol-fixed mpkCCDcl4
epithelial layers, under control conditions and after incubation for 24 h with 
either arginine vasopressin (AVP; 10-8M) or forskolin (10-5M).  
Immunofluorescence was simultaneously performed with Ab3 (green; column 1) 
and goat anti-AQP2 (red; column 2) as primary antibodies. Overlay of Ab3 and anti-
AQP2 images is shown in column 3. Secondary staining was with donkey anti-
rabbit FITC and donkey anti-goat TRITC in all sections. Scale bars represent 20 m 
and apply to all images. Representative images from four separate experiments 
each are shown.  
Figure A:
Top row: xy sections under resting (untreated) conditions 
Middle row: xy sections after incubation with AVP 
Lower row: xz sections after incubation with AVP (apical surface uppermost) 
Figure B: 
Top row: xy sections under resting (untreated) conditions 
Middle row: xy sections after incubation with forskolin 
Lower row: xz sections after incubation with forskolin 
(Data for figure B from Dr G Carr, unpublished results) 
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Fig 6.1 A goes here 
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Fig 6.1 B goes here 
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Figure 6.2 CLSM images of methanol-fixed mpkCCDcl4 epithelial layers, under 
control conditions and after incubation for 24 h with arginine vasopressin 
(AVP; 10-8M), using anti-calbindin antibody.   
Immunofluorescence was simultaneously performed with Ab3 (green; column 1) 
and goat anti-calbindin-D28K (red; column 2) as primary antibodies. Overlay of Ab3 
and anti-calbindin-D28K images is shown in column 3. Secondary antibodies were 
donkey anti-rabbit FITC and donkey anti-goat TRITC respectively in all sections. 
Scale bars represent 20 m and apply to all images. Representative images from 
three separate experiments each are shown.  
First row: xy sections under control (untreated) conditions 
Second row: xy sections after incubation with AVP 
Third row: xz sections after incubation with AVP (apical surface uppermost) 
Fourth row: Cytofluorogram for Ab3 immunofluorescence (x-axis) and anti-
calbindin-D28K immunofluorescence (y-axis) 
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Fig 6.2 here 
(Davidson & Halestrap, 1988) 
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These results are consistent with colocalisation of ANK and calbindin-D28K at the apical 
membrane, and with ANK immunofluorescence alone in intracellular and lateral membrane 
locations. The absence of any sequence similarity between the C-terminal epitope of ANK 
(to which Ab3 is raised) and calbindin-D28K, recognition by different secondary antibodies 
and the antibody controls preclude non-specific recognition of the ANK-positive cells by 








The results show that ANK is capable of being upregulated by AVP, and the similar results 
obtained with forskolin confirm that this is via a cAMP-dependent mechanism. Given the 
localisation of ANK in the CCD, we had predicted that ANK would be upregulated by AVP 
in cells that stained positively for AQP2, i.e. principal cells, with ANK-positive AQP2-
negative cells (representing intercalated cells) being in the minority. Instead, 
immunofluorescence of ANK and AQP2 in AVP-treated sections resulted in the 
identification of multiple cellular phenotypes. In contrast, the results of calbindin 
immunofluorescence showed identical colocalisation with ANK at the apical membrane 
after AVP treatment. Over 90% of the cells did not stain positively for AQP2, 
demonstrating that the mpkCCDcl4 cell line used in the experiments may not consist of 
normally functioning principal cells and is therefore not truly clonal. The same anti-AQP2 
antibody was able to identify principal cells in human (Chapter 3) and mouse tissue (Carr et 
al., 2007) which correlated with tissue morphology, and colocalisation with ANK was 
demonstrated in both species. ANK is present in -intercalated cells (section 3.2.6), and this 
may account for a small proportion of the ANK-positive AQP2-negative immunofluorescent 
cells. This unexpected cellular heterogeneity with very low overall immunofluorescence 
means that attempts to measure PPi transport to apical and basal solutions under AVP-
stimulated conditions in this cell line would be very likely to yield a false negative result. 
Recloning of the cell line with expansion of the ANK-positive phenotype would allow 






The distribution of upregulated cells in this cell line may suggest that functional ANK 
expression is not solely limited to the principal cells of the collecting duct. AQP2 
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expression is found uniquely and precisely in the apical membranes of cortical, medullary 
and papillary collecting ducts in kidneys of human, rat (Marples et al., 1995) and horse 
(Floyd et al., 2007). In contrast, active renal calcium transport occurs in both the DCT and 
connecting tubule (Hoenderop et al., 2005); (Hoenderop et al., 2002). Additionally, 
calbindin-D28K is also found in CCD of rabbit and in the medullary collecting duct of certain 
rat and monkey species (Moutairou et al., 1996). Since calbindin-D28K is unique to calcium-
transporting epithelia (Schlatter, 2006), this again suggests that the mpkCCDcl4 cell line is 
not a true clone of collecting duct cells. During transcellular calcium transport, calbindin-
D28K traffics from the cytosol towards the apical membrane, where it buffers calcium 
entering the cell via the apical calcium transporter TRPV5 with which it colocalises and is 
coexpressed (Lambers et al., 2006). Subsequent facilitated exchange diffusion of calcium 
via calbindin is thought to deliver calcium to the basal sodium/calcium exchanger or 
calcium-ATPase for export to the blood whilst maintaining a low intracellular calcium. 
We have shown at least limited ANK expression in the thick ascending limb of human 
kidney (section 3.2.7), and the colocalisation with calbindin-D28K demonstrated here 
suggests some ANK expression in the distal tubule. Our results may therefore reflect the 
wider distribution of ANK in various nephron segments, such as thick ascending limb or 
distal tubule. Since these segments are not primarily AVP responsive, ANK expressed in 
each segment may require regulation in different ways. The crystallisation tendency of high 
luminal calcium concentrations in any of these segments would be reduced by allowing 
increased calcium buffering via TRPV5/calbindin at the same time as promoting PPi export 
into the lumen via ANK. Given that most calcium transport occurs in the distal tubule rather 







Immunofluorescence studies in the mpkCCDcl4 cell line have shown that ANK is 
upregulated by AVP treatment, but biochemical confirmation of function is limited by very 
low overall detectable expression in this system and possibly by heterogeneity of the clonal 
cell line. ANK may also be expressed in calcium-transporting nephron segments, which is 
consistent with localisation data obtained in Chapter 3. Confirmation of AVP regulation of 
the ANK gene is now required. This would also allow clarification of the transcriptional 
regulation of ANK under AVP-stimulated conditions. It may also help to identify interacting 
or co-regulated proteins.  
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Investigation of the effects on the pattern of gene expression in mpkCCDcl4 cells in response 
to AVP stimulation allows confirmation of transcriptional regulation by AVP. The 
experimental aim was to identify the genes expressed when mpkCCDcl4 cells are stimulated 
by AVP under the same conditions as in the immunofluorescence experiment, and to 
determine if ANK is among them. The secondary aim was to quantify any up- or down-
regulation. The expression profile thus generated is a surrogate for the resulting proteome. 
Even though the percentage of positively immunofluorescent cells with AVP was low in the 
immunofluorescence experiment, this is not necessarily proportional to mRNA copy 





Normalised, quality controlled probesets were used to generate a list of genes expressed 
differentially between control and AVP-treated samples. The threshold of significance was 
set at p = 0.05, with these results further selected for an up- or down-regulation with fold 
change of at least 1.18 compared to controls. This resulted in a list of 364 genes which were 
differentially expressed due to AVP (Figure 6.3 and Figure 6.4). Multiple probesets may 
map to a single gene, but the selection criteria resulted in only one of the two probesets for 
the highly AVP-upregulated PDE4b gene being included in the final analysis (Figure 6.4 
and Figure 6.6).  
The effect of this selection was checked by rearranging the 364 probesets, coloured 
according to their NIVs, by control versus treated (columns in Figure 6.5) and by those 
probesets with higher expression (redder; rows in Figure 6.5) versus those with lower 
expression (bluer; rows in Figure 6.5). These corresponded to genes upregulated by AVP 
and genes downregulated by AVP, respectively. The pattern of colours confirms that there 
are only two visible groups, indicating that the only significant differences were between the 
AVP-treated and untreated conditions.  








The full list of probesets representing genes which were up- or down-regulated, with fold 
changes, is given in Appendix 1. Specific genes of interest are shown in Table 6.1 and as an 
expression profile plot (Figure 6.6). Upregulation was confirmed of PDE4b, AQP2 and 







The probeset with the highest fold change in the array was one of those for PDE4b. PDEs 
are enzymes that hydrolyse cyclic nucleotides, and are a major determinant of intracellular 
cyclic nucleotide concentration (Cheng & Grande, 2007). In tubular epithelia (cell line 
LLC-PK1) catabolism of the AVP-dependent cAMP pool occurs by PDE1 and PDE4 
(Cheng & Grande, 2007), but PDE4 is the most highly expressed isoenzyme in rat renal 
cortex (Matousovic et al., 1997). An increase in cAMP induces PDE4 gene expression 
(Manganiello, 2002). PDE4b together with AQP2 represented positive controls for AVP 
treatment. Despite only 6% of cells being positive for immunofluorescence of AQP2, a 3.4-
fold change in corresponding mRNA availability was found after significance testing. Under 
these circumstances the 1.4-fold increase in ANK gene expression demonstrates clear 
upregulation of ANK in mpkCCDcl4 cells with AVP treatment, and suggests that the actual 
amount of gene expression in individual cells that express ANK might in fact be very high 








The gene for the potentially interacting protein SLC27A2 (section 5.3.7.3) was not 
identified here above background in any of the six arrays, this being confirmed subsequently 
by PCR (section 6.4.2.2.6). Only one SLC27A2 probeset, consisting of ten oligonucleotide 
probes, was available but the sequences of all ten probes were found to map as expected to 
the consensus NC_000068.6 sequence of SLC27A2. Of note, SLC27A2 is localised to 
proximal tubule of rat kidney (Thukral et al., 2005) whereas the mpkCCDcl4 cells used here 
are a collecting duct cell line. In addition, it is located intracellularly in peroxisomes and ER 
of liver cells (Steinberg et al., 1999). Transfection of SLC27A2 into mpkCCDcl4 cells in our 
laboratory gave intracellular rather than membrane staining, consistent with published 
findings (Dr G Carr, unpublished results). This is unlike SLC27A1 which is also expressed 
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in kidney but located in the plasma membrane (Schaffer & Lodish, 1994), and is shown to 
be present but not upregulated by AVP in this experiment. The yeast two-hybrid screen 
answered a different question to the microarray experiment: it suggested SLC27A2 as a 
potential binding partner, which could be true even if its expression is minimal.  
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Figure 6.3 Change in expression of each probeset (gene) according to array.  
Chapter 6 – Regulation of ANK in the mpkCCDcl4 cell line 
__________________________________________________________________________________________________________________________________________ 
200
Figure 6.4 Change in probeset (gene) expression due to AVP treatment, for normalised 
and quality-controlled microarray data.  
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Figure 6.5 Hierarchical clustering of quality controlled probesets (genes), selected for 
p<0.05 and fold change >1.18.  
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Table 6.1 Some of the genes differentially expressed on AVP-stimulation of 
mpkCCDcl4 cells.  
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Figure 6.6 Change in expression of five genes with AVP treatment.  






A search of the ArrayExpress database19 for published microarray experiments involving 
ANK in mouse tissue or cell lines yielded only six experiments, all involving mouse kidney 
tissue, and showed very low basal expression with respect to other tissues. Robert Nicoud et 
al (Robert-Nicoud et al., 2001) treated mpkCCDcl4 cells with 10
-8 M vasopressin for 4 hours 
and looked at the resulting transcriptome to try and identify new AVP-dependent signalling 
pathways. mRNA was collected, and sequence tags were analysed by attempting to match 
them against known mouse genes in a process called “serial analysis of gene expression”
(SAGE). SAGE gives a list of many short sequence tags and the number of times each of 
these transcripts is observed. It therefore differs from a microarray screen in which only 
sequences to which a probe already exists can be detected, and even then there is potential 
for mis-hybridisation. If the genes to be investigated are already known, SAGE can allow 
more accurate quantification of gene expression than a DNA microarray study. 
Unfortunately, this database, as given in their paper, can no longer be located. 
Another earlier study, also by the Knepper group (Legato et al., 2003) also used results from 
both SAGE and microarray techniques in the mpkCCDcl4 cell line to collate a list of the 
major collecting duct proteins under resting conditions (data at 
http://cddb.nhlbi.nih.gov/cddb/). This was an early, basic list of genes involved in transport 
and cellular regulation in this cell line, which has since been superseded by the results 
available from analysis of microarray data by software such as GeneSpring.  More recently, 
the Knepper group (Yu et al., 2009) used Affymetrix GeneChip® Mouse Genome 430 2.0 
Arrays to analyse gene expression in the mpkCCDcl4 cell line, looking for regulators of 
AQP2 gene expression. They found that AQP2 immunofluorescence of cells in confluent 
mpkCCDcl4 monolayers was variable, just as we noted (section 6.2.1.1). In order to avoid 
this heterogeneity they subcloned the original mpkCCDc14 cell line on the basis of naturally 
varying aquaporin-2 (AQP2) protein expression levels after incubation with 10-10 M AVP 
basolaterally for five days. Microarray screens were carried out on five different clones and 
the original cell line. Results also included a post-normalisation ratio of gene expression of 
the clone with the highest AQP2 expression (clone 11 in their database) to the clone which 
lacked AQP2 expression  (clone 2),  even though both were stimulated with  10-10 M AVP. 
                                                
19 www.ebi.ac.uk/arrayexpress using gene ID ENSMUSG00000022265 
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For AQP2, there was a 42-fold increase with treatment. Details of their published searchable 
database are given below20.  
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The Knepper study was similar to ours apart from their use of 100-fold lower AVP 
concentration and the lack of non-AVP treated mpkCCDcl4 clones, although their ‘clone 2’ 
had almost no AQP2 gene or protein expression (Yu et al., 2009). We used GeneSpring GX 
10 to re-analyse the raw Knepper dataset under our normalisation and quality-control 
criteria to determine any differences in relative ANK expression using this lower AVP 
concentration (Figure 6.7). Only 30 (0.4% of the total) probesets in the Knepper list were 
not present in our quality-controlled list (QC in Figure 6.7), indicating a very high degree of 
overlap. All Knepper probesets were included within our pre-quality-controlled list (T in 
Figure 6.7). Of our final t-tested list of 364 differentially expressed genes, about half 
appeared in the Knepper list, and ANK was among these (Figure 6.7 B).  
Knepper probesets were further selected for a fold change of at least 2.0 from the clone 
expressing highest AQP2 (clone 11) to the lowest (clone 2), and compared to our final 
differentially expressed list of 364 genes. 75 probesets were shared, including AQP2 and 
ANK, but PDE4b was not, and ANK was downregulated by 3.8-fold in the clone with 
highest AQP2 expression compared to that with the lowest. It is possible that ANK requires 
a higher AVP concentration to promote expression or that ANK is downregulated over the 
five days of 10-10 M AVP stimulation. The lack of PDE expression supports the idea that 
AVP may cause upregulation over shorter time periods. It is known that some AVP-
stimulated gene transcription can be maximal at around 30 minutes (Mayr & Montminy, 
2001); see below for further discussion on this) and greater than 24 hours of exposure to 
AVP can result in marked morphological changes in the principal cell, which can affect 
gene transcription independently of AVP (Robert-Nicoud et al., 2001).  
Despite Knepper’s comparison of AQP2-sensitive and -insensitive clones, the difference 
compared to our results suggests that ANK may require a higher level of AVP to enable 
expression, and/or there is a difference between acute and chronic regulation. Further 
investigation of this result in comparison with studies into the mechanism of action of AVP 
is performed below. Such a scenario is consistent with the overall hypothesis that ANK is 
                                                
20 Database is available at http://dir.nhlbi.nih.gov/papers/lkem/mpkccdtr/default.aspx. Raw data is available 
from Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo; GSE13672; Yu et al., 2009). 
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AVP binding to the V2 receptor activates the cAMP system. cAMP activates the cAMP-
response element binding protein (CREB) by phosphorylating its Ser-133 residue (Mayr & 
Montminy, 2001). Activated CREB binds to genes which contain a cAMP-responsive 
element (CRE) motif causing gene transcription, peaking at about 30 minutes after cAMP 
stimulation, although not all genes containing CRE are activated by cAMP. CREs are most 
functional when located within 100 base pairs of the “TATA” box transcription promoter, 
and hence this can be used to predict which genes contain CRE, and might therefore be 
cAMP responsive (Table 6.2). Zhang et al. (2005) performed modified microarray analysis 
on various cell lines to differentiate tissue-specific functions of CREB, resulting in an 
expression profile unique to each tissue in response to cAMP activation. These data are 
published online at http://natural.salk.edu/CREB.  
We hypothesised that genes in our QC list (Figure 6.7) that do not contain CRE motifs are 
unlikely to be functionally significant. The overlap between the list of genes containing 
CREB (~600 genes) and our QC list (364 genes) was computed using Ingenuity software 
(www.ingenuity.com). 256 of the 364 differentially expressed genes overlapped with the 
CREB database list, including ANK and AQP2. 
Conserved CRE sites, whether full or half sites, are the most likely functional CREs, and 
they usually occur within 100 base pairs of the “TATA” box transcription promoter (Mayr 
& Montminy, 2001). These data show that ANK has a non-conserved half site between 
3743 and 3030 base pairs prior to the start of the coding sequence, which suggests that it 
may not be entirely regulated by cAMP in this way. Forskolin stimulation of tissues was 
performed on HEK293 cells, followed by chromatin immunoprecipitation and microarray 
hybridisation in arrays of various cell lines. This genome-wide location analysis allowed 
functional determination of CRE activation, although the results are not directly comparable 
to ours as we used AVP rather than forskolin. Again, this gave similar results to the table 
above (Table S4 at http://natural.salk.edu/CREB). On the other hand, ANK does not appear 
in the list of cAMP responsive genes (as observed after forskolin treatment) in the non-
polarised non-collecting duct cell line HEK293T generated by an Affymetrix array 
experiment (Table S5 at http://natural.salk.edu/CREB), but this simply reflects the tissue-
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specificity of responses.  
There is little evidence in terms of appropriate CRE sites on the ANK gene promoter 
available for regulation by cAMP. This suggests that AVP may not be the only acute 
transcriptional regulator of ANK, and supports the findings of increased ANK expression at 
24 hours, but not at 5 days, after stimulation with higher AVP concentration.  
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Figure 6.7 Summary of rationalisation of microarray data and overlap with Knepper 
dataset.  
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Table 6.2 Prediction of functional CREs on promoters of mouse genes. 
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6.4 Confirmation of upregulated genes by quantitative RT-PCR 
1$ 	
The expression profile resulting from stimulation of mpkCCDcl4 cells with AVP for 24 h 
appeared to support the findings of upregulation of AQP2 and ANK seen on 
immunofluorescence. However, the fold increase of ANK mRNA was relatively small, and 
differences from previously published datasets were noted. Confirmation by actual detection 
of transcriptional regulation in the same mRNA as used above was now performed by 
quantitative PCR using gene-specific primers. The aim was to quantify the expression levels 







Standard curves were obtained by amplification of either pre-sequenced clones or RT 
products, in order to estimate the efficiency of DNA amplification of known dilutions of 
DNA from six genes (Figure 6.8). All data points touched the regression line, indicating that 
dilutional errors were minimal. Amplification curves were parallel and equally separated in 
all cases (Figure 6.9). 
All standard curves gave efficiencies very close to the optimum of 2.0, corresponding to a 
slope of -3.2. The curve for ANK did not encompass the very low range of ANK crossing 
points obtained in the experiment, and so extrapolation of the curve was required. Although 
not desirable, this is probably a reasonable estimate given that errors were very low. 
Analysis of the Tms showed that a single identical product was formed in all dilutions of a 
standard, with the exception of SLC27A1, where two products were found (see section 
6.4.2.2.5 below).  
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Figure 6.8 Standard curves showing efficiency of DNA amplification of known 
dilutions of DNA from six genes.  
The “crossing point” (Cp) is the amplification cycle number at which a sample’s 
fluorescence first rises above background fluorescence. More dilute samples (less 
initial DNA in the sample) thus require more cycles to become visible above 
background noise, resulting in a higher crossing point. Standard curves comprise 
the crossing point for each dilution (green dots) plotted against the logarithm of the 
sample’s initial DNA concentration (x axis), and a linear regression is calculated 
(blue line). The slope of each standard curve indicates the rate at which 
amplification of the initial DNA template proceeds. This can also be expressed as 
efficiency, where efficiency = 10
(-1/slope)
. The perfect amplification would result in a 
doubling of the initial DNA, giving an efficiency of 2 (corresponding to a slope of -
3.3). The mean squared error of fitting to the regression line was < 0.03 in all cases 
(acceptable < 0.2).  
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Fig 6.8 here 
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Figure 6.9 Examples of amplification curves.  
The fluorescence (arbitrary units) of each amplification reaction is shown as a 
function of the cycle number. Each curve commences as a near-horizontal line until 
fluorescence from the PCR product rises above background. This is followed by an 
exponential phase and concludes with a plateau as one or more ingredients in the 
reaction is used up. (A) Amplification of seven 1:10 serial dilutions of a plasmid 
DNA containing the coding sequence of ANK using specific primers (this was used 
to generate the standard curve in the previous figure). Amplification of the most 
concentrated ANK sample (left-most curve) commenced earlier and finished sooner 
than those for successive dilutions. Each dilution was performed in duplicate. (B) 
Amplification of experimental cDNA samples using the same ANK-specific 
oligonucleotide primers. The exponential phase commences beyond cycle 30, 
indicating relatively small amounts of ANK cDNA template in the samples. This can 
be compared to amplification curves of experimental cDNA samples obtained using 
AQP2-specific oligonucleotide primers (C) and GAPDH oligonucleotide primers (D), 
where the exponential phase commences earlier than for ANK. 
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fig 6.9 here 






Only one (C2) out of the three untreated samples generated a product of correct Tm
(highlighted in red in Table 6.3), as defined by the Tm of the standards. The others led only 
to a product with lower Tm, most likely primer dimer, resulting in either a higher Cp or 
undefined Cp. In contrast, AVP treatment led to the correct product in all three RT positive 
samples, with Cp around 30-32. All control samples (RT negative samples, no RNA, no 
template) were satisfactory, and yielded primer dimer, non-specific products, or no product. 
Similar results were obtained in two separate experiments using the same samples. As a 
result of this lack of consistent product from untreated samples in multiple experiments, fold 
change for PDE4b can not be calculated.  
6.4.2.2.2 AQP2 
Results were similar to those of PDE4b. Only one of the untreated samples, but all three 
AVP-treated samples, generated a product of the correct Tm (highlighted in red in Table 6.3; 
see also Figure 6.10). Other untreated samples and all negative controls yielded either 
primer dimer (~78 °C) or non-specific product. Accordingly, a valid fold change result for 
AQP2 can not be calculated.  
6.4.2.2.3 ANK 
Primers optimised to yield a single product of Tm of ~86.6 °C from the cloned ANK coding 
sequence were obtained (section 2.12.2.3). This was confirmed by obtaining a high quality 
ANK standard curve (Figure 6.8). Despite this, multiple products were obtained in the 
experimental samples using these primers (Table 6.3 and Figure 6.10). These can be 
grouped as shown in Table 6.4. 
One RT negative sample (AVP1) contained a product of correct Tm, although analysis of Cp 
shows that it had 64-fold (26) lower yield with respect to the corresponding RT positive, 
and that another non-specific product was also formed. This indicates slight contamination 
of the RT negative in this case. Other negative controls yielded primer dimer (blue in Table 
6.4) or non-specific product (green in Table 6.4). 
Chapter 6 – Regulation of ANK in the mpkCCDcl4 cell line 
__________________________________________________________________________________________________________________________________________ 
216
Table 6.3 Results of real time RT-PCR amplification of mpkCCDcl4 samples with and without 
AVP treatment. 
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 RT positive RT negative 
1st product 2nd product 1st product 2nd product
C1 77.0 86.3 83.1 
C2 86.7  77.6 
C3 86.6 83.0 77.0 
AVP1 86.9 86.8 79.7 
AVP2 86.5 79.2 77.3 
AVP3 86.4 79.2 82.7 76.7 
No RNA  83.4 77.4 n/a n/a 
Table 6.4 Melting temperatures (°C) for amplificati on products of experimental samples using 
ANK-specific optimised primers. Results are given for the most abundant (1
st
 product) and lesser 
product (2
nd
 product) for RT positive and negative samples for each of three untreated (C) and three 
AVP-treated (AVP) samples, together with the no-RNA control. A second product was not obtained 
in every case (left blank on table). The results segregated into three groups (Figure 6.10), labelled 
here as red (corresponding to the single product obtained from standards), green and blue. The 
PCR negative (water) control gave one product at 74.9°C. Similar results were obtained in a 
separate repeat experiment using the same experimental samples.  
6.4.2.2.4 GAPDH 
GAPDH was used as the reference gene for the reasons given in section 2.12.3.2. As with 
ANK, the correct product was also formed in two of the RT negatives (C3- and AVP1-), but 
the difference in Cps was at least 12 cycles, giving a fold difference of at least 4000. This 
indicates a very small amount of genomic DNA contamination in two of the six untreated 
samples, despite DNAse treatment. Otherwise, a single product of the expected Tm was 
obtained in all six RT positive samples.  
6.4.2.2.5 SLC27A1 
No clone was available for SLC27A1 so the standards were obtained by amplification and 
re-dilution of experimental RT products using the commercially available optimised 
primers. Unusually, the resulting standard curve yielded two products, the product with Tm
of ~84 °C showing 50% of the fluorescence of the product at 89 °C. RT positive samples 
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yielded a product with AVP1 at 12.7 fluorescence units (arbitrary scale) at 89 °C, and 
another with C2 at 7.5 units at 84.7 °C. All other RT positives yielded either no product or 
non-specific products of <0.5 units. Similarly, all controls yielded either no product or non-
specific products.  
6.4.2.2.6 SLC27A2 
Amplification of the SLC27A2 IMAGE clone yielded a single well-defined product with Tm
over a narrow range of 82.2-82.5 °C. However, no such product was obtained with any of 
the experimental samples, and hence Pfaffl analysis was not possible. This failure to 
amplify using SLC27A2 oligonucleotide primers was confirmed by performing an end-point 
PCR, the products of which were run on a 2.5% gel and also yielded no products (Figure 
6.10). End-point PCR using primers designed to amplify calbindin-D28K similarly showed 
no bands. 
  GAPDH ANK 
Untreated 28.30 33.47
AVP treated 26.46 31.84
Untreated - AVP treated 
(Cp) 1.84 1.64
Efficiency 1.967 1.992
Change (efficiencyCp) 3.47 3.09




Table 6.5 Cp values and fold change calculations for RT-PCR amplification.  
Average Cp values (number of cycles; see text) are given for amplification of samples either 
untreated or treated with AVP, for pairs of GAPDH and ANK gene-specific primers. The difference in 
cycles (Cp) is calculated. Efficiency of gene amplification was calculated from standard curves 
(Figure 6.8). Fold change between untreated and AVP treated conditions is calculated as 
efficiencyCp. Fold changes in target gene expression are normalised against the change in 
reference gene (GAPDH) expression. Values for PDE4b and AQP2 could not be calculated (see 
text).  
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Figure 6.10 Identification of amplification products by determination of 
melting peaks.  
Top row: Melting peaks for products generated by amplification of clones or RT 
products in a standard dilution series (as shown in figure 6.8). For each gene, 
identity of a single correctly-sized product from each dilution is confirmed by melting 
temperatures (Tm) occurring over a very narrow range.  
Middle row: Melting peaks for products generated by amplification of experimental 
cDNA samples segregate into multiple groups (red indicates one peak per sample, 
green indicates two peaks per sample). Using AQP2 and ANK primer pairs, some 
products resulted in overlapping peaks each at the correct Tm as identified by the 
standards (blue dotted lines). RT negative, RNA negative and cDNA template 
negative controls usually produced products of lower Tm (other peaks). In the case 
of SLC27A2, no product of correct Tm was amplified. This was confirmed by end-
point PCR analysis (lower figure) of products obtained with this primer pair which 
was designed to give products of 74 bp. Lanes: low range DNA ladder (L), one 
AVP-treated RNA sample with (A+) and without (A-) RT, one untreated RNA 
sample with (C+) and without RT (C-), and PCR negative control (X).  
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Fig 6.10 here 
(Kowalczuk et al., 2008) 







The RNA samples used in these experiments were identical to those used in the microarray 
experiment. They had been quality controlled and tested as described in section 2.11.2. The 
melting temperature (Tm) is characteristic of each amplified product. Analysis of the melting 
curves formed when the fluorescence of each product is plotted against temperature was 
used to identify correct products, as defined by those obtained using the same primers 
against standards obtained either from a clone or amplified and re-diluted from RT products. 
Melting peaks tended to segregate into those indicating the expected product (mostly found 
in RT positive test samples), and those indicating secondary and tertiary products, primer 
dimer or no product at all.  
RT positive samples sometimes yielded more than one product despite optimisation of 
primers, and RT negative sample controls yielded primer dimer or non-specific products. 
Since the extracted RNA was DNase treated before RT, these extra products are unlikely to 
consist of genomic DNA. Any trace RT activity of the DNA polymerase on any RNA that 
was carried over would have been little or nil, because RNaseH was used to destroy RNA at 
the end of the RT. Products obtained in the no-RNA control were of lower Tm, excluding 
contamination of the RT reagents with the exception of that for GAPDH. In the latter case, 
the lack of product with RT negatives, or the very large cycle differences between RT 
positive and negative pairs, together with the very precise overlapping of all Tm curves for 
GAPDH suggests that this contamination can be dismissed. Contamination from the PCR 
was excluded in all cases as the no-template (water) control always gave either a different 






Expression profiling demonstrated 10-fold differential expression of PDE4b in response to 
AVP (Figure 6.4). Confirmation of this using real-time PCR, a highly sensitive technique, 
was expected but did not occur. Calculation of fold change was not possible since untreated 
samples gave rise to either no defined Cp or no appropriate product. Since cAMP induces 
PDE gene expression (see section 2.12.3.2), a lack of detectable gene expression in 
untreated samples might be expected; in two of the untreated samples the primers simply 
dimerised giving a product of lower Tm. This might explain why only one of the two PDE4b
probesets was significant on expression profiling (Figure 6.4). It would have been useful to 
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verify the specificity of the primers, but these facts make it highly likely that PDE4b is 
differentially expressed, even though the fold change with respect to the untreated state can 




Using AQP2 oligonucleotide primers, only one of the three untreated samples resulted in a 
product of correct Tm, yet all three AVP-treated samples formed that product. This 
correlates with the immunofluorescence results (section 6.2.1.1), where no AQP2 
immunofluorescence was observed in the resting state, with very marked 
immunofluorescence after AVP treatment. For similar reasons to those given for PDE4b
analysis above, calculation of fold change was not possible in order to confirm the 3.4-fold 







Products coloured in blue in Table 6.4 are most likely primer dimers. In the case of C1, 
primer dimer was more abundant (fluorescent) than expected product, suggesting low 
starting levels of ANK cDNA in the sample. Since SYBR green detects the total 
fluorescence of any and all products, the presence of a significant amount of secondary non-
specific product could artefactually increase the apparent Cp for the correct product. In fact, 
the non-specific peaks (Figure 6.10) are more intensely fluorescent than the true peaks, and 
may result in an overestimation of its true expression. Pfaffl analysis shows a normalised 
fold change of ~1 with AVP treatment.  
Taken together, these results illustrate the importance of examining Tm first, but suggest that 
there is no detectable change in ANK expression due to AVP treatment. In contrast, 
microarray analysis showed a relatively small AVP-induced fold increase of 1.4. 
Although fold changes do not relect the absolute amount of expression, it is possible that 
ANK is expressed at very low average levels in the template. Immunofluorescent staining of 
similarly treated cells was clearly seen in only ~2% of cells in the field of view. The 
apparent clumping of positive cells on the immunofluorescence suggests that RNA 
sampling could change markedly over a very small area, accounting for the large variability 
in quantification between samples. Both of these could potentially be improved by cell 
sorting to enrich the AVP-stimulated ANK-positive cell population.  








Results of RT positive samples with GAPDH confirmed the validity of GAPDH as the 
reference gene. The mean Cp value between treated and untreated conditions was 1.8 and 
Cps were in the range 23-30. Since GAPDH has previously been shown to be unaltered in 
experiments involving AVP (see section 2.12.3.2), this change likely represents higher 
initial RNA content of the AVP-treated samples, despite attempting to load equal amounts. 
It illustrates why normalisation to expression of a non-changing standard gene (as was 
calculated using the Pfaffl method) is essential in these experiments. It would be desirable 
to normalise against more than one standard gene, such as -actin, especially when 








A good quality standard curve (Figure 6.8) was obtained for SLC27A1 despite amplification 
of two products (Table 6.3). Either the bought-in primers were not optimal, or there was 
very little initial SLC27A1 cDNA, causing amplification to be slower and possibly 
inaccurate. The latter is supported by sample Cp values that were far higher than those for 
other primer sets, although detailed comparison of these values with those from other 
primers would require absolute quantification techniques rather than the methods used here. 
An SLC27A1-positive control tissue or clone would have been desirable. Since there were 
no instances of the same products resulting in both untreated and treated categories, it was 
not possible to include SLC27A1 in the Pfaffl analysis. 
The SLC27A2 experiment was the only one in which a non-optimised primer set was used. 
However, it was designed to span exon-exon boundaries (details in section 2.12.2.3) and 
using an annealing Tm of 60 °C was proven to be highly efficacious in amplifying the 
cloned SLC27A2 cDNA on the standard curve. The Tms of experimental samples from real-
time PCR (Table 6.5), and the appearance of the lower end of the end-point PCR gel (Figure 
6.10), are consistent with the formation of primer dimer only. Thus SLC27A2 was not 
amplified at all, strongly suggesting that it is not present in any of these samples. Although a 
different primer pair could be used for reconfirmation, this is not necessary since these data 
confirm the results of the microarray analysis. However, a useful positive control might be 
to use RNA extracted from a proximal tubular cell line. 




mpkCCDcl4 cells stimulated for 24 h with AVP caused significant upregulation of PDE4b
and AQP2. Expression profiling confirmed that ANK was upregulated to a much lower 
extent under these conditions, but this finding was not supported by quantitative PCR using 
the same mRNA samples. Immunofluorescence showed that only a small proportion of cells 
showed upregulation of ANK and AQP2, as well as displaying cellular heterogeneity, which 
may have contributed to underestimation of ANK transcriptional upregulation. Similarly, co-
localisation of calbindin-D28K with ANK was observed, yet calbindin-D28K mRNA was not 
detected using gene-specific primers on end-point PCR (data not shown). An alternative 
explanation is that protein translation and post-translational events such as altered 
trafficking to the apical cell surface are the main regulators of apical ANK expression.   
A previous study performed on subcloned mpkCCDcl4 populations at 100-fold lower AVP 
concentration over a much longer time period did not confirm PDE expression and 
suggested ANK downregulation. Mouse ANK possesses two half CRE sites but these are 
well upstream from the start codon, and they are not conserved between mouse and human 
genomes. Taken together, these data suggest that if transcriptional activation of ANK occurs, 
it is in an agonist, chronicity and species-dependent manner. 
The yeast two-hybrid experiment yielding SLC27A2 as a potential interacting protein was 
performed on a whole mouse kidney cDNA library, but gene expression of SLC27A2 was 
not confirmed in this collecting duct cell line. Its tissue and subcellular localisation may 
explain why it is unlikely to be present in this nephron segment. Although this does not 
exclude interaction in other segments, it is less likely that SLC27A2 is the interacting 
partner protein for ANK within the mouse collecting duct. 
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7 Concluding discussion 





The published literature on ANK has focused on calcification abnormalities in bones and 
joints due to mutations affecting the gene encoding ANK. Since over-expression of ANK in 
fibroblasts increases extracellular PPi whilst reducing intracellular PPi (Ho et al., 2000) it is 
likely that ANK is either a membrane transporter of PPi or closely involved in its regulation. 
This effect is reversed in fibroblasts cultured from ANKank/ank animals (Ho et al., 2000). In 
addition, extracellular probenecid inhibits ANK function in ANK-expressing cells, 
suggesting that ANK is likely to be the PPi transporter itself (Ho et al., 2000). Ho et al.’s 
observation that calcification of the kidneys occurred in the ANKank/ank mouse knockout 
prompted our hypothesis of ANK expression and function in the kidney.  
The origin of urinary PPi is still unknown. PPi in the bloodstream is filtered by the 
glomerulus and mostly hydrolysed in the proximal tubule. The majority of PPi-generating 
reactions are intracellular, and there is a need in many of these reactions to immediately 
remove PPi in order to enable the reaction to proceed without inhibition by end-products 
(see below). These facts together suggest that much urinary PPi is locally generated within 
the kidney. However, the proportion of locally generated and effluxed PPi versus filtered or 
luminally produced PPi is unknown. 
Although Gurley et al. (2006b) claimed to be the first to demonstrate actual membrane 
transport of PPi by ANK, they were unable to measure PPi efflux from oocytes. They 
postulated, but did not prove, that the membrane localisation and the transporter structure of 
ANK allowed it to function either as a PPi transporter itself, or as a regulator of a PPi 
transporter already present in oocyte membranes. Although the present work was also 
unable to show efflux from oocytes, the data from the yeast two-hybrid protein interactions 
and whole-genome regulation experiments are now able to throw some light on possible 






A major part of this thesis was the use of the oocyte expression system of Gurdon et al.
(1971) for heterologous overexpression of ANK. This robust functional model allows 
expression of almost any protein, but no significant influx/efflux was found despite 
Chapter 7 – Concluding discussion 
__________________________________________________________________________________________________________________________________________ 
226
confirmation of membrane localisation. Flux experiments in oocytes (Chapter 5) were 
complicated by significant technical problems when using PPi as a substrate. Oocytes are 
large cells, so the initial influx rate could be subsequently limited by intracellular diffusion. 
ANK may be present on the intracellular membranes of the numerous yolk platelets of the 
oocyte, causing compartmentalisation of injected PPi and inhibition of efflux. The size of 
these cells may mean that they are able to rapidly buffer or metabolise injected PPi, 
reducing apparent efflux. Finally, oocyte systems are less suitable when the transporter Km
is below the minimum substrate concentration needed to achieve robustly detectable 







PPi is a small, highly charged molecule that is produced by about 190 biochemical reactions 
(Heinonen, 2001), including the synthesis of DNA, RNA, amino acids, proteins and lipids, 
and participates in the regulation of several metabolic reactions. The reaction ATP  AMP 
+ PPi liberates 20 kJ/mol more energy than ATP  ADP + Pi (Heinonen, 2001). Therefore 
synthetic reactions progress more favourably when coupled to the formation of PPi from 
ATP (or other nucleotide triphosphates). For this process to continue, the PPi end-product 
must be rapidly removed from the reaction, shifting the equilibrium in favour of the reaction 
products rendering the reaction irreversible. PPi removal is likely to occur in more than one 
way, such as by pyrophosphatases, spontaneous hydrolysis or membrane transport. Until 
recent work on the peroxisome was published (Visser et al., 2005), studies have overlooked 
the possibility that PPi could be removed by transport across membranes. This is 
particularly surprising because PPi transport between compartments has been implicitly 
assumed in cellular work since the 1960s, but no mechanism was put forward until the 
discovery of the ANK protein by Ho et al. (2000).  
ANK mRNA is ubiquitous in tissues and evolutionarily highly conserved in vertebrates, 
strongly suggesting that it has an important role in cell function that is not restricted to 
calcified tissues. It is present on intracellular and extracellular membranes (see below). 
Most published work has concentrated on the role of ANK in bone metabolism, supported 
by good evidence of the clinical effects on bones and joints occurring in the ANK null 
(Gurley et al., 2006a) and homozygous Phe377del (Chen et al., 2009) mouse models. The 
present hypothesis, based on work performed in mouse kidney (Carr et al., 2007) and 
outlined in Moochhala et al. (Moochhala et al., 2008) investigates for the first time the role 
of ANK in the kidney, another system in which the regulation of crystallisation is crucial. 
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However it is important to consider that the role of ANK in pyrophosphate 
transport/metabolism may be equally important in other systems and especially in the 
intracellular environment. Finally, no data exist on the regulation of ANK, acutely or in the 
longer term. Information about regulation can help to elucidate protein function under 
different physiological conditions.  




Plasma membrane expression of ANKH in human kidney has been confirmed by Western 
blot and immunofluorescence. Our experiments confirmed that ANK was present at both 
apical and basal membranes of collecting duct cells, and a mouse cell model revealed 
increased traffic of ANK to the apical membrane in response to stimulation with AVP. PPi 
influx via ANKH is neither physiologically relevant nor supported by our data in any 
meaningful way, especially since a relatively large oocyte-surface PPase activity was 
detected. However, no consistent and significant increase in efflux of labelled PPi in ANK-
injected over water-injected oocytes was detected, despite positive localisation by 
immunofluorescence.  
Very little free PPi is likely to exist in the cytosol under normal conditions since most 
intracellular PPi is compartmentalised into organelles (Davidson & Halestrap, 1988) and 
highly active pyrophosphatases exist (Shatton et al., 1981). Since relatively large amounts 
of PPi were injected into oocytes, the lack of detectable efflux or leak is an important 
finding. Apart from technique limitations, possible mechanistic explanations include a 
requirement for: activation by one or more proteins; multiple subunits forming a functional 
channel (for example, as in the case of the epithelial sodium transporter ENaC); activation 








The presence of a required partner protein can lead to a large increase in function. For 
example, Kowalczuk et al. (2008) demonstrated a 10-fold augmentation of amino acid flux 
due to the transporter hBAT1 in oocytes, in the presence of a relatively smaller amount of 
partner protein (25 ng BAT1 transporter + 10 ng ACE2, after optimisation). Wang et al.
(2009) suggest that the dominant nature of ANK mutations in both CMD and familial 
CPPDD (Table 1.1) suggests an interaction with another component. ANK is present in 
many tissues (section 1.4.4.3) and might therefore have more than one interactor.  
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The distal tubular sodium/phosphate transporter PiT-1 (SLC20A1) has been shown to co-
immunoprecipitate ANKH (Wang et al., 2009), but we did not detect this interaction using 
the N-terminal ANK fragment as bait in a yeast two-hybrid screen. Since the location of the 
interacting domain is unclear, this interaction is not excluded by our findings, although 
Wang et al. did show that the M48T (likely N-terminal) mutation in ANK prevented its co-
immunoprecipitation with PiT-1. Indeed, given that the N-terminal has been successfully 
used for GFP (Carr et al., 2007) and FLAG (section 2.3.3.4) tags, it is possible that a C-
terminal interaction site could have resulted in further physiologically relevant interactions. 
In addition, yeast two-hybrid interactions occur within the cytosol and may possibly exclude 
membrane proteins. 
Evidence of protein-protein interaction is not the same as proof of coupled function. Thus 
Wang et al.’s findings are unlikely to suggest that PiT-1 is the actual PPi transporter with 
ANK acting as a regulator or cofactor, since they did not prove that ANK binds directly to 
PiT-1 (Wang et al., 2009) and the highly charged nature of PPi makes it improbable that it 
could share a common membrane transporter with Pi. In contrast, the interaction of 
SLC27A2 with ANK (section 5.3.7.3), together with its intracellular localisation, kidney 
expression and lack of membrane-associated PPase, suggests that ANK is a candidate 
peroxisomal membrane PPi transporter. PPi export to the cytosol rather than enzyme-
mediated PPi hydrolysis has physiological utility in this location, but this PPi flux from 
vesicle to cytosol would not be detectable by radiolabelled PPi injected into the cytosol. We 
have so far found no evidence that a similar metabolic construct occurs at the plasma 









Our results and those of others (section 6.3.3.4) suggest that regulation by AVP occurs 
acutely (over minutes) rather than chronically. Although our collecting duct model was 
limited by cellular heterogeneity, clear apical trafficking of ANK was demonstrated in 
response to AVP. Despite this, the results of the expression profile and quantitative PCR 
were more equivocal, suggesting that regulation by AVP may not occur via transcriptional 
regulation. Alternatives could include movement of vesicles, similar to that of AQP2 
regulation, phosphorylation, other compartmentalisation in the cell, or the effect of 
extracellular nucleotides, which are capable of downregulating AQP2 in this cell line 
(Wildman et al., 2009).  
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These alternative possibilities may be linked to other transport mechanisms. Davidson & 
Halestrap (1988) found that intra-mitochondrial PPi concentration in hepatocytes was 
increased by stimulation with gluconeogenic hormones such as glucagon and AVP. AVP 
produced a much larger increase in intracellular PPi concentration than glucagon. 
Interestingly, AVP’s effect was abolished in the absence of extracellular calcium ions, 
despite the fact that AVP is capable of releasing intracellular calcium stores by itself. These 
facts raise the possibility that membrane transport of calcium and PPi may be linked in these 
cells.  
In rat renal collecting duct cells, Goel et al. (Goel et al., 2007) showed that the apically 
located calcium channel TRPC3 colocalised with AQP2 in intracellular vesicles and 
trafficked to the apical membrane in response to AVP. They also demonstrated 
transepithelial calcium flux due to TRPC3 at the apical membrane. Not only is this an 
example of co-ordinated regulation of AQP2 with another apical membrane transporter, but 
by allowing a reduction of luminal calcium concentration at times of increased water 
reabsorption, it may contribute to the prevention of luminal calcium crystallisation. In 
contrast, the apical calcium receptor (CaR) in rat IMCD contributes to a reduction in AVP 
effect, limiting apical water permeability when luminal calcium rises (Sands et al., 1997). 
Similarly, our evidence for co-ordinated acute regulation of ANK and AQP2 (see section 
6.2.1.1) would have physiological utility by increasing luminal PPi concentration. 
Combining these mechanisms links aspects of calcium, PPi and water transport at the apical 




The origin of PPi available for efflux into the collecting duct lumen remains unclear. 
Evidence obtained from other tissues suggests that the cytosolic PPi concentration is likely 
to be low. Since most PPi in liver is produced in the mitochondria (Davidson & Halestrap, 
1988), it is likely that PPi would be exported from the mitochondria to the cytosol. Here, 
PPi may be hydrolysed (PPi survived for less than 0.5 s in bacteria (p. 23 in (Heinonen, 
2001)) by cytosolic PPases. On the other hand, enough PPi-generating reactions may occur 
in the cytosol at the apical aspect of the cell to allow adequate substrate for PPi efflux. PPi 
may also locally buffer calcium ions, for example in the primary cilium (as suggested in 
(Carr et al., 2009)), although too high concentrations of calcium or PPi would cause 
precipitation of insoluble CaPPi. Cytosolic PPi could also be transported across membranes 
into other cellular compartments, or out of the cell into the tubular lumen, these processes 
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requiring a membrane PPi transporter acting intracellularly as well as on the plasma 
membrane. Carr et al. (2007) showed in mIMCD-3 cells using a GFP-tagged ANK 
construct that ANK is present in intracellular membranes such as endoplasmic reticulum, 
Golgi, acidic endosomes and especially in mitochondria. ANK in these locations could 
allow movement of PPi across these membranes. Thus PPi may have roles in calcium 
binding and hence compartmentalisation of both calcium and itself. Our finding of an 
association between ANK and calbindin-D28K under AVP-stimulation is consistent with this, 
although the mechanism is unclear.  





1. ANKH mRNA is expressed in humans, and ANKH protein is present in human 
kidney, where it localises to the collecting duct and is present in both principal and 
-intercalated cells. ANKH is present at both apical and basolateral membranes in 
these locations. Expression in other nephron locations is less evident. This places 
ANKH in the most useful location for its proposed function in the limitation of 
calcium crystal formation. 
2. An ANKH-NT-3XFLAG fusion construct was overexpressed in the membrane of 
Xenopus oocytes, with little or no expression occurring in the cytoplasm. Purity of 
oocyte membrane fractions using Western blotting, and exact localisation of the 
plasma membrane using immunofluorescence, were confirmed by detection of 
overexpression of the membrane protein CD98. Colocalisation of the ANKH-FLAG 
construct with CD98 confirmed that the ANKH construct was localised to the oocyte 
plasma membrane. This finding verified that ANKH, cloned into the pcDNA3.1 
vector used in these experiments, was expressed in the oocyte membrane without the 
need for a -globin gene, as previously suggested by Gurley et al. (2006b), and 
could therefore be used in functional experiments. 
3. The Kingsley group (Gurley et al., 2006b) had apparently demonstrated influx of 
PPi into ANKH-overexpressing Xenopus oocytes, but meaningful and reproducible 
PPi influx was not confirmed here. In contrast to Gurley’s results, hydrolysis of PPi 
at the oocyte surface was confirmed using a highly sensitive PPi assay at a rate of 
~13 pmol/oocyte/h. Similarly, no significant or consistent PPi efflux was observed 
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from ANKH-expressing oocytes pre-injected with radiolabelled PPi, despite a 
satisfactory positive efflux control experiment using the transported organic dye 
Lucifer yellow. A genome-wide screen was performed using the yeast two-hybrid 
method, in which an N-terminal ANK fragment was bait and a mouse kidney cDNA 
library was prey. This suggested potential interacting proteins, of which SLC27A2 
was most likely to be a genuine result and which catalyses a reaction that generates 
PPi. 
These results for PPi influx and hydrolysis conflict strongly with those of Gurley et 
al. The lack of any detectable PPi transmembrane flux in this system may be 
explained by pyrophosphatase activity (hydrolysis) or by the necessity for a binding 
partner. Since pyrophosphatase activity is not known in peroxisomes, the 
ANKH/SLC27A2 complex may be a candidate protein for the putative peroxisomal 
membrane PPi transporter. 
4. AVP stimulation of mpkCCDcl4 cell monolayers showed marked apical localisation 
of AQP2 in 6.6% of cells, with apical localisation of ANK in 1.8% of a different 
population of cells in the same monolayer. AVP stimulation resulted in 
colocalisation between ANK and calbindin-D28K also at the apical membrane. The 
change in pattern of gene expression after AVP treatment in these monolayers was 
determined using expression profiling. This showed a 3.4-fold increase in AQP2
expression and a 1.4-fold increase in ANK expression. Attempted verification of 
these results using quantitative RT-PCR revealed a normalised fold change of 0.9 for 
ANK, with a lack of detectable AQP2 in untreated cells preventing fold change 
calculation for AQP2.  
Despite the obvious heterogeneity in the mpkCCDcl4 cell line, apical trafficking of 
ANK occurs in response to AVP, in support of the hypothesis. Similar results 
obtained with calbindin suggest that ANK function may not be restricted to the 
collecting duct. Although the expression of ANK was increased on the microarray in 
response to AVP, this was not observed using quantitative RT-PCR. This may imply 
that changes in expression occur more transiently than in these experiments, or that 
altered trafficking is a more important regulator in this situation than transcriptional 
upregulation.  






Using the data obtained from this thesis as well as published data allows a model to be 
suggested for ANKH function in the collecting duct cell (Figure 7.1). Four possible roles for 
ANKH are outlined.  
Intracellularly, ANKH and SLC27A2 form a functional couple that moves PPi produced in 
peroxisomes into the cytosol as described in section 5.3.7.3. Mitochondria produce PPi in 
synthetic reactions (Davidson & Halestrap, 1988); p. 61 in Heinonen (2001)) and ANK is 
detectable on the mitochondrial membrane in inner medullary collecting duct cells (Carr et 
al., 2007). ANKH may function in this location to rapidly remove PPi from the 
mitochondria to allow reactions to proceed. Once in the cytosol, PPi can be hydrolysed by 
cytosolic pyrophosphatases. Similar processes may occur in other organelles, and indeed 
ANK is detectable in the membranes of acidic endosomes in mouse collecting duct cells 
(Carr et al., 2007). Another possibility is that ANKH may act in reverse to store PPi from 
the cytosol in intracellular vesicles, which are then trafficked apically, fusing with the 
membrane. In this way, ANKH would eventually arrive at the apical membrane and the PPi 
load would be discharged luminally.  
In the collecting duct cell, AVP activates the basal V2 receptor. During the resulting 
production of cAMP, a contribution to cytosolic PPi is made. ANKH, as well as AQP2, is 
acutely regulated by AVP. AQP2 channels in vesicles migrate and fuse with the apical 
membrane (Nielsen et al., 2002). ANKH may be transported to the membrane by a similar 
mechanism, either in the same vesicles as AQP2 (as is the case with the apical calcium 
transporter TRPC3 in these cells), in different vesicles or via a chaperone molecule. 
However, the former possibility is less likely given that ANK was not present in the AQP2 
vesicle proteome (Barile et al., 2005). Calbindin-D28K, also present in the collecting duct 
(Roth et al., 1982), may be involved in this process, perhaps as a chaperone when it is 
recycled to the apical membrane. ANK requires a partner protein (possibly itself a channel) 
at the apical membrane in order to function and allow exit of PPi, but its identity is 
unknown. 
The interaction of ANKH with PiT-1 (Wang et al., 2009) has been demonstrated in murine 
chondrocytes. A proposed mechanism is outlined by (Wang et al., 2005), and allows the re-
entry of Pi arising from breakdown of PPi previously exported by ANKH. This is directed at 
the stimulation of TNAP activity at the cell surface which reduces the PPi concentration of 
the matrix to promote bone formation. This is less relevant in the kidney as TNAP is more 
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prevalent in proximal segments. Although PiT-1 is likely to be located basolaterally (Collins
et al., 2004), basolateral PPi export would reduce calcification in the renal interstitium 
which is a known mechanism of stone formation (Sayer et al., 2004). Of note, PiT-1 is 
inhibited by alkaline pH (Collins et al., 2004), which would limit influx of TNAP-produced 
Pi via PiT-1 under conditions favouring calcium phosphate stone formation. 
In parallel studies in our laboratory (Carr et al., 2009), ANK was found to localise to cilia 
and basal body in mouse kidney tissue and two collecting duct cell lines. Cilia are 
chemosensors and ciliated collecting duct epithelia demonstrate large increases in 
intracellular calcium in response to mechanical deformation (Praetorius & Spring, 2003). 
There is a need for rapid buffering of calcium activity, and this interesting intracellular 





At a molecular level, these findings offer the first insight into how PPi might be transported 
across membranes in humans, and suggest that ANKH is likely to function as a PPi 
transporter in an obligatory manner as part of a protein complex. In this way, intact PPi can 
be compartmentalised, preserving it for use within vesicular structures elsewhere in the cell 
or in the extracellular medium in a more energy-efficient way than by first hydrolysing it to 
orthophosphate. More generally, the lack of data on PPi in mammalian cellular energetics 
may arise from the existence of PPi only transiently as an intermediate in tightly spatially 
coupled biochemical reactions.  
7.4 Future work 
The observations can be taken forward in several important directions. PPi transport could 
be accurately measured using the highly-sensitive fluorescence assay in cell layers of 
collecting duct cell lines under various conditions. Flux experiments using techniques such 
as HPLC or mass spectrometry would improve upon radioactive tracer studies by 
specifically identifying intact PPi. Regulation by alteration of gene transcription over longer 
periods of time needs to be investigated, and may result in an increase in the amount of 
ANKH protein rather than trafficking of existing protein. Since gene regulation occurs in 
response to Pi or PPi levels (Harmey et al., 2004; Wang et al., 2009), it is possible that high 
levels of injected PPi may actually reduce gene transcription. Co-immunoprecipitation of 
ANK might help to confirm interacting proteins.  
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Clinical studies of the urine of calcium stone formers would need to be preceded by studies 
of urinary PPi using the highly-sensitive fluorescence assay. Initial attempts at this have 
been limited by interference due to urochrome (urobilin), and ion exchange methods may be 
useful in purifying PPi in urine samples. A key question is whether hypopyrophosphaturia is 
a metabolic risk factor for calcium stone formation, or merely an effect of depletion of PPi 
levels in patients who form stones. Such a study might include proteomic measurement of 
ANKH present in urinary exosomes of stone forming patients and normal controls, to 
determine a positive (cause) or negative (effect) correlation between urinary PPi and ANKH 
levels. If hypopyrophosphaturia persists even when hypercalciuria is treated, it may be a 
risk factor for calcium stone formation. This risk factor may be potentially modifiable by 
therapy with bisphosphonates, a commonly used stable analogue of PPi.  
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Figure 7.1 Potential roles of ANK in the principal cell of the renal collecting 
duct
(A) Intracellular: PPi is produced in the cytosol as a result of biochemical reaction 
inside organelles, coupled to ANK in the organelle membrane. Most PPi is rapidly 
degraded by intracellular PPases, but potentially PPi could be also 
compartmentalised into vesicles that could discharge PPi apically.  
(B) Apical membrane: AVP activates the basolateral V2 receptor, generating PPi 
and stimulating the movement of vesicles containing AQP2 to the apical surface. 
These vesicles may also contain ANK along with calcium channels such as TRPC3, 
for eventual fusion with the apical membrane. Alternatively, ANK may exist inside 
its own vesicles, or be chaperoned to the membrane by the calcium-transporting 
protein calbindin-D28K. At the apical surface, calbindin binds to calcium ions 
entering the cell via TRPV6 and is recycled. At the apical surface, ANK associates 
with its partner protein to enable PPi export into the lumen. This PPi is either 
cytosolic or arises as a reaction product of the partner protein.  
(C) Basolateral membrane: ANK interacts with the sodium phosphate transporter 
PiT-1 (Type III NaPi, SLC20A1) allowing basal PPi export into the renal interstitium, 
with possible recycling of hydrolysed products. The ectoenzyme NPP1 allows local 
generation of PPi.  
(D) Primary cilium: ANK present in the cilium and basal body allows release of PPi 
from vesicles to provide rapid local buffering of large calcium fluxes induced by cilial 
deformation.  
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Appendix 1 (following pages): Full list of genes differentially expressed on 
AVP-stimulation of mpkCCDcl4 cells.
The list was generated by performing unpaired t-testing (accepting significance at p
< 0.05) and selecting for fold change (FC) > 1.18, ordering by increasing fold 
change. The direction of gene regulation under AVP-stimulated conditions relative 
to control is given. Each line represents a probeset that meets these criteria.  
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Figure 5.14 Possible interaction between FATP and ANKH. Long chain fatty
acids diffuse or are transported across the membrane by FATP (1). An associated
acyl CoA synthetase catalyses the esterification of the fatty acid (2). Energy comes
from ATP, and produces PPi. To prevent reversal of this reaction (3), PPi must be





























Figure 3.7 Detection of a single nucleotide polymorphism in ANKH coding
sequence in six human subjects. Part of the contiguous nucleotide sequence for one
of the subjects is shown (above). This fragment was sequenced twice (E1a, E1b) using
different primer sets, and is aligned with the ANKH coding sequence NM054027.
Extracts from sequencing chromatograms (below) show that the nucleotide at position
294 (317 on sequence above) was either a cytosine (C) or thymine (T), or both alleles
were present. The resulting codons GCC or GCT are synonymous for alanine at residue
position 97. This SNP is annotated as RS17251667.
100
Figure 3.4 Expression of an ANK amplification product in human kidney cell line 
and tissue
(A) RT-PCR of an internal (490bp) ANK product. mRNA expression is observed in human
embryonic kidney (HEK293) cells (HEK) and human renal cortex (K). IMAGE clone
3927236 cDNA (Geneservice) containing human full length ANK coding sequence
(IMAGE) is the positive control. The water control (C) and ladder (L) in 100bp steps are
also shown. Comparison with results for the mouse collecting duct cell line mpkCCDcl4
(mCCD) and mouse kidney tissue (mK) (run on a separate gel) are shown. RT negative
and RNA negative controls have been omitted.
(B) Example of sequencing chromatogram for product from HEK293 cells. Identity of
PCR products was confirmed by direct sequencing. Identical sequencing was observed
for human renal cortex and IMAGE clone.





Figure 2.11 Validation of total RNA quality. Three control (C) and three AVP-treated
(AVP) RNA samples were run on an Agilent bioanalyzer 2100. All results show two
high and well-defined ribosomal peaks (28S, 18S). The small additional peaks below
the ribosomal bands indicate a tiny amount of RNA degradation. The lack of peaks
after the 28S ribosomal peak indicates a lack of genomic contamination. The table







Sample ID l(260/280) Concentration 
(ng/ml)
Yield (mg)
C1 2.03 399.6 3.2
C2 2.04 400.4 3.2
C3 2.04 431.8 3.5
AVP1 2.03 397.1 3.2
AVP2 2.04 505.0 4.0
AVP3 2.04 461.2 3.7
76























Figure 2.12 Normalisation of raw data. The log summarised values for each
probe across all six samples is subtracted from each probe at each sample, hence
reducing background ‘noise’ in the data. The resulting normalised intensity values
(NIV) allow description of the position of each probe above the median (positive
NIVs) or below it (negative NIVs). The data are seen here to distribute evenly
across the experiment for all six samples, whether control (C) or treated (AVP).
79
Figure 2.13 Hierarchical clustering of
normalised microarray data. The full normalised
and quality-controlled probeset list (containing
25343 probesets) was clustered by normalised
intensity value (NIV) according to both probesets
(rows) and control versus treatment (columns),
using a Pearson centred correlation with average
linkage.
Red indicates positive NIVs maximally above the
median expression for that particular probeset
across all six arrays, blue similarly indicates
negative NIVs maximally below median
expression. Shades of colour reflect NIVs
between these extremes. Yellow denotes an NIV
of zero, indicating no change between control and









































































































































































































































































































































































































































































































































Figure 6.3 Change in expression of each probeset (gene) according to array. Each
trend line connects a particular probeset at its normalised intensity value (NIV) in each of
the six arrays (C1-3 control, AVP1-3 treated), with the crossover in NIV between
conditions, if any, seen in the middle. An NIV of zero indicates the median value of the
gene across all six arrays. (A) shows the raw data; (B) shows the final data (quality-
controlled and t-tested). This comprises only the 364 probesets that changed by greater
than 1.18-fold in either direction between the two conditions of the experiment, causing the
central area of graph (B) to be blank. Detail of changes in specific genes are shown in
Figure 6.6.
C1              C2             C3 AVP1        AVP2         AVP3






































































Figure 6.4 Change in probeset (gene) expression due to AVP treatment, for
normalised and quality-controlled microarray data. All normalised quality-
controlled data points are arranged by fold change of each gene in control arrays with
respect to AVP-treated arrays (x-axis) and by p value (both expressed as log
transformed values). Values above the horizontal green line represent those with
p<0.05, and values lateral to the vertical green lines represent fold changes of >1.18
in each direction. The combination of these two cut-offs is represented by the red
values, which number 364 in total. Notable probesets with large fold changes are
labelled. There were two probesets for PDE4b, only one of which was significant.



































C1         C2          C3 AVP1      AVP2     AVP3
1      2     3 1      2     3
C AVP
Figure 6.5 Hierarchical clustering of quality controlled 
probesets (genes), selected for p<0.05 and fold change 
>1.18.
(A) These 364 probesets were clustered by normalised 
intensity value (NIV) according to both probesets (rows) and 
control versus treatment (columns), using a Pearson centred 
correlation with average linkage. The results were then 
rearranged according to colour. The top half represents genes 
that are upregulated with AVP, and vice versa. (B) A magnified 
portion of the outlined area (green box) is shown.
Red indicates positive NIVs maximally above the median
expression for that particular probeset across all six arrays,
blue similarly indicates negative NIVs maximally below median
expression. Shades of colour reflect NIVs between these
































Figure 6.6 Change in expression of five genes with AVP treatment. Each
trend line connects a particular probeset plotted at its normalised intensity value
(NIV) in each of the six arrays (C1-3: control, AVP:1-3 treated). An NIV of zero
indicates the median value of the probeset across all six arrays. Fold changes
are given in Table 6.3. Results for both available PDE4b probesets are plotted,
but only one of these (*) is significant. * denotes p<0.05.
PDE4b
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Figure 6.7 Summary of rationalisation of microarray data and overlap with Knepper dataset.
(A) The original 45101 probesets on the microarray (T) were reduced to 25343 probesets after
normalisation and quality-control of the probeset list (QC). There was a high degree of
overlap with the Knepper dataset (K), with only 30 genes of the 7618 in the Knepper dataset
not being included in our QC list.
(B) The QC list was subjected to selection by t-test and fold change >1.18. This gives probesets
that are differentially expressed with AVP treatment (QCtp). Only about half of these
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